CN101495135B - 通过使用单链多肽融合蛋白进行疼痛的治疗 - Google Patents
通过使用单链多肽融合蛋白进行疼痛的治疗 Download PDFInfo
- Publication number
- CN101495135B CN101495135B CN2007800280890A CN200780028089A CN101495135B CN 101495135 B CN101495135 B CN 101495135B CN 2007800280890 A CN2007800280890 A CN 2007800280890A CN 200780028089 A CN200780028089 A CN 200780028089A CN 101495135 B CN101495135 B CN 101495135B
- Authority
- CN
- China
- Prior art keywords
- leu
- asn
- ile
- lys
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 143
- 230000036407 pain Effects 0.000 title claims abstract description 133
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 102
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 48
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 44
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 44
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 43
- 230000004927 fusion Effects 0.000 claims abstract description 180
- 108091005804 Peptidases Proteins 0.000 claims abstract description 99
- 239000004365 Protease Substances 0.000 claims abstract description 95
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 49
- 230000027455 binding Effects 0.000 claims abstract description 37
- 230000008685 targeting Effects 0.000 claims abstract description 31
- 231100000065 noncytotoxic Toxicity 0.000 claims abstract description 21
- 230000002020 noncytotoxic effect Effects 0.000 claims abstract description 21
- 210000001163 endosome Anatomy 0.000 claims abstract description 17
- 210000000172 cytosol Anatomy 0.000 claims abstract description 8
- 230000012202 endocytosis Effects 0.000 claims abstract description 3
- 238000000746 purification Methods 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 96
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 81
- 239000000463 material Substances 0.000 claims description 72
- 238000002372 labelling Methods 0.000 claims description 57
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical group C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims description 54
- 108020004414 DNA Proteins 0.000 claims description 51
- 102400001111 Nociceptin Human genes 0.000 claims description 42
- 108090000622 Nociceptin Proteins 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 41
- 102000005962 receptors Human genes 0.000 claims description 33
- 108020003175 receptors Proteins 0.000 claims description 33
- 239000000556 agonist Substances 0.000 claims description 32
- 125000000539 amino acid group Chemical group 0.000 claims description 30
- 239000002581 neurotoxin Substances 0.000 claims description 29
- 231100000618 neurotoxin Toxicity 0.000 claims description 29
- 230000008676 import Effects 0.000 claims description 27
- 239000003053 toxin Substances 0.000 claims description 27
- 231100000765 toxin Toxicity 0.000 claims description 27
- 108700012359 toxins Proteins 0.000 claims description 27
- 230000006337 proteolytic cleavage Effects 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 125000006850 spacer group Chemical group 0.000 claims description 17
- 230000007541 cellular toxicity Effects 0.000 claims description 16
- 241001112695 Clostridiales Species 0.000 claims description 14
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 14
- 230000028023 exocytosis Effects 0.000 claims description 13
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 7
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 7
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 7
- 238000005267 amalgamation Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 claims description 6
- 108010042237 Methionine Enkephalin Proteins 0.000 claims description 5
- 241000710961 Semliki Forest virus Species 0.000 claims description 5
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 claims description 5
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 claims description 4
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 claims description 4
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 4
- 102400001370 Galanin Human genes 0.000 claims description 4
- 101800002068 Galanin Proteins 0.000 claims description 4
- 101710154606 Hemagglutinin Proteins 0.000 claims description 4
- 241000714192 Human spumaretrovirus Species 0.000 claims description 4
- 102400000243 Leu-enkephalin Human genes 0.000 claims description 4
- 108010022337 Leucine Enkephalin Proteins 0.000 claims description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 4
- 101710176177 Protein A56 Proteins 0.000 claims description 4
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 claims description 4
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 4
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 4
- 239000000185 hemagglutinin Substances 0.000 claims description 4
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241000193738 Bacillus anthracis Species 0.000 claims description 3
- 102400000748 Beta-endorphin Human genes 0.000 claims description 3
- 101800005049 Beta-endorphin Proteins 0.000 claims description 3
- 108010065372 Dynorphins Proteins 0.000 claims description 3
- 102400000988 Met-enkephalin Human genes 0.000 claims description 3
- 102100024622 Proenkephalin-B Human genes 0.000 claims description 3
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 3
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- -1 diphtherotoxin Proteins 0.000 claims 2
- 108020004635 Complementary DNA Proteins 0.000 claims 1
- 238000010804 cDNA synthesis Methods 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 45
- 230000003040 nociceptive effect Effects 0.000 abstract description 23
- 230000001953 sensory effect Effects 0.000 abstract description 11
- 238000003776 cleavage reaction Methods 0.000 abstract description 4
- 239000012528 membrane Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000007017 scission Effects 0.000 abstract description 3
- 230000005945 translocation Effects 0.000 abstract description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 9
- 102000035195 Peptidases Human genes 0.000 description 80
- 230000009182 swimming Effects 0.000 description 74
- 235000019419 proteases Nutrition 0.000 description 67
- 241000588724 Escherichia coli Species 0.000 description 52
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 50
- 238000010008 shearing Methods 0.000 description 46
- 108010074860 Factor Xa Proteins 0.000 description 45
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 45
- 102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 44
- 238000012360 testing method Methods 0.000 description 41
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 38
- 206010019233 Headaches Diseases 0.000 description 36
- 210000005036 nerve Anatomy 0.000 description 35
- 231100000869 headache Toxicity 0.000 description 34
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 208000033808 peripheral neuropathy Diseases 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 108020004705 Codon Proteins 0.000 description 30
- 208000004296 neuralgia Diseases 0.000 description 30
- 230000008569 process Effects 0.000 description 29
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 29
- 230000032258 transport Effects 0.000 description 29
- 150000001413 amino acids Chemical group 0.000 description 28
- 108010017391 lysylvaline Proteins 0.000 description 28
- 108091008146 restriction endonucleases Proteins 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 210000003594 spinal ganglia Anatomy 0.000 description 26
- 229960002504 capsaicin Drugs 0.000 description 25
- 235000017663 capsaicin Nutrition 0.000 description 25
- 230000002441 reversible effect Effects 0.000 description 25
- 208000024891 symptom Diseases 0.000 description 24
- 230000006870 function Effects 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 239000007924 injection Substances 0.000 description 23
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 23
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 22
- 108010051110 tyrosyl-lysine Proteins 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000001119 neuropathy Diseases 0.000 description 20
- 230000007823 neuropathy Effects 0.000 description 20
- 229920000936 Agarose Polymers 0.000 description 18
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 208000011580 syndromic disease Diseases 0.000 description 17
- 108700010070 Codon Usage Proteins 0.000 description 16
- 208000019695 Migraine disease Diseases 0.000 description 16
- 108010050848 glycylleucine Proteins 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 16
- 241000193403 Clostridium Species 0.000 description 15
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 15
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 15
- 101710138657 Neurotoxin Proteins 0.000 description 15
- 108010047857 aspartylglycine Proteins 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 230000001537 neural effect Effects 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 206010027599 migraine Diseases 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000013519 translation Methods 0.000 description 14
- 208000009935 visceral pain Diseases 0.000 description 14
- MHHAWNPHDLCPLF-ULQDDVLXSA-N Val-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=CC=C1 MHHAWNPHDLCPLF-ULQDDVLXSA-N 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 13
- 238000011068 loading method Methods 0.000 description 13
- 201000005518 mononeuropathy Diseases 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 230000037324 pain perception Effects 0.000 description 13
- 108010012581 phenylalanylglutamate Proteins 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 12
- BTEMNFBEAAOGBR-BZSNNMDCSA-N Leu-Tyr-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BTEMNFBEAAOGBR-BZSNNMDCSA-N 0.000 description 12
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 description 12
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 12
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 12
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 108010089804 glycyl-threonine Proteins 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 208000021722 neuropathic pain Diseases 0.000 description 12
- 108010061238 threonyl-glycine Proteins 0.000 description 12
- 108010078580 tyrosylleucine Proteins 0.000 description 12
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 11
- UTLCRGFJFSZWAW-OLHMAJIHSA-N Asp-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O UTLCRGFJFSZWAW-OLHMAJIHSA-N 0.000 description 11
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 11
- 239000007995 HEPES buffer Substances 0.000 description 11
- WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 230000020341 sensory perception of pain Effects 0.000 description 11
- YUOXLJYVSZYPBJ-CIUDSAMLSA-N Asn-Pro-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O YUOXLJYVSZYPBJ-CIUDSAMLSA-N 0.000 description 10
- 102100028169 BET1-like protein Human genes 0.000 description 10
- 101710138653 BET1-like protein Proteins 0.000 description 10
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
- NTBDVNJIWCKURJ-ACZMJKKPSA-N Glu-Asp-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NTBDVNJIWCKURJ-ACZMJKKPSA-N 0.000 description 10
- YPQDTQJBOFOTJQ-SXTJYALSSA-N Ile-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N YPQDTQJBOFOTJQ-SXTJYALSSA-N 0.000 description 10
- XHBYEMIUENPZLY-GMOBBJLQSA-N Ile-Pro-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O XHBYEMIUENPZLY-GMOBBJLQSA-N 0.000 description 10
- CIJLNXXMDUOFPH-HJWJTTGWSA-N Ile-Pro-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CIJLNXXMDUOFPH-HJWJTTGWSA-N 0.000 description 10
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 description 10
- LXVFHIBXOWJTKZ-BZSNNMDCSA-N Phe-Asn-Tyr Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O LXVFHIBXOWJTKZ-BZSNNMDCSA-N 0.000 description 10
- WUXCHQZLUHBSDJ-LKXGYXEUSA-N Ser-Thr-Asp Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WUXCHQZLUHBSDJ-LKXGYXEUSA-N 0.000 description 10
- NLSNVZAREYQMGR-HJGDQZAQSA-N Thr-Asp-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NLSNVZAREYQMGR-HJGDQZAQSA-N 0.000 description 10
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 10
- 230000009429 distress Effects 0.000 description 10
- 229960002870 gabapentin Drugs 0.000 description 10
- 150000002460 imidazoles Chemical class 0.000 description 10
- 229910052759 nickel Inorganic materials 0.000 description 10
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 9
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 9
- BKFXFUPYETWGGA-XVSYOHENSA-N Asn-Phe-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BKFXFUPYETWGGA-XVSYOHENSA-N 0.000 description 9
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 description 9
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 9
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 9
- 208000007514 Herpes zoster Diseases 0.000 description 9
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 9
- 208000016604 Lyme disease Diseases 0.000 description 9
- YIBOAHAOAWACDK-QEJZJMRPSA-N Lys-Ala-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YIBOAHAOAWACDK-QEJZJMRPSA-N 0.000 description 9
- MDDUIRLQCYVRDO-NHCYSSNCSA-N Lys-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN MDDUIRLQCYVRDO-NHCYSSNCSA-N 0.000 description 9
- 241000588653 Neisseria Species 0.000 description 9
- 108010025020 Nerve Growth Factor Proteins 0.000 description 9
- 241001597008 Nomeidae Species 0.000 description 9
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 9
- 102000050389 Syntaxin Human genes 0.000 description 9
- 108010092854 aspartyllysine Proteins 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 108010037850 glycylvaline Proteins 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 108010034529 leucyl-lysine Proteins 0.000 description 9
- 229940053128 nerve growth factor Drugs 0.000 description 9
- 108010051242 phenylalanylserine Proteins 0.000 description 9
- 230000035807 sensation Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 8
- ZMWDUIIACVLIHK-GHCJXIJMSA-N Asn-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N ZMWDUIIACVLIHK-GHCJXIJMSA-N 0.000 description 8
- COUZKSSMBFADSB-AVGNSLFASA-N Asn-Glu-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N COUZKSSMBFADSB-AVGNSLFASA-N 0.000 description 8
- LZLCLRQMUQWUHJ-GUBZILKMSA-N Asn-Lys-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N LZLCLRQMUQWUHJ-GUBZILKMSA-N 0.000 description 8
- JWKDQOORUCYUIW-ZPFDUUQYSA-N Asn-Lys-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JWKDQOORUCYUIW-ZPFDUUQYSA-N 0.000 description 8
- JNCRAQVYJZGIOW-QSFUFRPTSA-N Asn-Val-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNCRAQVYJZGIOW-QSFUFRPTSA-N 0.000 description 8
- RYEWQKQXRJCHIO-SRVKXCTJSA-N Asp-Asn-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 RYEWQKQXRJCHIO-SRVKXCTJSA-N 0.000 description 8
- DOQUICBEISTQHE-CIUDSAMLSA-N Gln-Pro-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O DOQUICBEISTQHE-CIUDSAMLSA-N 0.000 description 8
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 8
- MXXXVOYFNVJHMA-IUCAKERBSA-N Gly-Arg-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN MXXXVOYFNVJHMA-IUCAKERBSA-N 0.000 description 8
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 8
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 8
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 8
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 8
- GYAFMRQGWHXMII-IUKAMOBKSA-N Ile-Asp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N GYAFMRQGWHXMII-IUKAMOBKSA-N 0.000 description 8
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 8
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 8
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 8
- JKGHDYGZRDWHGA-SRVKXCTJSA-N Leu-Asn-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JKGHDYGZRDWHGA-SRVKXCTJSA-N 0.000 description 8
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 8
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 8
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 8
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 8
- YEIYAQQKADPIBJ-GARJFASQSA-N Lys-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N)C(=O)O YEIYAQQKADPIBJ-GARJFASQSA-N 0.000 description 8
- YWJQHDDBFAXNIR-MXAVVETBSA-N Lys-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N YWJQHDDBFAXNIR-MXAVVETBSA-N 0.000 description 8
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 8
- 206010036105 Polyneuropathy Diseases 0.000 description 8
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 8
- FIODMZKLZFLYQP-GUBZILKMSA-N Pro-Val-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FIODMZKLZFLYQP-GUBZILKMSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- ZKOKTQPHFMRSJP-YJRXYDGGSA-N Ser-Thr-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKOKTQPHFMRSJP-YJRXYDGGSA-N 0.000 description 8
- 108010055044 Tetanus Toxin Proteins 0.000 description 8
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 8
- SWSUXOKZKQRADK-FDARSICLSA-N Trp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N SWSUXOKZKQRADK-FDARSICLSA-N 0.000 description 8
- WSFXJLFSJSXGMQ-MGHWNKPDSA-N Tyr-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N WSFXJLFSJSXGMQ-MGHWNKPDSA-N 0.000 description 8
- OJCISMMNNUNNJA-BZSNNMDCSA-N Tyr-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 OJCISMMNNUNNJA-BZSNNMDCSA-N 0.000 description 8
- COYSIHFOCOMGCF-UHFFFAOYSA-N Val-Arg-Gly Natural products CC(C)C(N)C(=O)NC(C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-UHFFFAOYSA-N 0.000 description 8
- VHRLUTIMTDOVCG-PEDHHIEDSA-N Val-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](C(C)C)N VHRLUTIMTDOVCG-PEDHHIEDSA-N 0.000 description 8
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 108010049041 glutamylalanine Proteins 0.000 description 8
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 8
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 108010020615 nociceptin receptor Proteins 0.000 description 8
- 230000036285 pathological change Effects 0.000 description 8
- 231100000915 pathological change Toxicity 0.000 description 8
- 210000001428 peripheral nervous system Anatomy 0.000 description 8
- 230000007824 polyneuropathy Effects 0.000 description 8
- 108010079317 prolyl-tyrosine Proteins 0.000 description 8
- 208000000029 referred pain Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 8
- 206010044652 trigeminal neuralgia Diseases 0.000 description 8
- NWFLONJLUJYCNS-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]acetyl]amino]acetyl]amino]-3-phenylpropanoic acid Chemical compound C=1C=CC=CC=1CC(C(O)=O)NC(=O)CNC(=O)CNC(=O)C(N)CC1=CC=CC=C1 NWFLONJLUJYCNS-UHFFFAOYSA-N 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 7
- LWUWMHIOBPTZBA-DCAQKATOSA-N Ala-Arg-Lys Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O LWUWMHIOBPTZBA-DCAQKATOSA-N 0.000 description 7
- PZBSKYJGKNNYNK-ULQDDVLXSA-N Arg-Leu-Tyr Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O PZBSKYJGKNNYNK-ULQDDVLXSA-N 0.000 description 7
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 7
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 7
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 7
- AKEBUSZTMQLNIX-UWJYBYFXSA-N Asn-Ala-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N AKEBUSZTMQLNIX-UWJYBYFXSA-N 0.000 description 7
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 7
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 7
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 7
- ZUFPUBYQYWCMDB-NUMRIWBASA-N Asn-Thr-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZUFPUBYQYWCMDB-NUMRIWBASA-N 0.000 description 7
- KBQOUDLMWYWXNP-YDHLFZDLSA-N Asn-Val-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)N)N KBQOUDLMWYWXNP-YDHLFZDLSA-N 0.000 description 7
- KTTCQQNRRLCIBC-GHCJXIJMSA-N Asp-Ile-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O KTTCQQNRRLCIBC-GHCJXIJMSA-N 0.000 description 7
- NHSDEZURHWEZPN-SXTJYALSSA-N Asp-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC(=O)O)N NHSDEZURHWEZPN-SXTJYALSSA-N 0.000 description 7
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 7
- WOPJVEMFXYHZEE-SRVKXCTJSA-N Asp-Phe-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WOPJVEMFXYHZEE-SRVKXCTJSA-N 0.000 description 7
- GWWSUMLEWKQHLR-NUMRIWBASA-N Asp-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GWWSUMLEWKQHLR-NUMRIWBASA-N 0.000 description 7
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 7
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 7
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 7
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 7
- DIXKFOPPGWKZLY-CIUDSAMLSA-N Glu-Arg-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O DIXKFOPPGWKZLY-CIUDSAMLSA-N 0.000 description 7
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 7
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 7
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 7
- IQACOVZVOMVILH-FXQIFTODSA-N Glu-Glu-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O IQACOVZVOMVILH-FXQIFTODSA-N 0.000 description 7
- MIIGESVJEBDJMP-FHWLQOOXSA-N Glu-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 MIIGESVJEBDJMP-FHWLQOOXSA-N 0.000 description 7
- KXTAGESXNQEZKB-DZKIICNBSA-N Glu-Phe-Val Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=CC=C1 KXTAGESXNQEZKB-DZKIICNBSA-N 0.000 description 7
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 7
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 7
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 7
- YABRDIBSPZONIY-BQBZGAKWSA-N Gly-Ser-Met Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O YABRDIBSPZONIY-BQBZGAKWSA-N 0.000 description 7
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 7
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 7
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 7
- MTFVYKQRLXYAQN-LAEOZQHASA-N Ile-Glu-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O MTFVYKQRLXYAQN-LAEOZQHASA-N 0.000 description 7
- 241000880493 Leptailurus serval Species 0.000 description 7
- CZCSUZMIRKFFFA-CIUDSAMLSA-N Leu-Ala-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O CZCSUZMIRKFFFA-CIUDSAMLSA-N 0.000 description 7
- HBJZFCIVFIBNSV-DCAQKATOSA-N Leu-Arg-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O HBJZFCIVFIBNSV-DCAQKATOSA-N 0.000 description 7
- ZTLGVASZOIKNIX-DCAQKATOSA-N Leu-Gln-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZTLGVASZOIKNIX-DCAQKATOSA-N 0.000 description 7
- HVJVUYQWFYMGJS-GVXVVHGQSA-N Leu-Glu-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVJVUYQWFYMGJS-GVXVVHGQSA-N 0.000 description 7
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 7
- NDORZBUHCOJQDO-GVXVVHGQSA-N Lys-Gln-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O NDORZBUHCOJQDO-GVXVVHGQSA-N 0.000 description 7
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 7
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 7
- IMDJSVBFQKDDEQ-MGHWNKPDSA-N Lys-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)N IMDJSVBFQKDDEQ-MGHWNKPDSA-N 0.000 description 7
- UAPZLLPGGOOCRO-IHRRRGAJSA-N Met-Asn-Phe Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N UAPZLLPGGOOCRO-IHRRRGAJSA-N 0.000 description 7
- XDGFFEZAZHRZFR-RHYQMDGZSA-N Met-Leu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDGFFEZAZHRZFR-RHYQMDGZSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- WIVCOAKLPICYGY-KKUMJFAQSA-N Phe-Asp-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N WIVCOAKLPICYGY-KKUMJFAQSA-N 0.000 description 7
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 7
- XEXSSIBQYNKFBX-KBPBESRZSA-N Phe-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=CC=C1 XEXSSIBQYNKFBX-KBPBESRZSA-N 0.000 description 7
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 7
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 7
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 7
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 7
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 7
- WSTIOCFMWXNOCX-YUMQZZPRSA-N Ser-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N WSTIOCFMWXNOCX-YUMQZZPRSA-N 0.000 description 7
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 7
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 7
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 7
- FGBLCMLXHRPVOF-IHRRRGAJSA-N Ser-Tyr-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FGBLCMLXHRPVOF-IHRRRGAJSA-N 0.000 description 7
- 208000008548 Tension-Type Headache Diseases 0.000 description 7
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 7
- SLUWOCTZVGMURC-BFHQHQDPSA-N Thr-Gly-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O SLUWOCTZVGMURC-BFHQHQDPSA-N 0.000 description 7
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 7
- JVTHMUDOKPQBOT-NSHDSACASA-N Trp-Gly-Gly Chemical compound C1=CC=C2C(C[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O)=CNC2=C1 JVTHMUDOKPQBOT-NSHDSACASA-N 0.000 description 7
- FMOSEWZYZPMJAL-KKUMJFAQSA-N Tyr-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N FMOSEWZYZPMJAL-KKUMJFAQSA-N 0.000 description 7
- NKMFRGPKTIEXSK-ULQDDVLXSA-N Tyr-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N NKMFRGPKTIEXSK-ULQDDVLXSA-N 0.000 description 7
- COYSIHFOCOMGCF-WPRPVWTQSA-N Val-Arg-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N COYSIHFOCOMGCF-WPRPVWTQSA-N 0.000 description 7
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 7
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 7
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 7
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 7
- 108010070783 alanyltyrosine Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 7
- 108010077245 asparaginyl-proline Proteins 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 108010009297 diglycyl-histidine Proteins 0.000 description 7
- 230000004064 dysfunction Effects 0.000 description 7
- 229930186900 holotoxin Natural products 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 108010003700 lysyl aspartic acid Proteins 0.000 description 7
- 108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 description 7
- 108010083476 phenylalanyltryptophan Proteins 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000002356 skeleton Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 6
- SHYYAQLDNVHPFT-DLOVCJGASA-N Ala-Asn-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SHYYAQLDNVHPFT-DLOVCJGASA-N 0.000 description 6
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 6
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 6
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 6
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 6
- UDSVWSUXKYXSTR-QWRGUYRKSA-N Asn-Gly-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UDSVWSUXKYXSTR-QWRGUYRKSA-N 0.000 description 6
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 6
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 6
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 6
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 6
- 108010059378 Endopeptidases Proteins 0.000 description 6
- 102000005593 Endopeptidases Human genes 0.000 description 6
- BZULIEARJFRINC-IHRRRGAJSA-N Gln-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BZULIEARJFRINC-IHRRRGAJSA-N 0.000 description 6
- AQNYKMCFCCZEEL-JYJNAYRXSA-N Glu-Lys-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 AQNYKMCFCCZEEL-JYJNAYRXSA-N 0.000 description 6
- JDUKCSSHWNIQQZ-IHRRRGAJSA-N Glu-Phe-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JDUKCSSHWNIQQZ-IHRRRGAJSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- TVDHVLGFJSHPAX-UWVGGRQHSA-N Gly-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 TVDHVLGFJSHPAX-UWVGGRQHSA-N 0.000 description 6
- ULZCYBYDTUMHNF-IUCAKERBSA-N Gly-Leu-Glu Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ULZCYBYDTUMHNF-IUCAKERBSA-N 0.000 description 6
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 6
- FIMNVXRZGUAGBI-AVGNSLFASA-N His-Glu-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FIMNVXRZGUAGBI-AVGNSLFASA-N 0.000 description 6
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 6
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 6
- JLWLMGADIQFKRD-QSFUFRPTSA-N Ile-His-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CN=CN1 JLWLMGADIQFKRD-QSFUFRPTSA-N 0.000 description 6
- KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 6
- MDVZJYGNAGLPGJ-KKUMJFAQSA-N Leu-Asn-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MDVZJYGNAGLPGJ-KKUMJFAQSA-N 0.000 description 6
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 6
- AVEGDIAXTDVBJS-XUXIUFHCSA-N Leu-Ile-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AVEGDIAXTDVBJS-XUXIUFHCSA-N 0.000 description 6
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 6
- ZDJQVSIPFLMNOX-RHYQMDGZSA-N Leu-Thr-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N ZDJQVSIPFLMNOX-RHYQMDGZSA-N 0.000 description 6
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 6
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 6
- 208000000112 Myalgia Diseases 0.000 description 6
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 6
- 206010029216 Nervousness Diseases 0.000 description 6
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 6
- OQTDZEJJWWAGJT-KKUMJFAQSA-N Phe-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O OQTDZEJJWWAGJT-KKUMJFAQSA-N 0.000 description 6
- RGMLUHANLDVMPB-ULQDDVLXSA-N Phe-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N RGMLUHANLDVMPB-ULQDDVLXSA-N 0.000 description 6
- VPVHXWGPALPDGP-GUBZILKMSA-N Pro-Asn-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPVHXWGPALPDGP-GUBZILKMSA-N 0.000 description 6
- KYKKKSWGEPFUMR-NAKRPEOUSA-N Ser-Arg-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KYKKKSWGEPFUMR-NAKRPEOUSA-N 0.000 description 6
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 6
- IMDMLDSVUSMAEJ-HJGDQZAQSA-N Thr-Leu-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IMDMLDSVUSMAEJ-HJGDQZAQSA-N 0.000 description 6
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 6
- AYPAIRCDLARHLM-KKUMJFAQSA-N Tyr-Asn-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O AYPAIRCDLARHLM-KKUMJFAQSA-N 0.000 description 6
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 6
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 108010062796 arginyllysine Proteins 0.000 description 6
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 6
- 208000037976 chronic inflammation Diseases 0.000 description 6
- 230000006020 chronic inflammation Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 206010013023 diphtheria Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 6
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 6
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 6
- 108010023364 glycyl-histidyl-arginine Proteins 0.000 description 6
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 6
- 108010047926 leucyl-lysyl-tyrosine Proteins 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 235000019833 protease Nutrition 0.000 description 6
- 229960001052 streptozocin Drugs 0.000 description 6
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 231100000167 toxic agent Toxicity 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 210000000707 wrist Anatomy 0.000 description 6
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 5
- WKOBSJOZRJJVRZ-FXQIFTODSA-N Ala-Glu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WKOBSJOZRJJVRZ-FXQIFTODSA-N 0.000 description 5
- SOBIAADAMRHGKH-CIUDSAMLSA-N Ala-Leu-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SOBIAADAMRHGKH-CIUDSAMLSA-N 0.000 description 5
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 5
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 5
- VKCOHFFSTKCXEQ-OLHMAJIHSA-N Asn-Asn-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VKCOHFFSTKCXEQ-OLHMAJIHSA-N 0.000 description 5
- JRVABKHPWDRUJF-UBHSHLNASA-N Asn-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N JRVABKHPWDRUJF-UBHSHLNASA-N 0.000 description 5
- SEKBHZJLARBNPB-GHCJXIJMSA-N Asn-Ile-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O SEKBHZJLARBNPB-GHCJXIJMSA-N 0.000 description 5
- WXVGISRWSYGEDK-KKUMJFAQSA-N Asn-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N WXVGISRWSYGEDK-KKUMJFAQSA-N 0.000 description 5
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 5
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 5
- 241000193155 Clostridium botulinum Species 0.000 description 5
- 241000193449 Clostridium tetani Species 0.000 description 5
- 208000016192 Demyelinating disease Diseases 0.000 description 5
- 206010012305 Demyelination Diseases 0.000 description 5
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
- RUFHOVYUYSNDNY-ACZMJKKPSA-N Glu-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O RUFHOVYUYSNDNY-ACZMJKKPSA-N 0.000 description 5
- JZJGEKDPWVJOLD-QEWYBTABSA-N Glu-Phe-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JZJGEKDPWVJOLD-QEWYBTABSA-N 0.000 description 5
- FMVLWTYYODVFRG-BQBZGAKWSA-N Gly-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN FMVLWTYYODVFRG-BQBZGAKWSA-N 0.000 description 5
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 5
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- FJWYJQRCVNGEAQ-ZPFDUUQYSA-N Ile-Asn-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N FJWYJQRCVNGEAQ-ZPFDUUQYSA-N 0.000 description 5
- ZZHGKECPZXPXJF-PCBIJLKTSA-N Ile-Asn-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZZHGKECPZXPXJF-PCBIJLKTSA-N 0.000 description 5
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 5
- 206010065390 Inflammatory pain Diseases 0.000 description 5
- HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 5
- OXKYZSRZKBTVEY-ZPFDUUQYSA-N Leu-Asn-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O OXKYZSRZKBTVEY-ZPFDUUQYSA-N 0.000 description 5
- KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 description 5
- OIFHHODAXVWKJN-ULQDDVLXSA-N Met-Phe-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 OIFHHODAXVWKJN-ULQDDVLXSA-N 0.000 description 5
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 5
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 5
- SKGLAZSLOGYCCA-PEFXOJROSA-N Neuromedin N (1-4) Chemical compound CC[C@@H](C)[C@@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H]([C@H](C)CC)C(O)=O)CC1=CC=C(O)C=C1 SKGLAZSLOGYCCA-PEFXOJROSA-N 0.000 description 5
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 5
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 5
- 108010005730 R-SNARE Proteins Proteins 0.000 description 5
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 5
- DJACUBDEDBZKLQ-KBIXCLLPSA-N Ser-Ile-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O DJACUBDEDBZKLQ-KBIXCLLPSA-N 0.000 description 5
- PLQWGQUNUPMNOD-KKUMJFAQSA-N Ser-Tyr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O PLQWGQUNUPMNOD-KKUMJFAQSA-N 0.000 description 5
- 102000002215 Synaptobrevin Human genes 0.000 description 5
- 206010043269 Tension headache Diseases 0.000 description 5
- KRDSCBLRHORMRK-JXUBOQSCSA-N Thr-Lys-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O KRDSCBLRHORMRK-JXUBOQSCSA-N 0.000 description 5
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 5
- BYOHPUZJVXWHAE-BYULHYEWSA-N Val-Asn-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N BYOHPUZJVXWHAE-BYULHYEWSA-N 0.000 description 5
- PQSNETRGCRUOGP-KKHAAJSZSA-N Val-Thr-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O PQSNETRGCRUOGP-KKHAAJSZSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 108010038633 aspartylglutamate Proteins 0.000 description 5
- 230000007845 axonopathy Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000012412 chemical coupling Methods 0.000 description 5
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000010217 densitometric analysis Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 108010010147 glycylglutamine Proteins 0.000 description 5
- 108010015792 glycyllysine Proteins 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 108010038320 lysylphenylalanine Proteins 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 108010068488 methionylphenylalanine Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000008058 pain sensation Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000003625 skull Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 108010073969 valyllysine Proteins 0.000 description 5
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 4
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 4
- UZGFHWIJWPUPOH-IHRRRGAJSA-N Arg-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UZGFHWIJWPUPOH-IHRRRGAJSA-N 0.000 description 4
- KWQPAXYXVMHJJR-AVGNSLFASA-N Asn-Gln-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KWQPAXYXVMHJJR-AVGNSLFASA-N 0.000 description 4
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 4
- ATYWBXGNXZYZGI-ACZMJKKPSA-N Asp-Asn-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ATYWBXGNXZYZGI-ACZMJKKPSA-N 0.000 description 4
- SPKCGKRUYKMDHP-GUDRVLHUSA-N Asp-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N SPKCGKRUYKMDHP-GUDRVLHUSA-N 0.000 description 4
- UMHUHHJMEXNSIV-CIUDSAMLSA-N Asp-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(O)=O UMHUHHJMEXNSIV-CIUDSAMLSA-N 0.000 description 4
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 4
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 4
- 241000193171 Clostridium butyricum Species 0.000 description 4
- KCSDYJSCUWLILX-BJDJZHNGSA-N Cys-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CS)N KCSDYJSCUWLILX-BJDJZHNGSA-N 0.000 description 4
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 4
- JXBZEDIQFFCHPZ-PEFMBERDSA-N Gln-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N JXBZEDIQFFCHPZ-PEFMBERDSA-N 0.000 description 4
- YPMDZWPZFOZYFG-GUBZILKMSA-N Gln-Leu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YPMDZWPZFOZYFG-GUBZILKMSA-N 0.000 description 4
- LTUVYLVIZHJCOQ-KKUMJFAQSA-N Glu-Arg-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LTUVYLVIZHJCOQ-KKUMJFAQSA-N 0.000 description 4
- PVBBEKPHARMPHX-DCAQKATOSA-N Glu-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O PVBBEKPHARMPHX-DCAQKATOSA-N 0.000 description 4
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 4
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 4
- ZCOJVESMNGBGLF-GRLWGSQLSA-N Glu-Ile-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZCOJVESMNGBGLF-GRLWGSQLSA-N 0.000 description 4
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 4
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 4
- OFIHURVSQXAZIR-SZMVWBNQSA-N Glu-Lys-Trp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O OFIHURVSQXAZIR-SZMVWBNQSA-N 0.000 description 4
- DXVOKNVIKORTHQ-GUBZILKMSA-N Glu-Pro-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O DXVOKNVIKORTHQ-GUBZILKMSA-N 0.000 description 4
- SYAYROHMAIHWFB-KBIXCLLPSA-N Glu-Ser-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYAYROHMAIHWFB-KBIXCLLPSA-N 0.000 description 4
- QRWPTXLWHHTOCO-DZKIICNBSA-N Glu-Val-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QRWPTXLWHHTOCO-DZKIICNBSA-N 0.000 description 4
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 4
- QPDUVFSVVAOUHE-XVKPBYJWSA-N Gly-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(O)=O QPDUVFSVVAOUHE-XVKPBYJWSA-N 0.000 description 4
- FNXSYBOHALPRHV-ONGXEEELSA-N Gly-Val-Lys Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN FNXSYBOHALPRHV-ONGXEEELSA-N 0.000 description 4
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 4
- WZDCVAWMBUNDDY-KBIXCLLPSA-N Ile-Glu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)O)N WZDCVAWMBUNDDY-KBIXCLLPSA-N 0.000 description 4
- HPCFRQWLTRDGHT-AJNGGQMLSA-N Ile-Leu-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O HPCFRQWLTRDGHT-AJNGGQMLSA-N 0.000 description 4
- FGBRXCZYVRFNKQ-MXAVVETBSA-N Ile-Phe-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N FGBRXCZYVRFNKQ-MXAVVETBSA-N 0.000 description 4
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 4
- HJDZMPFEXINXLO-QPHKQPEJSA-N Ile-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N HJDZMPFEXINXLO-QPHKQPEJSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 4
- RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 4
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 4
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 4
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 4
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 4
- QLDHBYRUNQZIJQ-DKIMLUQUSA-N Leu-Ile-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QLDHBYRUNQZIJQ-DKIMLUQUSA-N 0.000 description 4
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 4
- ONPJGOIVICHWBW-BZSNNMDCSA-N Leu-Lys-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ONPJGOIVICHWBW-BZSNNMDCSA-N 0.000 description 4
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 4
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 4
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 4
- ABHIXYDMILIUKV-CIUDSAMLSA-N Lys-Asn-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ABHIXYDMILIUKV-CIUDSAMLSA-N 0.000 description 4
- HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 4
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 4
- QQPSCXKFDSORFT-IHRRRGAJSA-N Lys-Lys-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN QQPSCXKFDSORFT-IHRRRGAJSA-N 0.000 description 4
- VVURYEVJJTXWNE-ULQDDVLXSA-N Lys-Tyr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O VVURYEVJJTXWNE-ULQDDVLXSA-N 0.000 description 4
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 4
- HZLSUXCMSIBCRV-RVMXOQNASA-N Met-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N HZLSUXCMSIBCRV-RVMXOQNASA-N 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 description 4
- DZVXMMSUWWUIQE-ACRUOGEOSA-N Phe-His-Tyr Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)N DZVXMMSUWWUIQE-ACRUOGEOSA-N 0.000 description 4
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 4
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 4
- XWYXZPHPYKRYPA-GMOBBJLQSA-N Pro-Asn-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XWYXZPHPYKRYPA-GMOBBJLQSA-N 0.000 description 4
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 4
- 108010003201 RGH 0205 Proteins 0.000 description 4
- FCRMLGJMPXCAHD-FXQIFTODSA-N Ser-Arg-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O FCRMLGJMPXCAHD-FXQIFTODSA-N 0.000 description 4
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 4
- YBXMGKCLOPDEKA-NUMRIWBASA-N Thr-Asp-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YBXMGKCLOPDEKA-NUMRIWBASA-N 0.000 description 4
- GNHRVXYZKWSJTF-HJGDQZAQSA-N Thr-Asp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GNHRVXYZKWSJTF-HJGDQZAQSA-N 0.000 description 4
- GARULAKWZGFIKC-RWRJDSDZSA-N Thr-Gln-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GARULAKWZGFIKC-RWRJDSDZSA-N 0.000 description 4
- GMXIJHCBTZDAPD-QPHKQPEJSA-N Thr-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N GMXIJHCBTZDAPD-QPHKQPEJSA-N 0.000 description 4
- WPVGRKLNHJJCEN-BZSNNMDCSA-N Tyr-Asp-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WPVGRKLNHJJCEN-BZSNNMDCSA-N 0.000 description 4
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 4
- XFEMMSGONWQACR-KJEVXHAQSA-N Tyr-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O XFEMMSGONWQACR-KJEVXHAQSA-N 0.000 description 4
- LDKDSFQSEUOCOO-RPTUDFQQSA-N Tyr-Thr-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LDKDSFQSEUOCOO-RPTUDFQQSA-N 0.000 description 4
- NYTKXWLZSNRILS-IFFSRLJSSA-N Val-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N)O NYTKXWLZSNRILS-IFFSRLJSSA-N 0.000 description 4
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 4
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 108010047495 alanylglycine Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 108010077515 glycylproline Proteins 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 210000005012 myelin Anatomy 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108010031719 prolyl-serine Proteins 0.000 description 4
- 108010070643 prolylglutamic acid Proteins 0.000 description 4
- 108010053725 prolylvaline Proteins 0.000 description 4
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 4
- 201000009890 sinusitis Diseases 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- 229940118376 tetanus toxin Drugs 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 108010009962 valyltyrosine Proteins 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000014654 Adna Species 0.000 description 3
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 3
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 description 3
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 3
- OKIKVSXTXVVFDV-MMWGEVLESA-N Ala-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C)N OKIKVSXTXVVFDV-MMWGEVLESA-N 0.000 description 3
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- 102100034273 Annexin A7 Human genes 0.000 description 3
- 108010039940 Annexin A7 Proteins 0.000 description 3
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 3
- ULRPXVNMIIYDDJ-ACZMJKKPSA-N Asn-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N ULRPXVNMIIYDDJ-ACZMJKKPSA-N 0.000 description 3
- BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 description 3
- ANPFQTJEPONRPL-UGYAYLCHSA-N Asn-Ile-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O ANPFQTJEPONRPL-UGYAYLCHSA-N 0.000 description 3
- XVBDDUPJVQXDSI-PEFMBERDSA-N Asn-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N XVBDDUPJVQXDSI-PEFMBERDSA-N 0.000 description 3
- LSJQOMAZIKQMTJ-SRVKXCTJSA-N Asn-Phe-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LSJQOMAZIKQMTJ-SRVKXCTJSA-N 0.000 description 3
- ZNYKKCADEQAZKA-FXQIFTODSA-N Asn-Ser-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O ZNYKKCADEQAZKA-FXQIFTODSA-N 0.000 description 3
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 3
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 3
- HJCGDIGVVWETRO-ZPFDUUQYSA-N Asp-Lys-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O)C(O)=O HJCGDIGVVWETRO-ZPFDUUQYSA-N 0.000 description 3
- BYLPQJAWXJWUCJ-YDHLFZDLSA-N Asp-Tyr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O BYLPQJAWXJWUCJ-YDHLFZDLSA-N 0.000 description 3
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 3
- 206010009137 Chronic sinusitis Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 208000005577 Gastroenteritis Diseases 0.000 description 3
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 3
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 3
- UQKVUFGUSVYJMQ-IRIUXVKKSA-N Gln-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)N)N)O UQKVUFGUSVYJMQ-IRIUXVKKSA-N 0.000 description 3
- HPBKQFJXDUVNQV-FHWLQOOXSA-N Gln-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O HPBKQFJXDUVNQV-FHWLQOOXSA-N 0.000 description 3
- VDMABHYXBULDGN-LAEOZQHASA-N Gln-Val-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O VDMABHYXBULDGN-LAEOZQHASA-N 0.000 description 3
- MLCPTRRNICEKIS-FXQIFTODSA-N Glu-Asn-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MLCPTRRNICEKIS-FXQIFTODSA-N 0.000 description 3
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 3
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 3
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 3
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 3
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 3
- LXXANCRPFBSSKS-IUCAKERBSA-N Gly-Gln-Leu Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LXXANCRPFBSSKS-IUCAKERBSA-N 0.000 description 3
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 3
- MREVELMMFOLESM-HOCLYGCPSA-N Gly-Trp-Val Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(O)=O MREVELMMFOLESM-HOCLYGCPSA-N 0.000 description 3
- 206010065952 Hyperpathia Diseases 0.000 description 3
- LQSBBHNVAVNZSX-GHCJXIJMSA-N Ile-Ala-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N LQSBBHNVAVNZSX-GHCJXIJMSA-N 0.000 description 3
- HVWXAQVMRBKKFE-UGYAYLCHSA-N Ile-Asp-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N HVWXAQVMRBKKFE-UGYAYLCHSA-N 0.000 description 3
- IGJWJGIHUFQANP-LAEOZQHASA-N Ile-Gly-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N IGJWJGIHUFQANP-LAEOZQHASA-N 0.000 description 3
- XOZOSAUOGRPCES-STECZYCISA-N Ile-Pro-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XOZOSAUOGRPCES-STECZYCISA-N 0.000 description 3
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 3
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 3
- KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 3
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 3
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 3
- QJXHMYMRGDOHRU-NHCYSSNCSA-N Leu-Ile-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O QJXHMYMRGDOHRU-NHCYSSNCSA-N 0.000 description 3
- MJWVXZABPOKJJF-ACRUOGEOSA-N Leu-Phe-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MJWVXZABPOKJJF-ACRUOGEOSA-N 0.000 description 3
- ODRREERHVHMIPT-OEAJRASXSA-N Leu-Thr-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ODRREERHVHMIPT-OEAJRASXSA-N 0.000 description 3
- ALSRJRIWBNENFY-DCAQKATOSA-N Lys-Arg-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O ALSRJRIWBNENFY-DCAQKATOSA-N 0.000 description 3
- GJJQCBVRWDGLMQ-GUBZILKMSA-N Lys-Glu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O GJJQCBVRWDGLMQ-GUBZILKMSA-N 0.000 description 3
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 3
- PRSBSVAVOQOAMI-BJDJZHNGSA-N Lys-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN PRSBSVAVOQOAMI-BJDJZHNGSA-N 0.000 description 3
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 description 3
- KTINOHQFVVCEGQ-XIRDDKMYSA-N Lys-Trp-Asp Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(O)=O)C(O)=O KTINOHQFVVCEGQ-XIRDDKMYSA-N 0.000 description 3
- XYLSGAWRCZECIQ-JYJNAYRXSA-N Lys-Tyr-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 XYLSGAWRCZECIQ-JYJNAYRXSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- CAODKDAPYGUMLK-FXQIFTODSA-N Met-Asn-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CAODKDAPYGUMLK-FXQIFTODSA-N 0.000 description 3
- DJBCKVNHEIJLQA-GMOBBJLQSA-N Met-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCSC)N DJBCKVNHEIJLQA-GMOBBJLQSA-N 0.000 description 3
- YLBUMXYVQCHBPR-ULQDDVLXSA-N Met-Leu-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YLBUMXYVQCHBPR-ULQDDVLXSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- WMGVYPPIMZPWPN-SRVKXCTJSA-N Phe-Asp-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N WMGVYPPIMZPWPN-SRVKXCTJSA-N 0.000 description 3
- XNQMZHLAYFWSGJ-HTUGSXCWSA-N Phe-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XNQMZHLAYFWSGJ-HTUGSXCWSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- WVOXLKUUVCCCSU-ZPFDUUQYSA-N Pro-Glu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVOXLKUUVCCCSU-ZPFDUUQYSA-N 0.000 description 3
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 3
- GKMYGVQDGVYCPC-IUKAMOBKSA-N Thr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)N GKMYGVQDGVYCPC-IUKAMOBKSA-N 0.000 description 3
- RRRRCRYTLZVCEN-HJGDQZAQSA-N Thr-Leu-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O RRRRCRYTLZVCEN-HJGDQZAQSA-N 0.000 description 3
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 3
- WVVOFCVMHAXGLE-LFSVMHDDSA-N Thr-Phe-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(O)=O WVVOFCVMHAXGLE-LFSVMHDDSA-N 0.000 description 3
- KZURUCDWKDEAFZ-XVSYOHENSA-N Thr-Phe-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O KZURUCDWKDEAFZ-XVSYOHENSA-N 0.000 description 3
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 3
- LNGFWVPNKLWATF-ZVZYQTTQSA-N Trp-Val-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LNGFWVPNKLWATF-ZVZYQTTQSA-N 0.000 description 3
- FJKXUIJOMUWCDD-FHWLQOOXSA-N Tyr-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O FJKXUIJOMUWCDD-FHWLQOOXSA-N 0.000 description 3
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 3
- FTKXYXACXYOHND-XUXIUFHCSA-N Val-Ile-Leu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O FTKXYXACXYOHND-XUXIUFHCSA-N 0.000 description 3
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 3
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 3
- 208000001407 Vascular Headaches Diseases 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000000326 densiometry Methods 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 108010026333 seryl-proline Proteins 0.000 description 3
- 108010071207 serylmethionine Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229910052567 struvite Inorganic materials 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- RHMALYOXPBRJBG-CGUXNFSNSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[2-[[(2s,3r)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]- Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RHMALYOXPBRJBG-CGUXNFSNSA-N 0.000 description 2
- SKPQXOSVPKPXML-ULQDDVLXSA-N 2-[[(2s)-1-[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NCCC1)CC1=CC=CC=C1 SKPQXOSVPKPXML-ULQDDVLXSA-N 0.000 description 2
- 206010049714 Abdominal migraine Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- XCVRVWZTXPCYJT-BIIVOSGPSA-N Ala-Asn-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N XCVRVWZTXPCYJT-BIIVOSGPSA-N 0.000 description 2
- CFPQUJZTLUQUTJ-HTFCKZLJSA-N Ala-Ile-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)N CFPQUJZTLUQUTJ-HTFCKZLJSA-N 0.000 description 2
- HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 2
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 2
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 2
- XQNRANMFRPCFFW-GCJQMDKQSA-N Ala-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C)N)O XQNRANMFRPCFFW-GCJQMDKQSA-N 0.000 description 2
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- JUWQNWXEGDYCIE-YUMQZZPRSA-N Arg-Gln-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O JUWQNWXEGDYCIE-YUMQZZPRSA-N 0.000 description 2
- NYZGVTGOMPHSJW-CIUDSAMLSA-N Arg-Glu-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N NYZGVTGOMPHSJW-CIUDSAMLSA-N 0.000 description 2
- FRMQITGHXMUNDF-GMOBBJLQSA-N Arg-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N FRMQITGHXMUNDF-GMOBBJLQSA-N 0.000 description 2
- HJDNZFIYILEIKR-OSUNSFLBSA-N Arg-Ile-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HJDNZFIYILEIKR-OSUNSFLBSA-N 0.000 description 2
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 2
- PAPSMOYMQDWIOR-AVGNSLFASA-N Arg-Lys-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PAPSMOYMQDWIOR-AVGNSLFASA-N 0.000 description 2
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 2
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 2
- IOTKDTZEEBZNCM-UGYAYLCHSA-N Asn-Asn-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOTKDTZEEBZNCM-UGYAYLCHSA-N 0.000 description 2
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 2
- JREOBWLIZLXRIS-GUBZILKMSA-N Asn-Glu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JREOBWLIZLXRIS-GUBZILKMSA-N 0.000 description 2
- UBKOVSLDWIHYSY-ACZMJKKPSA-N Asn-Glu-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O UBKOVSLDWIHYSY-ACZMJKKPSA-N 0.000 description 2
- JQSWHKKUZMTOIH-QWRGUYRKSA-N Asn-Gly-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N JQSWHKKUZMTOIH-QWRGUYRKSA-N 0.000 description 2
- PTSDPWIHOYMRGR-UGYAYLCHSA-N Asn-Ile-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O PTSDPWIHOYMRGR-UGYAYLCHSA-N 0.000 description 2
- LTZIRYMWOJHRCH-GUDRVLHUSA-N Asn-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N LTZIRYMWOJHRCH-GUDRVLHUSA-N 0.000 description 2
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 2
- BZWRLDPIWKOVKB-ZPFDUUQYSA-N Asn-Leu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BZWRLDPIWKOVKB-ZPFDUUQYSA-N 0.000 description 2
- TZFQICWZWFNIKU-KKUMJFAQSA-N Asn-Leu-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 TZFQICWZWFNIKU-KKUMJFAQSA-N 0.000 description 2
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 2
- AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 2
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 2
- PIABYSIYPGLLDQ-XVSYOHENSA-N Asn-Thr-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PIABYSIYPGLLDQ-XVSYOHENSA-N 0.000 description 2
- DPWDPEVGACCWTC-SRVKXCTJSA-N Asn-Tyr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O DPWDPEVGACCWTC-SRVKXCTJSA-N 0.000 description 2
- LTDGPJKGJDIBQD-LAEOZQHASA-N Asn-Val-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O LTDGPJKGJDIBQD-LAEOZQHASA-N 0.000 description 2
- LMIWYCWRJVMAIQ-NHCYSSNCSA-N Asn-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N LMIWYCWRJVMAIQ-NHCYSSNCSA-N 0.000 description 2
- IXIWEFWRKIUMQX-DCAQKATOSA-N Asp-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O IXIWEFWRKIUMQX-DCAQKATOSA-N 0.000 description 2
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 2
- CASGONAXMZPHCK-FXQIFTODSA-N Asp-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N CASGONAXMZPHCK-FXQIFTODSA-N 0.000 description 2
- ZELQAFZSJOBEQS-ACZMJKKPSA-N Asp-Asn-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZELQAFZSJOBEQS-ACZMJKKPSA-N 0.000 description 2
- KNMRXHIAVXHCLW-ZLUOBGJFSA-N Asp-Asn-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)C(=O)O KNMRXHIAVXHCLW-ZLUOBGJFSA-N 0.000 description 2
- KIJLEFNHWSXHRU-NUMRIWBASA-N Asp-Gln-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KIJLEFNHWSXHRU-NUMRIWBASA-N 0.000 description 2
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 2
- CYCKJEFVFNRWEZ-UGYAYLCHSA-N Asp-Ile-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CYCKJEFVFNRWEZ-UGYAYLCHSA-N 0.000 description 2
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 2
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 2
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 2
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- 108091028026 C-DNA Proteins 0.000 description 2
- 102100038518 Calcitonin Human genes 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 241000186542 Clostridium baratii Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
- 101800005209 Deltorphin Proteins 0.000 description 2
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010049119 Emotional distress Diseases 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 2
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 description 2
- MFLMFRZBAJSGHK-ACZMJKKPSA-N Gln-Cys-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N MFLMFRZBAJSGHK-ACZMJKKPSA-N 0.000 description 2
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 2
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 2
- ZWABFSSWTSAMQN-KBIXCLLPSA-N Glu-Ile-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O ZWABFSSWTSAMQN-KBIXCLLPSA-N 0.000 description 2
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 2
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 2
- IOUQWHIEQYQVFD-JYJNAYRXSA-N Glu-Leu-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IOUQWHIEQYQVFD-JYJNAYRXSA-N 0.000 description 2
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 2
- SWRVAQHFBRZVNX-GUBZILKMSA-N Glu-Lys-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O SWRVAQHFBRZVNX-GUBZILKMSA-N 0.000 description 2
- FGGKGJHCVMYGCD-UKJIMTQDSA-N Glu-Val-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGGKGJHCVMYGCD-UKJIMTQDSA-N 0.000 description 2
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 2
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 2
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 2
- MZZSCEANQDPJER-ONGXEEELSA-N Gly-Ala-Phe Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MZZSCEANQDPJER-ONGXEEELSA-N 0.000 description 2
- BGVYNAQWHSTTSP-BYULHYEWSA-N Gly-Asn-Ile Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BGVYNAQWHSTTSP-BYULHYEWSA-N 0.000 description 2
- HDNXXTBKOJKWNN-WDSKDSINSA-N Gly-Glu-Asn Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O HDNXXTBKOJKWNN-WDSKDSINSA-N 0.000 description 2
- CUYLIWAAAYJKJH-RYUDHWBXSA-N Gly-Glu-Tyr Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CUYLIWAAAYJKJH-RYUDHWBXSA-N 0.000 description 2
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 2
- IGOYNRWLWHWAQO-JTQLQIEISA-N Gly-Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 IGOYNRWLWHWAQO-JTQLQIEISA-N 0.000 description 2
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 2
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 2
- FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 2
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 2
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 2
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- MBSSHYPAEHPSGY-LSJOCFKGSA-N His-Ala-Met Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O MBSSHYPAEHPSGY-LSJOCFKGSA-N 0.000 description 2
- CHZRWFUGWRTUOD-IUCAKERBSA-N His-Gly-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N CHZRWFUGWRTUOD-IUCAKERBSA-N 0.000 description 2
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 description 2
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 2
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 2
- SCHZQZPYHBWYEQ-PEFMBERDSA-N Ile-Asn-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SCHZQZPYHBWYEQ-PEFMBERDSA-N 0.000 description 2
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 2
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 2
- NPROWIBAWYMPAZ-GUDRVLHUSA-N Ile-Asp-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N NPROWIBAWYMPAZ-GUDRVLHUSA-N 0.000 description 2
- LJKDGRWXYUTRSH-YVNDNENWSA-N Ile-Gln-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N LJKDGRWXYUTRSH-YVNDNENWSA-N 0.000 description 2
- JDAWAWXGAUZPNJ-ZPFDUUQYSA-N Ile-Glu-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N JDAWAWXGAUZPNJ-ZPFDUUQYSA-N 0.000 description 2
- LPFBXFILACZHIB-LAEOZQHASA-N Ile-Gly-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)N LPFBXFILACZHIB-LAEOZQHASA-N 0.000 description 2
- UWLHDGMRWXHFFY-HPCHECBXSA-N Ile-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@@H]1C(=O)O)N UWLHDGMRWXHFFY-HPCHECBXSA-N 0.000 description 2
- OUUCIIJSBIBCHB-ZPFDUUQYSA-N Ile-Leu-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O OUUCIIJSBIBCHB-ZPFDUUQYSA-N 0.000 description 2
- GAZGFPOZOLEYAJ-YTFOTSKYSA-N Ile-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N GAZGFPOZOLEYAJ-YTFOTSKYSA-N 0.000 description 2
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 2
- PWUMCBLVWPCKNO-MGHWNKPDSA-N Ile-Leu-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PWUMCBLVWPCKNO-MGHWNKPDSA-N 0.000 description 2
- UDBPXJNOEWDBDF-XUXIUFHCSA-N Ile-Lys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)O)N UDBPXJNOEWDBDF-XUXIUFHCSA-N 0.000 description 2
- VZSDQFZFTCVEGF-ZEWNOJEFSA-N Ile-Phe-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O VZSDQFZFTCVEGF-ZEWNOJEFSA-N 0.000 description 2
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 2
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 2
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 2
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 2
- GVEODXUBBFDBPW-MGHWNKPDSA-N Ile-Tyr-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 GVEODXUBBFDBPW-MGHWNKPDSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 2
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 2
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 2
- QLQHWWCSCLZUMA-KKUMJFAQSA-N Leu-Asp-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QLQHWWCSCLZUMA-KKUMJFAQSA-N 0.000 description 2
- QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 2
- DXYBNWJZJVSZAE-GUBZILKMSA-N Leu-Gln-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N DXYBNWJZJVSZAE-GUBZILKMSA-N 0.000 description 2
- LLBQJYDYOLIQAI-JYJNAYRXSA-N Leu-Glu-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LLBQJYDYOLIQAI-JYJNAYRXSA-N 0.000 description 2
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 2
- ZRHDPZAAWLXXIR-SRVKXCTJSA-N Leu-Lys-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O ZRHDPZAAWLXXIR-SRVKXCTJSA-N 0.000 description 2
- RZXLZBIUTDQHJQ-SRVKXCTJSA-N Leu-Lys-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O RZXLZBIUTDQHJQ-SRVKXCTJSA-N 0.000 description 2
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 2
- WXDRGWBQZIMJDE-ULQDDVLXSA-N Leu-Phe-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O WXDRGWBQZIMJDE-ULQDDVLXSA-N 0.000 description 2
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 2
- MVHXGBZUJLWZOH-BJDJZHNGSA-N Leu-Ser-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MVHXGBZUJLWZOH-BJDJZHNGSA-N 0.000 description 2
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 2
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 2
- DGWXCIORNLWGGG-CIUDSAMLSA-N Lys-Asn-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O DGWXCIORNLWGGG-CIUDSAMLSA-N 0.000 description 2
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 2
- KWUKZRFFKPLUPE-HJGDQZAQSA-N Lys-Asp-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWUKZRFFKPLUPE-HJGDQZAQSA-N 0.000 description 2
- QQUJSUFWEDZQQY-AVGNSLFASA-N Lys-Gln-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN QQUJSUFWEDZQQY-AVGNSLFASA-N 0.000 description 2
- XREQQOATSMMAJP-MGHWNKPDSA-N Lys-Ile-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XREQQOATSMMAJP-MGHWNKPDSA-N 0.000 description 2
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 2
- JPYPRVHMKRFTAT-KKUMJFAQSA-N Lys-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N JPYPRVHMKRFTAT-KKUMJFAQSA-N 0.000 description 2
- LMGNWHDWJDIOPK-DKIMLUQUSA-N Lys-Phe-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LMGNWHDWJDIOPK-DKIMLUQUSA-N 0.000 description 2
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 2
- DNWBUCHHMRQWCZ-GUBZILKMSA-N Lys-Ser-Gln Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DNWBUCHHMRQWCZ-GUBZILKMSA-N 0.000 description 2
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 2
- ZVZRQKJOQQAFCF-ULQDDVLXSA-N Lys-Tyr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZVZRQKJOQQAFCF-ULQDDVLXSA-N 0.000 description 2
- PPNCMJARTHYNEC-MEYUZBJRSA-N Lys-Tyr-Thr Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 PPNCMJARTHYNEC-MEYUZBJRSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- DNDVVILEHVMWIS-LPEHRKFASA-N Met-Asp-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DNDVVILEHVMWIS-LPEHRKFASA-N 0.000 description 2
- SJLPOVNXMJFKHJ-ULQDDVLXSA-N Met-Phe-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N SJLPOVNXMJFKHJ-ULQDDVLXSA-N 0.000 description 2
- MPCKIRSXNKACRF-GUBZILKMSA-N Met-Pro-Asn Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O MPCKIRSXNKACRF-GUBZILKMSA-N 0.000 description 2
- YFGBQHOOROIVKG-FKBYEOEOSA-N Met-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-FKBYEOEOSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 206010029174 Nerve compression Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010033474 Pain of skin Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- HTTYNOXBBOWZTB-SRVKXCTJSA-N Phe-Asn-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HTTYNOXBBOWZTB-SRVKXCTJSA-N 0.000 description 2
- KAGCQPSEVAETCA-JYJNAYRXSA-N Phe-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N KAGCQPSEVAETCA-JYJNAYRXSA-N 0.000 description 2
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 2
- KBVJZCVLQWCJQN-KKUMJFAQSA-N Phe-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KBVJZCVLQWCJQN-KKUMJFAQSA-N 0.000 description 2
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 2
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 2
- ACJULKNZOCRWEI-ULQDDVLXSA-N Phe-Met-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O ACJULKNZOCRWEI-ULQDDVLXSA-N 0.000 description 2
- SRILZRSXIKRGBF-HRCADAONSA-N Phe-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N SRILZRSXIKRGBF-HRCADAONSA-N 0.000 description 2
- GPLWGAYGROGDEN-BZSNNMDCSA-N Phe-Phe-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O GPLWGAYGROGDEN-BZSNNMDCSA-N 0.000 description 2
- IPFXYNKCXYGSSV-KKUMJFAQSA-N Phe-Ser-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N IPFXYNKCXYGSSV-KKUMJFAQSA-N 0.000 description 2
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 2
- 241000097929 Porphyria Species 0.000 description 2
- 208000010642 Porphyrias Diseases 0.000 description 2
- KIPIKSXPPLABPN-CIUDSAMLSA-N Pro-Glu-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1 KIPIKSXPPLABPN-CIUDSAMLSA-N 0.000 description 2
- WOIFYRZPIORBRY-AVGNSLFASA-N Pro-Lys-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O WOIFYRZPIORBRY-AVGNSLFASA-N 0.000 description 2
- VGVCNKSUVSZEIE-IHRRRGAJSA-N Pro-Phe-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O VGVCNKSUVSZEIE-IHRRRGAJSA-N 0.000 description 2
- MHBSUKYVBZVQRW-HJWJTTGWSA-N Pro-Phe-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MHBSUKYVBZVQRW-HJWJTTGWSA-N 0.000 description 2
- JLMZKEQFMVORMA-SRVKXCTJSA-N Pro-Pro-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 JLMZKEQFMVORMA-SRVKXCTJSA-N 0.000 description 2
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 2
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 2
- OOZJHTXCLJUODH-QXEWZRGKSA-N Pro-Val-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 OOZJHTXCLJUODH-QXEWZRGKSA-N 0.000 description 2
- 102000011195 Profilin Human genes 0.000 description 2
- 108050001408 Profilin Proteins 0.000 description 2
- 102000002020 Protease-activated receptors Human genes 0.000 description 2
- 108050009310 Protease-activated receptors Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 2
- DKKGAAJTDKHWOD-BIIVOSGPSA-N Ser-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)C(=O)O DKKGAAJTDKHWOD-BIIVOSGPSA-N 0.000 description 2
- TYYBJUYSTWJHGO-ZKWXMUAHSA-N Ser-Asn-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TYYBJUYSTWJHGO-ZKWXMUAHSA-N 0.000 description 2
- BYIROAKULFFTEK-CIUDSAMLSA-N Ser-Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO BYIROAKULFFTEK-CIUDSAMLSA-N 0.000 description 2
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 2
- HEQPKICPPDOSIN-SRVKXCTJSA-N Ser-Asp-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HEQPKICPPDOSIN-SRVKXCTJSA-N 0.000 description 2
- VDVYTKZBMFADQH-AVGNSLFASA-N Ser-Gln-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VDVYTKZBMFADQH-AVGNSLFASA-N 0.000 description 2
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 2
- DSGYZICNAMEJOC-AVGNSLFASA-N Ser-Glu-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DSGYZICNAMEJOC-AVGNSLFASA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 2
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 2
- QJKPECIAWNNKIT-KKUMJFAQSA-N Ser-Lys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QJKPECIAWNNKIT-KKUMJFAQSA-N 0.000 description 2
- NUEHQDHDLDXCRU-GUBZILKMSA-N Ser-Pro-Arg Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O NUEHQDHDLDXCRU-GUBZILKMSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 2
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 2
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- DFTCYYILCSQGIZ-GCJQMDKQSA-N Thr-Ala-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFTCYYILCSQGIZ-GCJQMDKQSA-N 0.000 description 2
- CTONFVDJYCAMQM-IUKAMOBKSA-N Thr-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)N CTONFVDJYCAMQM-IUKAMOBKSA-N 0.000 description 2
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 2
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 2
- CRZNCABIJLRFKZ-IUKAMOBKSA-N Thr-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N CRZNCABIJLRFKZ-IUKAMOBKSA-N 0.000 description 2
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 2
- YGCDFAJJCRVQKU-RCWTZXSCSA-N Thr-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O YGCDFAJJCRVQKU-RCWTZXSCSA-N 0.000 description 2
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 2
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 2
- QGVBFDIREUUSHX-IFFSRLJSSA-N Thr-Val-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O QGVBFDIREUUSHX-IFFSRLJSSA-N 0.000 description 2
- KRCPXGSWDOGHAM-XIRDDKMYSA-N Trp-Lys-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O KRCPXGSWDOGHAM-XIRDDKMYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 2
- DANHCMVVXDXOHN-SRVKXCTJSA-N Tyr-Asp-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DANHCMVVXDXOHN-SRVKXCTJSA-N 0.000 description 2
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 2
- QHEGAOPHISYNDF-XDTLVQLUSA-N Tyr-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QHEGAOPHISYNDF-XDTLVQLUSA-N 0.000 description 2
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 2
- YMUQBRQQCPQEQN-CXTHYWKRSA-N Tyr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N YMUQBRQQCPQEQN-CXTHYWKRSA-N 0.000 description 2
- CNNVVEPJTFOGHI-ACRUOGEOSA-N Tyr-Lys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CNNVVEPJTFOGHI-ACRUOGEOSA-N 0.000 description 2
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 description 2
- LRHBBGDMBLFYGL-FHWLQOOXSA-N Tyr-Phe-Glu Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LRHBBGDMBLFYGL-FHWLQOOXSA-N 0.000 description 2
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 2
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 2
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
- QPZMOUMNTGTEFR-ZKWXMUAHSA-N Val-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N QPZMOUMNTGTEFR-ZKWXMUAHSA-N 0.000 description 2
- UDLYXGYWTVOIKU-QXEWZRGKSA-N Val-Asn-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UDLYXGYWTVOIKU-QXEWZRGKSA-N 0.000 description 2
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 2
- HHSILIQTHXABKM-YDHLFZDLSA-N Val-Asp-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(O)=O HHSILIQTHXABKM-YDHLFZDLSA-N 0.000 description 2
- COSLEEOIYRPTHD-YDHLFZDLSA-N Val-Asp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 COSLEEOIYRPTHD-YDHLFZDLSA-N 0.000 description 2
- JZWZACGUZVCQPS-RNJOBUHISA-N Val-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N JZWZACGUZVCQPS-RNJOBUHISA-N 0.000 description 2
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 2
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 description 2
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 2
- VTIAEOKFUJJBTC-YDHLFZDLSA-N Val-Tyr-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VTIAEOKFUJJBTC-YDHLFZDLSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 108010010430 asparagine-proline-alanine Proteins 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000009172 bursting Effects 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 108010060455 des-Tyr- beta-casomorphin Proteins 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 208000019479 dysautonomia Diseases 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 2
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000017730 intein-mediated protein splicing Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 2
- 108010000761 leucylarginine Proteins 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 108010005942 methionylglycine Proteins 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 208000019382 nerve compression syndrome Diseases 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 108091008700 nociceptors Proteins 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 108010018625 phenylalanylarginine Proteins 0.000 description 2
- 208000018290 primary dysautonomia Diseases 0.000 description 2
- 108010015796 prolylisoleucine Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 108010064884 trkA Receptor Proteins 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 108010029599 tyrosyl-glutamyl-tryptophan Proteins 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 108010027345 wheylin-1 peptide Proteins 0.000 description 2
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- YXXURDJTDAAEPH-UHFFFAOYSA-N 2-aminopropanethioic s-acid Chemical compound CC(N)C(S)=O YXXURDJTDAAEPH-UHFFFAOYSA-N 0.000 description 1
- VULLMZOQBGUKAT-VUXBHJHDSA-N 236098-40-1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 VULLMZOQBGUKAT-VUXBHJHDSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- AAQGRPOPTAUUBM-ZLUOBGJFSA-N Ala-Ala-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O AAQGRPOPTAUUBM-ZLUOBGJFSA-N 0.000 description 1
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 1
- VBDMWOKJZDCFJM-FXQIFTODSA-N Ala-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N VBDMWOKJZDCFJM-FXQIFTODSA-N 0.000 description 1
- GFBLJMHGHAXGNY-ZLUOBGJFSA-N Ala-Asn-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GFBLJMHGHAXGNY-ZLUOBGJFSA-N 0.000 description 1
- OMFMCIVBKCEMAK-CYDGBPFRSA-N Ala-Leu-Val-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O OMFMCIVBKCEMAK-CYDGBPFRSA-N 0.000 description 1
- PIXQDIGKDNNOOV-GUBZILKMSA-N Ala-Lys-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O PIXQDIGKDNNOOV-GUBZILKMSA-N 0.000 description 1
- XHNLCGXYBXNRIS-BJDJZHNGSA-N Ala-Lys-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XHNLCGXYBXNRIS-BJDJZHNGSA-N 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- IHRGVZXPTIQNIP-NAKRPEOUSA-N Ala-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)N IHRGVZXPTIQNIP-NAKRPEOUSA-N 0.000 description 1
- DGLQWAFPIXDKRL-UBHSHLNASA-N Ala-Met-Phe Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N DGLQWAFPIXDKRL-UBHSHLNASA-N 0.000 description 1
- XRUJOVRWNMBAAA-NHCYSSNCSA-N Ala-Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 XRUJOVRWNMBAAA-NHCYSSNCSA-N 0.000 description 1
- OSRZOHXQCUFIQG-FPMFFAJLSA-N Ala-Phe-Pro Chemical compound C([C@H](NC(=O)[C@@H]([NH3+])C)C(=O)N1[C@H](CCC1)C([O-])=O)C1=CC=CC=C1 OSRZOHXQCUFIQG-FPMFFAJLSA-N 0.000 description 1
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 1
- XAXMJQUMRJAFCH-CQDKDKBSSA-N Ala-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 XAXMJQUMRJAFCH-CQDKDKBSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 1
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 1
- MAISCYVJLBBRNU-DCAQKATOSA-N Arg-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N MAISCYVJLBBRNU-DCAQKATOSA-N 0.000 description 1
- PNIGSVZJNVUVJA-BQBZGAKWSA-N Arg-Gly-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O PNIGSVZJNVUVJA-BQBZGAKWSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 1
- UBCPNBUIQNMDNH-NAKRPEOUSA-N Arg-Ile-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O UBCPNBUIQNMDNH-NAKRPEOUSA-N 0.000 description 1
- LKDHUGLXOHYINY-XUXIUFHCSA-N Arg-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LKDHUGLXOHYINY-XUXIUFHCSA-N 0.000 description 1
- FNXCAFKDGBROCU-STECZYCISA-N Arg-Ile-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FNXCAFKDGBROCU-STECZYCISA-N 0.000 description 1
- SSZGOKWBHLOCHK-DCAQKATOSA-N Arg-Lys-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N SSZGOKWBHLOCHK-DCAQKATOSA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N Arg-Lys-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- QBQVKUNBCAFXSV-ULQDDVLXSA-N Arg-Lys-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QBQVKUNBCAFXSV-ULQDDVLXSA-N 0.000 description 1
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 1
- ISJWBVIYRBAXEB-CIUDSAMLSA-N Arg-Ser-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISJWBVIYRBAXEB-CIUDSAMLSA-N 0.000 description 1
- URAUIUGLHBRPMF-NAKRPEOUSA-N Arg-Ser-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O URAUIUGLHBRPMF-NAKRPEOUSA-N 0.000 description 1
- LYJXHXGPWDTLKW-HJGDQZAQSA-N Arg-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O LYJXHXGPWDTLKW-HJGDQZAQSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- CMLGVVWQQHUXOZ-GHCJXIJMSA-N Asn-Ala-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CMLGVVWQQHUXOZ-GHCJXIJMSA-N 0.000 description 1
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- ZPMNECSEJXXNBE-CIUDSAMLSA-N Asn-Cys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ZPMNECSEJXXNBE-CIUDSAMLSA-N 0.000 description 1
- QGNXYDHVERJIAY-ACZMJKKPSA-N Asn-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGNXYDHVERJIAY-ACZMJKKPSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- NVWJMQNYLYWVNQ-BYULHYEWSA-N Asn-Ile-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O NVWJMQNYLYWVNQ-BYULHYEWSA-N 0.000 description 1
- YYSYDIYQTUPNQQ-SXTJYALSSA-N Asn-Ile-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YYSYDIYQTUPNQQ-SXTJYALSSA-N 0.000 description 1
- GQRDIVQPSMPQME-ZPFDUUQYSA-N Asn-Ile-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O GQRDIVQPSMPQME-ZPFDUUQYSA-N 0.000 description 1
- ACKNRKFVYUVWAC-ZPFDUUQYSA-N Asn-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N ACKNRKFVYUVWAC-ZPFDUUQYSA-N 0.000 description 1
- FHETWELNCBMRMG-HJGDQZAQSA-N Asn-Leu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FHETWELNCBMRMG-HJGDQZAQSA-N 0.000 description 1
- NYGILGUOUOXGMJ-YUMQZZPRSA-N Asn-Lys-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O NYGILGUOUOXGMJ-YUMQZZPRSA-N 0.000 description 1
- NLDNNZKUSLAYFW-NHCYSSNCSA-N Asn-Lys-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLDNNZKUSLAYFW-NHCYSSNCSA-N 0.000 description 1
- RTFWCVDISAMGEQ-SRVKXCTJSA-N Asn-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N RTFWCVDISAMGEQ-SRVKXCTJSA-N 0.000 description 1
- UYCPJVYQYARFGB-YDHLFZDLSA-N Asn-Phe-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UYCPJVYQYARFGB-YDHLFZDLSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- VLDRQOHCMKCXLY-SRVKXCTJSA-N Asn-Ser-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VLDRQOHCMKCXLY-SRVKXCTJSA-N 0.000 description 1
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- PUUPMDXIHCOPJU-HJGDQZAQSA-N Asn-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O PUUPMDXIHCOPJU-HJGDQZAQSA-N 0.000 description 1
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 1
- BIGRHVNFFJTHEB-UBHSHLNASA-N Asn-Trp-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(O)=O)C(O)=O BIGRHVNFFJTHEB-UBHSHLNASA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- KSZHWTRZPOTIGY-AVGNSLFASA-N Asn-Tyr-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O KSZHWTRZPOTIGY-AVGNSLFASA-N 0.000 description 1
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 1
- NJIKKGUVGUBICV-ZLUOBGJFSA-N Asp-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O NJIKKGUVGUBICV-ZLUOBGJFSA-N 0.000 description 1
- QHAJMRDEWNAIBQ-FXQIFTODSA-N Asp-Arg-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O QHAJMRDEWNAIBQ-FXQIFTODSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- MUWDILPCTSMUHI-ZLUOBGJFSA-N Asp-Asn-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)C(=O)O MUWDILPCTSMUHI-ZLUOBGJFSA-N 0.000 description 1
- HOQGTAIGQSDCHR-SRVKXCTJSA-N Asp-Asn-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HOQGTAIGQSDCHR-SRVKXCTJSA-N 0.000 description 1
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 1
- KLYPOCBLKMPBIQ-GHCJXIJMSA-N Asp-Ile-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N KLYPOCBLKMPBIQ-GHCJXIJMSA-N 0.000 description 1
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
- DWOGMPWRQQWPPF-GUBZILKMSA-N Asp-Leu-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O DWOGMPWRQQWPPF-GUBZILKMSA-N 0.000 description 1
- GKWFMNNNYZHJHV-SRVKXCTJSA-N Asp-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC(O)=O GKWFMNNNYZHJHV-SRVKXCTJSA-N 0.000 description 1
- GPPIDDWYKJPRES-YDHLFZDLSA-N Asp-Phe-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GPPIDDWYKJPRES-YDHLFZDLSA-N 0.000 description 1
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- GXHDGYOXPNQCKM-XVSYOHENSA-N Asp-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O GXHDGYOXPNQCKM-XVSYOHENSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 description 1
- 101710117515 Botulinum neurotoxin type E Proteins 0.000 description 1
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010071380 Chronic hyperplastic eosinophilic sinusitis Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241001147768 Clostridium argentinense Species 0.000 description 1
- 101000933563 Clostridium botulinum Botulinum neurotoxin type G Proteins 0.000 description 1
- 101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 description 1
- 101000985020 Clostridium botulinum D phage Botulinum neurotoxin type D Proteins 0.000 description 1
- 241001147706 Clostridium sardiniense Species 0.000 description 1
- 241000193464 Clostridium sp. Species 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000032106 Complicated migraine Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- DGQJGBDBFVGLGL-ZKWXMUAHSA-N Cys-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CS)N DGQJGBDBFVGLGL-ZKWXMUAHSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000011392 Galanin receptor Human genes 0.000 description 1
- 108050001605 Galanin receptor Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- GMGKDVVBSVVKCT-NUMRIWBASA-N Gln-Asn-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GMGKDVVBSVVKCT-NUMRIWBASA-N 0.000 description 1
- PCKOTDPDHIBGRW-CIUDSAMLSA-N Gln-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)N)N)CN=C(N)N PCKOTDPDHIBGRW-CIUDSAMLSA-N 0.000 description 1
- BLOXULLYFRGYKZ-GUBZILKMSA-N Gln-Glu-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BLOXULLYFRGYKZ-GUBZILKMSA-N 0.000 description 1
- FKXCBKCOSVIGCT-AVGNSLFASA-N Gln-Lys-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FKXCBKCOSVIGCT-AVGNSLFASA-N 0.000 description 1
- GQTNWYFWSUFFRA-KKUMJFAQSA-N Gln-Met-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GQTNWYFWSUFFRA-KKUMJFAQSA-N 0.000 description 1
- UEILCTONAMOGBR-RWRJDSDZSA-N Gln-Thr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UEILCTONAMOGBR-RWRJDSDZSA-N 0.000 description 1
- ARYKRXHBIPLULY-XKBZYTNZSA-N Gln-Thr-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ARYKRXHBIPLULY-XKBZYTNZSA-N 0.000 description 1
- SDSMVVSHLAAOJL-UKJIMTQDSA-N Gln-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N SDSMVVSHLAAOJL-UKJIMTQDSA-N 0.000 description 1
- ZMXZGYLINVNTKH-DZKIICNBSA-N Gln-Val-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZMXZGYLINVNTKH-DZKIICNBSA-N 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- HUWSBFYAGXCXKC-CIUDSAMLSA-N Glu-Ala-Met Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O HUWSBFYAGXCXKC-CIUDSAMLSA-N 0.000 description 1
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- CVPXINNKRTZBMO-CIUDSAMLSA-N Glu-Arg-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)CN=C(N)N CVPXINNKRTZBMO-CIUDSAMLSA-N 0.000 description 1
- GFLQTABMFBXRIY-GUBZILKMSA-N Glu-Gln-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GFLQTABMFBXRIY-GUBZILKMSA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- QQLBPVKLJBAXBS-FXQIFTODSA-N Glu-Glu-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O QQLBPVKLJBAXBS-FXQIFTODSA-N 0.000 description 1
- LGYZYFFDELZWRS-DCAQKATOSA-N Glu-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O LGYZYFFDELZWRS-DCAQKATOSA-N 0.000 description 1
- XIKYNVKEUINBGL-IUCAKERBSA-N Glu-His-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)NCC(O)=O XIKYNVKEUINBGL-IUCAKERBSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- ITVBKCZZLJUUHI-HTUGSXCWSA-N Glu-Phe-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ITVBKCZZLJUUHI-HTUGSXCWSA-N 0.000 description 1
- DAHLWSFUXOHMIA-FXQIFTODSA-N Glu-Ser-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O DAHLWSFUXOHMIA-FXQIFTODSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- WSWWTQYHFCBKBT-DVJZZOLTSA-N Gly-Thr-Trp Chemical compound C[C@@H](O)[C@H](NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O WSWWTQYHFCBKBT-DVJZZOLTSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- DAKSMIWQZPHRIB-BZSNNMDCSA-N His-Tyr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DAKSMIWQZPHRIB-BZSNNMDCSA-N 0.000 description 1
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 1
- YOTNPRLPIPHQSB-XUXIUFHCSA-N Ile-Arg-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOTNPRLPIPHQSB-XUXIUFHCSA-N 0.000 description 1
- LEDRIAHEWDJRMF-CFMVVWHZSA-N Ile-Asn-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LEDRIAHEWDJRMF-CFMVVWHZSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- BALLIXFZYSECCF-QEWYBTABSA-N Ile-Gln-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N BALLIXFZYSECCF-QEWYBTABSA-N 0.000 description 1
- BEWFWZRGBDVXRP-PEFMBERDSA-N Ile-Glu-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BEWFWZRGBDVXRP-PEFMBERDSA-N 0.000 description 1
- SLQVFYWBGNNOTK-BYULHYEWSA-N Ile-Gly-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N SLQVFYWBGNNOTK-BYULHYEWSA-N 0.000 description 1
- YNMQUIVKEFRCPH-QSFUFRPTSA-N Ile-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)O)N YNMQUIVKEFRCPH-QSFUFRPTSA-N 0.000 description 1
- BBQABUDWDUKJMB-LZXPERKUSA-N Ile-Ile-Ile Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C([O-])=O BBQABUDWDUKJMB-LZXPERKUSA-N 0.000 description 1
- TWPSALMCEHCIOY-YTFOTSKYSA-N Ile-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N TWPSALMCEHCIOY-YTFOTSKYSA-N 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- OVDKXUDMKXAZIV-ZPFDUUQYSA-N Ile-Lys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OVDKXUDMKXAZIV-ZPFDUUQYSA-N 0.000 description 1
- XLXPYSDGMXTTNQ-UHFFFAOYSA-N Ile-Phe-Leu Natural products CCC(C)C(N)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 XLXPYSDGMXTTNQ-UHFFFAOYSA-N 0.000 description 1
- ZNOBVZFCHNHKHA-KBIXCLLPSA-N Ile-Ser-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZNOBVZFCHNHKHA-KBIXCLLPSA-N 0.000 description 1
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
- APQYGMBHIVXFML-OSUNSFLBSA-N Ile-Val-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N APQYGMBHIVXFML-OSUNSFLBSA-N 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 206010023335 Keratitis interstitial Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- PPTAQBNUFKTJKA-BJDJZHNGSA-N Leu-Cys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PPTAQBNUFKTJKA-BJDJZHNGSA-N 0.000 description 1
- DZQMXBALGUHGJT-GUBZILKMSA-N Leu-Glu-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O DZQMXBALGUHGJT-GUBZILKMSA-N 0.000 description 1
- HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
- KVMULWOHPPMHHE-DCAQKATOSA-N Leu-Glu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KVMULWOHPPMHHE-DCAQKATOSA-N 0.000 description 1
- LAGPXKYZCCTSGQ-JYJNAYRXSA-N Leu-Glu-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LAGPXKYZCCTSGQ-JYJNAYRXSA-N 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- JRJLGNFWYFSJHB-HOCLYGCPSA-N Leu-Gly-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O JRJLGNFWYFSJHB-HOCLYGCPSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- ARRIJPQRBWRNLT-DCAQKATOSA-N Leu-Met-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ARRIJPQRBWRNLT-DCAQKATOSA-N 0.000 description 1
- GSSMYQHXZNERFX-WDSOQIARSA-N Leu-Met-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N GSSMYQHXZNERFX-WDSOQIARSA-N 0.000 description 1
- AIRUUHAOKGVJAD-JYJNAYRXSA-N Leu-Phe-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIRUUHAOKGVJAD-JYJNAYRXSA-N 0.000 description 1
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 1
- AEDWWMMHUGYIFD-HJGDQZAQSA-N Leu-Thr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O AEDWWMMHUGYIFD-HJGDQZAQSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- AXVIGSRGTMNSJU-YESZJQIVSA-N Leu-Tyr-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@@H]2C(=O)O)N AXVIGSRGTMNSJU-YESZJQIVSA-N 0.000 description 1
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010050219 Lumbar radiculopathy Diseases 0.000 description 1
- NFLFJGGKOHYZJF-BJDJZHNGSA-N Lys-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN NFLFJGGKOHYZJF-BJDJZHNGSA-N 0.000 description 1
- WQWZXKWOEVSGQM-DCAQKATOSA-N Lys-Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN WQWZXKWOEVSGQM-DCAQKATOSA-N 0.000 description 1
- HGZHSNBZDOLMLH-DCAQKATOSA-N Lys-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N HGZHSNBZDOLMLH-DCAQKATOSA-N 0.000 description 1
- YVSHZSUKQHNDHD-KKUMJFAQSA-N Lys-Asn-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N YVSHZSUKQHNDHD-KKUMJFAQSA-N 0.000 description 1
- QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 1
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 1
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- MTBLFIQZECOEBY-IHRRRGAJSA-N Lys-Met-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O MTBLFIQZECOEBY-IHRRRGAJSA-N 0.000 description 1
- TWPCWKVOZDUYAA-KKUMJFAQSA-N Lys-Phe-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O TWPCWKVOZDUYAA-KKUMJFAQSA-N 0.000 description 1
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 1
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 1
- GIKFNMZSGYAPEJ-HJGDQZAQSA-N Lys-Thr-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O GIKFNMZSGYAPEJ-HJGDQZAQSA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- CRGKLOXHKICQOL-GARJFASQSA-N Met-Gln-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N CRGKLOXHKICQOL-GARJFASQSA-N 0.000 description 1
- WPTHAGXMYDRPFD-SRVKXCTJSA-N Met-Lys-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O WPTHAGXMYDRPFD-SRVKXCTJSA-N 0.000 description 1
- JOYFULUKJRJCSX-IUCAKERBSA-N Met-Met-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)NCC(O)=O JOYFULUKJRJCSX-IUCAKERBSA-N 0.000 description 1
- OOLVTRHJJBCJKB-IHRRRGAJSA-N Met-Tyr-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OOLVTRHJJBCJKB-IHRRRGAJSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000000060 Migraine with aura Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 241001440871 Neisseria sp. Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 101800003845 Neuropeptide Y Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100028646 Nociceptin receptor Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- HHOOEUSPFGPZFP-QWRGUYRKSA-N Phe-Asn-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O HHOOEUSPFGPZFP-QWRGUYRKSA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- AWAYOWOUGVZXOB-BZSNNMDCSA-N Phe-Asn-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 AWAYOWOUGVZXOB-BZSNNMDCSA-N 0.000 description 1
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 1
- XMPUYNHKEPFERE-IHRRRGAJSA-N Phe-Asp-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 XMPUYNHKEPFERE-IHRRRGAJSA-N 0.000 description 1
- GYEPCBNTTRORKW-PCBIJLKTSA-N Phe-Ile-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O GYEPCBNTTRORKW-PCBIJLKTSA-N 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 description 1
- RVEVENLSADZUMS-IHRRRGAJSA-N Phe-Pro-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O RVEVENLSADZUMS-IHRRRGAJSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- LTAWNJXSRUCFAN-UNQGMJICSA-N Phe-Thr-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O LTAWNJXSRUCFAN-UNQGMJICSA-N 0.000 description 1
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 1
- ZVJGAXNBBKPYOE-HKUYNNGSSA-N Phe-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 ZVJGAXNBBKPYOE-HKUYNNGSSA-N 0.000 description 1
- XALFIVXGQUEGKV-JSGCOSHPSA-N Phe-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 XALFIVXGQUEGKV-JSGCOSHPSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- HXOLCSYHGRNXJJ-IHRRRGAJSA-N Pro-Asp-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HXOLCSYHGRNXJJ-IHRRRGAJSA-N 0.000 description 1
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 1
- XYSXOCIWCPFOCG-IHRRRGAJSA-N Pro-Leu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XYSXOCIWCPFOCG-IHRRRGAJSA-N 0.000 description 1
- RFWXYTJSVDUBBZ-DCAQKATOSA-N Pro-Pro-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RFWXYTJSVDUBBZ-DCAQKATOSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010037778 Radiculitis brachial Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 102000000583 SNARE Proteins Human genes 0.000 description 1
- 108010041948 SNARE Proteins Proteins 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000017143 Secondary Headache disease Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- SWSRFJZZMNLMLY-ZKWXMUAHSA-N Ser-Asp-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O SWSRFJZZMNLMLY-ZKWXMUAHSA-N 0.000 description 1
- HVKMTOIAYDOJPL-NRPADANISA-N Ser-Gln-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O HVKMTOIAYDOJPL-NRPADANISA-N 0.000 description 1
- VQBCMLMPEWPUTB-ACZMJKKPSA-N Ser-Glu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O VQBCMLMPEWPUTB-ACZMJKKPSA-N 0.000 description 1
- OHKFXGKHSJKKAL-NRPADANISA-N Ser-Glu-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O OHKFXGKHSJKKAL-NRPADANISA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- RJHJPZQOMKCSTP-CIUDSAMLSA-N Ser-His-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O RJHJPZQOMKCSTP-CIUDSAMLSA-N 0.000 description 1
- LQESNKGTTNHZPZ-GHCJXIJMSA-N Ser-Ile-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O LQESNKGTTNHZPZ-GHCJXIJMSA-N 0.000 description 1
- BKZYBLLIBOBOOW-GHCJXIJMSA-N Ser-Ile-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O BKZYBLLIBOBOOW-GHCJXIJMSA-N 0.000 description 1
- KCNSGAMPBPYUAI-CIUDSAMLSA-N Ser-Leu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O KCNSGAMPBPYUAI-CIUDSAMLSA-N 0.000 description 1
- HEUVHBXOVZONPU-BJDJZHNGSA-N Ser-Leu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HEUVHBXOVZONPU-BJDJZHNGSA-N 0.000 description 1
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
- NNFMANHDYSVNIO-DCAQKATOSA-N Ser-Lys-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NNFMANHDYSVNIO-DCAQKATOSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 1
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 description 1
- PPCZVWHJWJFTFN-ZLUOBGJFSA-N Ser-Ser-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O PPCZVWHJWJFTFN-ZLUOBGJFSA-N 0.000 description 1
- VEVYMLNYMULSMS-AVGNSLFASA-N Ser-Tyr-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O VEVYMLNYMULSMS-AVGNSLFASA-N 0.000 description 1
- PCMZJFMUYWIERL-ZKWXMUAHSA-N Ser-Val-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMZJFMUYWIERL-ZKWXMUAHSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- VBPDMBAFBRDZSK-HOUAVDHOSA-N Thr-Asn-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O VBPDMBAFBRDZSK-HOUAVDHOSA-N 0.000 description 1
- GCXFWAZRHBRYEM-NUMRIWBASA-N Thr-Gln-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O GCXFWAZRHBRYEM-NUMRIWBASA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- CGCMNOIQVAXYMA-UNQGMJICSA-N Thr-Met-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O CGCMNOIQVAXYMA-UNQGMJICSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- NLWDSYKZUPRMBJ-IEGACIPQSA-N Thr-Trp-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O NLWDSYKZUPRMBJ-IEGACIPQSA-N 0.000 description 1
- XVHAUVJXBFGUPC-RPTUDFQQSA-N Thr-Tyr-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XVHAUVJXBFGUPC-RPTUDFQQSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- BDWDMRSGCXEDMR-WFBYXXMGSA-N Trp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N BDWDMRSGCXEDMR-WFBYXXMGSA-N 0.000 description 1
- GTNCSPKYWCJZAC-XIRDDKMYSA-N Trp-Asp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N GTNCSPKYWCJZAC-XIRDDKMYSA-N 0.000 description 1
- ABEVJDLMFPTGPS-SZMVWBNQSA-N Trp-Met-Met Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCSC)C(O)=O ABEVJDLMFPTGPS-SZMVWBNQSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- USYGMBIIUDLYHJ-GVARAGBVSA-N Tyr-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 USYGMBIIUDLYHJ-GVARAGBVSA-N 0.000 description 1
- FJBCEFPCVPHPPM-STECZYCISA-N Tyr-Ile-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O FJBCEFPCVPHPPM-STECZYCISA-N 0.000 description 1
- QSFJHIRIHOJRKS-ULQDDVLXSA-N Tyr-Leu-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QSFJHIRIHOJRKS-ULQDDVLXSA-N 0.000 description 1
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 1
- KHCSOLAHNLOXJR-BZSNNMDCSA-N Tyr-Leu-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHCSOLAHNLOXJR-BZSNNMDCSA-N 0.000 description 1
- DAOREBHZAKCOEN-ULQDDVLXSA-N Tyr-Leu-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O DAOREBHZAKCOEN-ULQDDVLXSA-N 0.000 description 1
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 1
- HSBZWINKRYZCSQ-KKUMJFAQSA-N Tyr-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O HSBZWINKRYZCSQ-KKUMJFAQSA-N 0.000 description 1
- ZOBLBMGJKVJVEV-BZSNNMDCSA-N Tyr-Lys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O ZOBLBMGJKVJVEV-BZSNNMDCSA-N 0.000 description 1
- YYLHVUCSTXXKBS-IHRRRGAJSA-N Tyr-Pro-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YYLHVUCSTXXKBS-IHRRRGAJSA-N 0.000 description 1
- BIVIUZRBCAUNPW-JRQIVUDYSA-N Tyr-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O BIVIUZRBCAUNPW-JRQIVUDYSA-N 0.000 description 1
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 1
- GZWPQZDVTBZVEP-BZSNNMDCSA-N Tyr-Tyr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O GZWPQZDVTBZVEP-BZSNNMDCSA-N 0.000 description 1
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- ZMDCGGKHRKNWKD-LAEOZQHASA-N Val-Asn-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N ZMDCGGKHRKNWKD-LAEOZQHASA-N 0.000 description 1
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 1
- OGNMURQZFMHFFD-NHCYSSNCSA-N Val-Asn-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N OGNMURQZFMHFFD-NHCYSSNCSA-N 0.000 description 1
- IQQYYFPCWKWUHW-YDHLFZDLSA-N Val-Asn-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N IQQYYFPCWKWUHW-YDHLFZDLSA-N 0.000 description 1
- ISERLACIZUGCDX-ZKWXMUAHSA-N Val-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N ISERLACIZUGCDX-ZKWXMUAHSA-N 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 1
- CVIXTAITYJQMPE-LAEOZQHASA-N Val-Glu-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CVIXTAITYJQMPE-LAEOZQHASA-N 0.000 description 1
- WFENBJPLZMPVAX-XVKPBYJWSA-N Val-Gly-Glu Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O WFENBJPLZMPVAX-XVKPBYJWSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- BZWUSZGQOILYEU-STECZYCISA-N Val-Ile-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BZWUSZGQOILYEU-STECZYCISA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- XXWBHOWRARMUOC-NHCYSSNCSA-N Val-Lys-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XXWBHOWRARMUOC-NHCYSSNCSA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 1
- YLBNZCJFSVJDRJ-KJEVXHAQSA-N Val-Thr-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O YLBNZCJFSVJDRJ-KJEVXHAQSA-N 0.000 description 1
- RLVTVHSDKHBFQP-ULQDDVLXSA-N Val-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 RLVTVHSDKHBFQP-ULQDDVLXSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003766 afferent neuron Anatomy 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010069926 arginyl-glycyl-serine Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 231100001102 clostridial toxin Toxicity 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- NTZGMAAQXGNGFH-VDVVPONDSA-N dnc013942 Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 NTZGMAAQXGNGFH-VDVVPONDSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 208000004967 femoral neuropathy Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000003546 flue gas Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010081551 glycylphenylalanine Proteins 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000006904 interstitial keratitis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108010034507 methionyltryptophan Proteins 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 206010052787 migraine without aura Diseases 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- 201000002003 mononeuritis multiplex Diseases 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000501 nonneurotoxic Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- 229930000184 phytotoxin Natural products 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001470 polyketone Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 210000002979 radial nerve Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000004284 spotted fever Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000658 ulnar nerve Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007332 vesicle formation Effects 0.000 description 1
- 210000003273 vestibular nerve Anatomy 0.000 description 1
- 201000000200 vestibular neuronitis Diseases 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
治疗分子的使用,用于特定疼痛病状的治疗,其中所述治疗分子是单链的多肽融合蛋白,其包含:非细胞毒性的蛋白酶,或其片段,所述蛋白酶或蛋白酶片段能够剪切疼痛感应传入器中胞吐融合器的蛋白;能够结合所述疼痛感觉传入器上结合位点的靶向部分,所述结合位点能够进行细胞内吞,以便被并入到所述疼痛感觉传入器的内涵体中;蛋白酶剪切位点,在该位点所述融合蛋白可被蛋白酶剪切,其中所述蛋白酶剪切位点位于所述非细胞毒性的蛋白酶或其片段和所述靶向部分之间;和转运区域,其能够从内涵体中转运所述蛋白酶或蛋白酶片段,跨内涵体膜并进入所述疼痛感觉传入器的细胞溶胶。
Description
本发明涉及非细胞毒性的融合蛋白的用途,用于特定类型疼痛的治疗。
根据其在靶细胞上产生效果的类型,毒素可被一般地分为两组。更详细地,第一组毒素杀死它们的天然靶细胞,并因此是通常所说的细胞毒性毒素分子。这一组的毒素特别地由植物毒素,如蓖麻毒素和相思豆毒素;并由细菌毒素,如白喉毒素和假单胞菌外毒素A(Pseudomonas exotoxin A)示例。细胞毒毒素在“魔法子弹”(如,免疫偶联物(immunoconjugate),其包含细胞毒毒素组分和与靶细胞特定标记进行结合的抗体)的设计中已经吸引了极大的兴趣,其被用于细胞紊乱和状况,如癌症的治疗。细胞毒毒素典型地通过抑制蛋白合成的细胞过程杀死它们的靶细胞。
第二组毒素,其被称作非细胞毒性的毒素,不杀死(如它们的名字所证实)它们天然的靶细胞。非细胞毒性的毒素与它们的细胞毒性相似物相比,吸引了较少的商用兴趣,并且通过抑制蛋白合成以外的细胞过程对靶细胞产生它们的影响。非细胞毒性的毒素通过多种植物,并通过多种微生物,如梭菌属某一种(Clostridium sp.)和奈瑟菌属某一种(Neisseria sp.)产生。
梭菌神经毒素是典型地具有150kDa数量级分子量的蛋白。它们由多种细菌属类物种产生,特别地由梭菌类产生,最重要地,由破伤风梭菌(C.tetani)和肉毒梭菌(C.botulinum)、丁酸梭菌(C.butyricum)和阿根廷梭菌(C.argentinense)的几种菌株产生。目前有8种不同类型的梭菌毒素,即:破伤风毒素,和血清型A、B、C1、D、E、F和G的肉毒菌神经毒素,并且它们都共享相似的结构和作用形式。
梭菌神经毒素代表了一组主要的非神经毒性的毒素分子,并通过宿主细菌作为单一多肽被合成,所述单一多肽通过蛋白水解剪切事件被翻译后修饰,以形成由二硫键连接在一起的两个多肽链。这两条链被称为具有约100kDa分子量的重链(H-链),和具有约50kDa分子量的轻链(L-链)。
L-链具有蛋白酶功能(锌依靠肽链内切酶活性)并显示出对胞吐(exocytic)过程中涉及的囊泡和/或质膜相关蛋白高的底物特异性。来自不同梭菌属种或血清型的L-链可以水解三种底物蛋白之一中的不同但特异的肽键,所述三种底物蛋白为小突触小泡蛋白(synaptobrevin)、突触融合蛋白(syntaxin)或SNAP-25。这些底物是神经分泌机制的重要组分。
奈瑟菌属,最重要地来自淋球菌(N.gonorrhoeae)的,产生功能相似的非细胞毒性蛋白酶。这些蛋白酶的一个实例是IgA蛋白酶(参见WO99/58571)。
现有技术中已经明确记载:毒素分子可以被重新靶向并非该毒素的天然靶细胞的细胞。当被所谓的重新靶向时,修饰的毒素能够结合目标靶细胞,并且接下来转运到细胞溶胶,能够对靶细胞产生其效应。所述重新靶向通过用不同的TM(靶向部分Targeting Moiety)替换该毒素的天然靶向部分(TM)完成。在这一点上,TM被选择以便其结合目标靶细胞,并允许修饰的毒素后续进入靶细胞内的内涵体之内。修饰的毒素也包含转运区域,以使非细胞毒性的蛋白酶进入细胞溶胶。该转运区域可以是该毒素的天然转运区域,或其可以是从具有转运活性的微生物蛋白中获得的不同转运区域。
上述TM替换可以通过普通技术人员公知的传统化学偶联技术被实现。在这一点上,参考Hermanson,G.T.(1996),Bioconjugatetechniques,Academic Press,并参考Wong,S.S.(1991),Chemistry ofprotein conjugation and cross-linking,CRC Press。
然而,化学偶联通常是不精确的。例如,偶联之后,TM可以在多于一个连接位点被连接到该偶联物的剩余部分。
化学偶联也难以控制。例如,TM可以在蛋白酶组分和/或转运组分的连接位点被连接到修饰毒素的剩余部分。当仅连接到所述组分之一(优选地在单一位点)对治疗效力是期望的时候,这是有问题的。
因此,化学偶联导致混合种类的修饰毒素分子,这是不理想的。
作为化学偶联的替代方案,TM代替可以被单一多肽融合蛋白的重组制备实现(参见WO98/07864)。该技术基于体内细菌机制,通过该机制,原生梭菌神经毒素(即,全毒素)被制备,并产生具有以下结构排列的融合蛋白:NH2-[蛋白酶组分]-[转运组分]-[TM]-COOH
根据WO98/07864,TM被置于朝向融合蛋白的C-末端。该融合蛋白随后通过用蛋白酶处理被激活,所述蛋白酶在蛋白酶组分和转运组分之间剪切。双链蛋白随后被产生,其包含共价连接(通过二硫键)到含有转运组分加TM的另一单一多肽链的,作为单一多肽链蛋白酶组分的蛋白酶组分。尽管WO98/07864的方法遵循了(按照融合蛋白的结构排列而言)梭菌全毒素的天然表达系统,但是本发明人已经发现该系统可以导致某些融合蛋白的产生,其对预期的靶细胞具有本质上降低的结合能力。
这一问题在治疗特定类型疼痛的情况下特别相关。
本发明通过提供用于生产治疗特定类型疼痛的药物的治疗分子的使用,解决了一个或多个上述问题,其中所述治疗分子是单链的多肽融合蛋白,其包含:a.非细胞毒性的蛋白酶(a non-cytotoxic protease)或其片段,所述蛋白酶或蛋白酶片段能够剪切疼痛感应传入器(或伤害感应传入器,nociceptive sensoryafferent)中细胞外融合器(exocytic fusion apparatus)的蛋白;b.能够结合疼痛感应传入器上之结合位点(BindingSite)的靶向部分(Targeting Moiety),所述结合位点能够进行细胞内吞作用,以被并入疼痛感应传入器中的内涵体内;c.蛋白酶剪切位点(protease cleavage site),在该位点 融合蛋白可被蛋白酶剪切,其中所述蛋白酶剪切位点位于非细胞毒性蛋白酶或其片段和靶向部分之间;和d.转运区域(translocation domain),其能够将蛋白酶或蛋白酶片段从内涵体中跨内涵体膜转运,并进入疼痛感应传入器的细胞溶胶中。
本发明人已经发现WO 98/07864的融合蛋白系统对需要N-末端区域与疼痛感应传入器上的结合位点相互作用的TMs来说不是最优化的。这一问题对于TMs来说特别尖锐,所述TMs需要特定的N-末端氨基酸残基或包括N-末端氨基酸残基的特定序列的氨基酸残基,用以与疼痛感应传入器上的结合位点相互作用。
与WO98/07864相反,本发明采用了非细胞毒性的融合蛋白,其中所述融合体的TM组分包括内部区域中的相关结合区域或朝向TM中部(即,线性肽序列的中部)放置的氨基酸序列,或优选地,朝向TM的N-末端放置,或更优选地位于或接近N-末端的氨基酸序列。所述N-末端区域能够结合疼痛感应传入器上的结合位点,并且所述TM优选地有对特定的和界定的氨基酸残基序列有要求,以在其N-末端是游离的。
本文所述的化合物可被用于治疗患有一种或多种类型慢性疼痛的患者,所述慢性疼痛包括神经性疼痛、炎症疼痛、头痛、身体疼痛、内脏疼痛和牵涉性疼痛。
“治疗”,用在这里,表示医学上的处理。它包括,例如,给予本发明的化合物,以预防疼痛或减轻其严重性。
术语“疼痛”,用在这里,表示任何不愉快的感官经历,通常与身体疾病相关。身体疾病对医生可能明显或可能不明显。疼痛有两种类型:慢性和急性。“急性疼痛”是突然发生的,短时间的疼痛。一种类型的急性疼痛,例如,是在皮肤或其它表面组织的伤口处,如由割伤或烧伤引起的,感觉到的皮肤疼痛。皮肤疼痛感受器仅终止于皮肤以下,并且由于高浓度的神经末端,产生良好定义的短期局部疼痛。“慢性疼痛”是急性疼痛以外的疼痛。慢性疼痛包括神经性疼痛、炎症疼痛、头痛、身体疼痛、内脏疼痛和牵涉性疼痛。
I.神经性疼痛
本发明所述的化合物可以被用于治疗由任何以下神经性疼痛状况引起的或与其相关的疼痛。“神经性疼痛”表示来自外周神经系统、中枢神经系统或两者的不正常的感觉输入,导致不适。
A.神经性疼痛的症状
神经性疼痛的症状可以包括持续、自发的疼痛,以及痛觉异常(allodynia)(对通常非疼痛的刺激的疼痛反应)、痛觉增敏(hyperalgesia)(对通常仅引起轻微不适的疼痛刺激,如针刺,产生的加重的反应)、或痛觉过敏(hyperpathia)(短暂的不适成为长期严重的疼痛)。
B.神经性疼痛的原因
神经性疼痛可由以下任意原因引起。1.外伤性损害,例如,如神经压迫伤(如,神经压迫、神经拉伸、神经卡压(nerve entrapment)或不完整的神经切面);脊柱伤(如,脊柱的一半切除);腿截肢;挫伤;炎症(如,脊柱炎症);或手术过程。2.缺血性事件,包括,例如,中风和心脏病发作。3.感染物4.暴露于毒性试剂,包括,例如,药物、酒精、重金属(如铅、砷、汞)、工业试剂(如,溶剂、源自胶水的烟气)或一氧化二氮。5.疾病,包括,例如炎症性疾病,神经性肿瘤,获得性免疫缺陷综合症(acquired immune deficiency syndrome(AIDS)),莱姆病(Lymesdisease),麻风病,代谢疾病,外周神经疾病,如神经瘤、单神经病或多神经病。C.神经性疼痛的种类1.神经痛神经痛是沿一条或多条特异神经路径辐射的疼痛,通常在神经结构上没有任何可显示的病理改变。神经痛的起因是多种多样的。化学腐蚀、炎症、外伤(包括手术)、被附近的结构(如肿瘤)压迫和感染 都可以引发神经痛。但是,在多种情况下,起因是未知的或不可识别的。神经痛在老年人中最常见,但是它可以发生在任何年龄。神经痛,包括但不限于三叉神经痛、疱疹后神经痛(post-herpetic neuralgia)、疱疹后神经痛(postherpetic neuralgia)、舌咽神经痛、坐骨神经痛和非典型性面部疼痛。
神经痛是分布在单一神经或多个神经中的疼痛。实例是三叉神经痛、非典型性面部疼痛和疱疹后神经痛(由带状疱疹或疱疹引起)。受影响的神经负责感觉从下颚到额头的面部区域中的触摸、温度和压力。该疾病通常引起短暂的剧痛,通常少于2分钟并仅发生在面部的一侧。疼痛可以多种方式描述,如“剧痛(stabbing)”、“剧烈的(sharp)”、“闪电般的(like lightning)”、“烧灼(burning)”和甚至“痒的(itchy)”。在非典型形式的三叉神经痛中,疼痛也可以严重的或仅疼痛存在,并持续延长的时间。与三叉神经痛(TN)相关的疼痛被识别为可以被经历的最剧烈的疼痛之一。
简单的刺激,如吃、说话、洗脸或任何轻微的触碰或感觉可以引起发作(甚至微风的感觉)。发作可以一群发生或作为单独的发作发生。
症状包括位于任何位置急剧、剧烈的疼痛或持续、烧灼的疼痛,通常位于或接近身体的表面,对每个期间来说发生在相同的位置;痛沿特定神经途径的疼;由于疼痛受影响的身体部分受损的功能,或由于伴随的运动神经损伤的肌肉衰弱;提高的皮肤敏感性或受影响皮肤区域的麻木(与局部麻醉相似的感觉,如奴佛卜因注射(Novacaineshot));和被解释为疼痛的任何触摸或压力。运动也可能是疼痛的。
三叉神经痛是最常见形式的神经痛。它影响面部主要的感官神经,三叉神经(“三叉的”文字上表示“三个起点(three origins)”,指的是神经分成3个分支)。其症状包括严重的疼痛在面部的一侧突然而短暂的发作,沿着该侧三叉神经所牵扯的区域。疼痛发作可能严重到足以引起面部扭曲,其典型地指疼痛抽筋(神经痉挛(ticdouloureux))。有时,三叉神经痛的起因是血管或小肿瘤压迫神经。疾病,诸如多发性硬化症(影响脑和脊柱的炎症性疾病)、某些形式的关节炎和糖尿病(高血糖)也可能引起三叉神经痛,但并非总能识别出 起因。在这种情况下,某些运动,如咀嚼、说话、吞咽或接触面部的区域可能引发剧烈疼痛的痉挛。
相关但相当不常见的神经痛影响舌咽神经,其为咽喉提供感觉。该神经痛的症状是位于咽喉的短暂、冲击状发作的疼痛。
神经痛可能发生在诸如带状疱疹的感染之后,带状疱疹由带状疱疹病毒,一种疱疹病毒引起。这种神经痛在带状疱疹的疹子痊愈后产生持续的灼烧疼痛。疼痛由于受影响区域的运动或与其接触而恶化。并非所有诊断为带状疱疹的那些患者继续经历疱疹后神经痛,它会比带状疱疹更疼。疼痛和敏感可以持续数月或甚至数年。疼痛通常是对任何接触,但特别是轻触不可忍受的敏感形式。疱疹后神经痛不限制在面部;它可以发生在身体的任何位置,但通常发生在带状疱疹疹子的部位。
由于疼痛和患病期间的社交孤立,抑郁是常见的。
疱疹后神经痛可能在初始的疱疹感染的标志已经消失很长时间后恶化。可能引起神经痛的其它感染性疾病是梅毒和莱姆病(Lymedisease)。
糖尿病是神经痛的另一常见诱因。这一非常常见的医学问题影响几乎1/20的美国成年人。糖尿病损害向神经提供循环的微小动脉,导致神经纤维故障及有时的神经损失。糖尿病可以产生几乎任何神经痛,包括三叉神经痛、腕管综合症(carpal tunnel syndrome)(手部和腕部的疼痛和麻木)和感觉异常性股痛(由于股外侧皮神经损伤引起的大腿麻木和疼痛)。血糖的严格控制可以预防糖尿病的神经损伤并可以加速发生神经痛的患者的恢复。
可能与神经痛相关的其它医学症状为慢性肾衰竭和卟啉症(porphyria)——一种遗传疾病,其中身体不能清除身体中血液正常分解后产生的某些物质本身。某些药物也可能引起这个问题。
2.传入神经阻滞传入神经阻滞表示来自身体一部分的感觉输入的缺失,并可以由外周感觉纤维或形成中枢神经系统的神经的打断而引起。传入神经阻滞疼痛症状包括,但不限于脑或脊柱的损伤、中风后疼痛、幻觉痛、 半身不遂、上臂神经丛撕裂伤、腰部神经根病(radiculopathies)。
3.复杂性局部疼痛综合症(CRPSs)CRPS是起因于感应维持疼痛(sympathetically-maintained)的慢性疼痛综合症,并以两种形式存在。CRPS 1现在代替术语“反射性交感神经营养不良综合症(reflex sympathetic dystrophy syndrome)”。它是一种慢性神经病变,最常见发生在轻微或重大创伤后的胳膊和腿部。CRPS 1与严重的疼痛;指甲、骨骼和皮肤上的变化;和对受影响肢体的触碰提高的敏感度相关联。CRPS 2替代术语皮肤灼热痛(causalgia),并且其起因于识别出的对神经的伤害。CRPS包括但不限于I型CRPS(反射性交感神经营养不良综合症)和II型CRPS(皮肤灼热痛)。
4.神经病变
神经病变是神经的功能或病理改变,并且通过感觉或运动神经元异常被临床表征。
中枢神经病变是中枢神经系统中的功能或病理改变。
外周神经病变是一个或多个外周神经中的功能或病理改变。外周神经从中枢神经系统(脑和脊柱)传递信息给肌肉和其它器官,并从皮肤、关节和其它器官传递回大脑。当这些神经无法携带信息往返大脑和脊柱时,外周神经病变发生,导致疼痛、感觉缺失、或无法控制肌肉。在一些情况下,控制血管、肠道和其它器官的神经的失效导致异常的血压、消化问题和其它基本身体过程的缺失。神经病变的风险因素包括糖尿病、酗酒和暴露于某些化学物质和药品。一些人具有神经病变的遗传倾向。在神经上长时间的压力是另一种发生神经损伤的风险。受压伤可能由长时间不动(如长时间的手术过程或长期患病)或由对神经的压迫引起。多神经病变表示通常同等影响两侧身体的广布过程。症状取决于何种类型的神经被影响。三种主要类型的神经为感觉、运动和自主神经。神经病变可以影响所有三种类型神经的任何一种或组合。症状也取决于该病症影响整个躯体或仅影响一束神经(如源自创伤)。慢性炎症性多神经病变的原因是异常的免疫反应。特异抗原、免疫过程和激发因子不同,并且在多种情况下是未知 的。它可能与其它症状关联发生,如HIV、炎症性肠病、红斑狼疮、慢性活动性肝炎和血细胞异常。
外周神经病变可能包括单一神经或神经束功能或病理的改变(单神经病变),或影响多个神经的功能或病理改变(多神经病变)。
外周神经病变遗传疾病进行性腓骨肌萎缩症(Charcot-Marie-Tooth disease)弗里德赖希氏共济失调(Friedreich′s ataxia)全身或代谢失调糖尿病(糖尿病神经痛)膳食缺乏(特别是维生素B-12)过量饮酒(酒精性神经痛)尿毒症(源自肾衰竭)癌症感染或炎症性病症AIDS肝炎科罗拉多壁虱热白喉格林-巴利综合症(Guillain-Barre syndrome)HIV感染而没有AIDS发展麻风病莱姆病(Lyme)结节性多动脉炎风湿性关节炎结节病干燥综合症(Sjogren syndrome) 梅毒全身红斑狼疮淀粉状物质(amyloid)暴露于有毒化合物吸入胶水或其它有毒化合物一氧化二氮工业试剂——特别是溶剂重金属(铅、砷、汞等)从属于像镇痛剂肾病的药物的神经痛多种诱因贫血(降低的氧/降低的血流)长时间暴露于冷的温度a.多神经病变多神经病变是外周神经病变,包括由多个外周神经损伤或解体引起的运动或某一区域感觉的缺失。多神经病变疼痛包括,但不限于脊髓灰质炎后综合症、乳房切除术后综合症(postmastectomy syndrome)、糖尿病神经痛、酒精性神经痛、淀粉状物质(amyloid)、毒素、AIDS、甲状腺机能减退、尿毒症、维生素缺乏、化疗引起的疼痛、2′,3′-双脱氧胞苷(ddC)治疗、格林-巴利综合症(Guillain-Barrésyndrome)或法布瑞氏症(Fabry′s disease)。b.单神经病变单神经病变是外周神经病变,包括由单一外周神经或神经束损伤或解体引起的运动或某一区域感觉的缺失。单神经病变最常见由起因于自创伤或外伤的局部区域损伤引起,尽管偶尔地,全身疾病可能引起单独的神经损伤(如多数单神经炎(mononeuritis multiplex))。常见的原因是直接外伤、对神经长时间的压迫、和由附近身体结构的肿胀或 受伤对神经的压迫。损伤包括神经髓鞘(遮盖物)的解体或部分神经细胞(轴突)的解体。损伤减缓或阻止了冲动通过神经的传导。单神经病变可能涉及身体的任何部分。单神经病变痛包括,但不限于坐骨神经功能异常、腓总神经功能异常、桡神经功能异常、尺神经功能异常、颅骨单神经病变VI、颅骨单神经病变VII、颅骨单神经病变III(压迫型)、颅骨单神经病变III(糖尿病型)、腋神经功能异常、腕管综合症、股神经功能异常、胫神经功能异常、面神经麻痹(Bell′s palsy)、胸廓出口综合症、腕管综合症和第六(外展)神经麻痹。c.普遍的外周神经病变普遍的外周神经病变是对称的,并且通常是由于各种全身疾病和病痛过程,这些疾病和病痛过程影响外周神经系统的整体。它们被进一步分为几个类别:i.远端轴突病变(Distal axonopathies)是神经元的一些代谢或毒性错乱的结果。它们可能由代谢疾病引起,例如糖尿病,肾衰竭,缺乏综合症(deficiency syndrome),如营养不良和酗酒,或毒素或药物的影响。远端轴突病变(也被成为逆行死亡神经病变(dying backneuropathy))是一种外周神经病变,其起因于外周神经系统(PNS)神经元的一些代谢或毒性的混乱。这是神经对代谢或毒素紊乱的最常见反应,并且照这样,可由代谢疾病引起,例如糖尿病,肾衰竭,缺乏综合症(deficiency syndrome),如营养不良和酗酒,或毒素或药物的影响。远端轴突病变的最常见诱因是糖尿病,并且最常见的远端轴突病变是糖尿病神经痛。ii.髓鞘质病是由于髓鞘质的主要攻击,引起冲动传导的急性失败。最常见的诱因是急性炎症性脱髓鞘多神经病变(acute inflammatorydemyelinating polyneutopathy(AIDP,也被称作格林-巴利综合症)),虽然其它诱因包括慢性炎症性脱髓鞘综合症(CIDP)、遗传代谢紊乱(如, 脑白质营养不良)或毒素。髓鞘质病是由于髓鞘或髓鞘化许旺细胞(myelinating Schwann cells)的大部分解体,其使得轴突完整,但引起冲动传导的急性衰竭。脱髓鞘化减缓或完全阻止了电冲动通过神经的传导。最常见的诱因是急性炎症性脱髓鞘多神经病变(AIDP,也被称作格林-巴利综合症),虽然其它诱因包括慢性炎症性脱髓鞘综合症(CIDP)、遗传代谢紊乱(如,脑白质营养不良或进行性腓骨肌萎缩)或毒素。iii.神经病变是外周神经系统(PNS)神经元破坏的结果。它们可能由运动神经元疾病,感觉神经病变(如,带状疱疹),毒素或自主神经功能异常。神经毒素可能引起神经病变,例如化学治疗试剂长春新碱。神经病变是由于外周神经系统(PNS)的神经元损伤,导致外周神经病变,引起的功能异常。它可能由运动神经元疾病,感觉神经病变(如,带状疱疹),有毒物质或自主神经功能异常。患有神经病变的人可能以多种形式存在,取决于诱因、其影响神经细胞的方式,和被影响最严重的神经细胞的类型。iv.聚焦节流神经病变(Focal entrapment neuropathies)(如腕管综合症)
II.炎症性疼痛
本发明所述的化合物可以被用于治疗由任何以下炎症性症状引起的或与其相关的疼痛。
A.关节炎关节炎包括,例如,风湿性关节炎;青少年风湿性关节炎;系统性红斑狼疮(SLE);痛风性关节炎;硬皮病;骨关节炎;牛皮癣关节炎;强直性脊柱炎;莱特氏综合症(Reiter′s syndrome)(反应性关节炎);成人斯提耳病(adult Still′s disease);病毒感染引起的关节炎;细菌感染引起的关节炎,例如,如淋病性关节炎和非淋病性细菌关节炎(脓 毒性关节炎);三期莱姆病(Tertiary Lyme disease);结核性关节炎;和真菌感染引起的关节炎,例如,如芽生菌病。
B.自免疫疾病自免疫疾病包括,例如格林-巴利综合症、桥本氏甲状腺炎(Hashimoto′s thyroiditis)、恶性贫血、爱迪生氏病(Addison′s disease)、I型糖尿病、系统性红斑狼疮、皮肌炎、干燥综合症(sjogren′s syndrome)、红斑狼疮、多发性硬化症、重症肌无力、莱特氏综合症和格雷氏病(Grave′s disease)。
C.结缔组织疾病结缔组织疾病包括,例如脊柱关节炎(spondyloarthritis)、皮肌炎和肌纤维痛(fibromyalgia)。
D.受伤由受伤引起的炎症可能引起慢性炎症性疼痛,所述受伤包括,例如组织或关节的挤压、刺穿、拉伸。
E.感染由感染引起的炎症可能引起慢性炎症性疼痛,所述感染包括,例如肺结核或间质性角膜炎。
F.神经炎神经炎是影响神经或一组神经的炎症性过程。症状取决于涉及的神经,但可能包括疼痛、感觉异常、局部麻痹或感觉减退(麻木)。实例包括:a.臂神经炎b.眼球后神经病变,一种炎症性过程,其影响恰好位于眼球后的视神经。c.视神经病变,一种影响视神经的炎症性过程,在受影响的眼中引起突然下降的视力。视神经炎的诱因未知。视神经(连接眼睛和脑的神经)的突然发炎导致髓鞘的肿胀和解体。炎症偶尔可能是病毒感染的结果,或其可能由自免疫疾病,如多发性硬化引起。风险因素与可能的诱因相关。 d.前庭神经炎,病毒感染引起的影响前庭神经的炎症性过程。
G.关节炎症关节的炎症,如由粘液囊炎或肌腱炎引起的,例如,可能引起慢性炎症性疼痛。
III.头痛
本发明所述的化合物可以被用于治疗由任何以下头痛症状引起的或与其相关的疼痛。头痛(医学上也被称为头痛(cephalgia))是头部轻微到严重疼痛的一种症状;有时颈部或上背部疼痛可能也被解释为头痛。它可能表明潜在的局部或全身疾病,或可能是其本身的疾病。
A.肌肉/肌原性头痛肌肉/肌原性头痛表现为包括面部和颈部肌肉的收紧(tightening)或紧张(tensing);它们可能向前额辐射。紧张性头痛是最常见形式的肌原性头痛。
紧张性头痛是涉及头部、头皮或颈部疼痛或不适的症状,通常与这些区域的肌肉紧张相关。紧张性头痛起因于颈部和头皮肌肉的收缩。这一肌肉收缩的一个原因是对压力、沮丧或紧张的反应。导致头部长时间保持在一个位置不运动的任何活动可以引起头痛。这样的活动包括打字或使用计算机,用手进行的精细工作和显微镜的使用。在寒冷的屋子中睡觉或以颈部处在不正常的位置下进行睡觉,也可能引发这一类型的头痛。紧张型头痛包括,但不限于阵发性紧张性头痛和慢性紧张性头痛。
B.血管性头痛最常见类型的血管性头痛是偏头痛。其它类型的血管性头痛包括集束性头痛,其引起紧张型头痛的反复阵发;和高血压导致的头痛。1.偏头痛偏头痛是异源疾病,其通常包括反复头痛。偏头痛与其它头痛不同,因为它们伴有其它症状发生,例如,如恶心、呕吐或对光敏感。在大多数人中,抽动的疼痛仅在头部一侧感受得到。临床症状,例如先兆 症状的类型、预征候的存在、或相关症状,如眩晕,可能在具有不同潜在病理生理和遗传机理的患者亚组中观察到。偏头痛包括,但不限于没有先兆的偏头痛(普通偏头痛)、具有先兆的偏头痛(传统偏头痛)、月经偏头痛、等价偏头痛(migraine equivalent)(无头痛性的偏头痛(acephalic headache))、复杂型偏头痛(complicated migraine)、腹型偏头痛(abdominal migraine)和混合型紧张偏头痛(mixed tensionmigraine)。2.集束型头痛集束型头痛影响一侧头部(单侧的)并且可能与眼睛流泪和鼻塞相关联。它们集群发生,每天在相同时间反复发生,持续数周后缓和。
D.高血压头痛
E.牵引性(Traction)和炎症性头痛牵引性和炎症性头痛通常是从中风到鼻窦炎的其它病症的症状。
F.激素型头痛
G.反弹性头痛反弹性头痛,也被称为药物过度使用头痛(medication overuseheadaches),在过度频繁服用药物以缓解头痛时发生。反弹性头痛每天经常发生,并可会非常疼痛。
H.慢性鼻窦炎头痛鼻窦炎是鼻旁窦细菌、真菌、病毒、过敏或自免疫的炎症。慢性鼻窦炎是普通感冒最常见的并发症之一。症状包括:鼻塞;面部疼痛;头痛;发烧;全身不适;浓绿或黄鼻涕;俯身时面部“肿胀(fullness)”感恶化。在少数情况下,慢性上颌鼻窦炎也可以由牙齿感染细菌的蔓延引起。慢性增生性嗜酸性鼻窦炎(Chronic hyperplastic eosinophilicsinusitis)是非感染形式的慢性鼻窦炎。
I.器质性头痛
J.猝发性头痛猝发性头痛是与癫痫活动关联的头痛。
IV.身体疼痛
本发明所述的化合物可以被用于治疗由任何以下身体疼痛状况引起的或与其相关的疼痛。身体疼痛开始于韧带、肌腱、骨骼、血管和甚至神经本身。其用身体疼痛感受器检测。在这些区域中的疼痛受体的缺乏产生比皮肤疼痛时间更长的,迟钝,局部化较差的疼痛;实例包括扭伤和骨折。额外的实例包括以下。
A.过度肌肉紧张过度肌肉紧张可以通过,例如扭伤或拉伤引起。
B.反复性动作疾病反复性动作病可以起因于手部、腕部、肘部、肩部、颈部、背部、臀部、膝盖、足部、腿部或脚踝的过度使用。
C.肌肉疾病引起身体疼痛的肌肉疾病包括,例如,多发性肌炎、皮肌炎、狼疮、肌纤维痛、风湿性多肌痛和横纹肌溶解。
D.肌肉痛肌肉痛是肌肉疼痛并且是多种疾病和紊乱的症状。肌肉痛最常见的诱因是肌肉或肌肉群的过度使用或过度拉伸。无外伤史的肌肉痛通常是由于病毒感染。较长时期的肌肉痛可能是代谢肌病、一些营养缺乏或慢性疲劳综合症的指示。
E.感染感染可以引起身体疼痛。这些感染的实例包括,例如,肌肉中的脓肿,旋毛虫病,流感,莱姆病(Lyme disease),疟疾,落基山斑疹热,禽流感,普通感冒,社区获得性肺炎,脑膜炎,猴痘,严重急性呼吸道综合症,中毒性休克综合症,旋毛虫病,伤寒症和上呼吸道感染。
F.药物药物可以引起身体疼痛。这样的药物包括,例如,可卡因,降低胆固醇的抑制素(statin)(如阿托伐他汀(atorvastatin)、辛找他汀(simvastatin)和洛弗斯特丁(lovastatin))和降低血压的ACE抑制剂(如依那普利(enalapril)和卡托普利(captopril))。
V.内脏疼痛
本发明所述的化合物可以被用于治疗由任何以下内脏疼痛状况引起的或与其相关的疼痛。内脏疼痛起始于身体的内脏或器官。内脏疼痛感受器被置于身体器官或内腔中。在这些区域中疼痛感受器的进一步缺乏产生了通常比身体疼痛更疼且时间更长的疼痛。内脏疼痛极其难定位,并且内脏组织的若干损伤显示出“牵涉性(referred)”疼痛,其中感觉被定位于与受伤位置完全无关的区域。内脏疼痛的实例包括以下。
A.功能性内脏疼痛功能性内脏疼痛包括,例如,肠道易激综合症(irritable bowelsyndrome)和慢性功能性腹痛(CFAP),功能性便秘和功能性消化不良,非心源性胸痛(NCCP)和慢性腹痛。
B.慢性胃肠炎慢性胃肠炎症包括,例如,胃炎,肠炎,像例如,克罗恩氏病(Crohn′sdisease)、溃疡性结肠炎、显微镜结肠炎、憩室炎(diverticulitis)和肠胃炎;间质性膀胱炎;肠缺血;胆囊炎;阑尾炎;食道胃酸逆流(gastroesophageal reflux);溃疡,肾结石,尿路感染,胰腺炎和疝气。
C.自免疫疼痛自免疫疼痛包括,例如,结节病和脉管炎。
D.器质性内脏疼痛器质性内脏疼痛包括,例如,起因于肠道外伤、炎症或病变性损伤,或由肿瘤侵入感觉神经分布产生。
E.治疗诱导的内脏疼痛治疗诱导的内脏疼痛包括,例如,接受化学疗法的疼痛,或接受放射性疗法的疼痛。
VI.牵涉性疼痛
本发明所述的化合物可以被用于治疗由任何以下牵涉性疼痛状况引起的或与其相关的疼痛。
牵涉性疼痛来自定位于与疼痛刺激部位不同区域的疼痛。通常,当神经在位于或接近其起点被压迫或损伤时,牵涉性疼痛发生。在这种情况下,疼痛的感觉一般在该神经达到的区域被感觉到,尽管损伤起始于另外的地方。常见的实例发生在椎间盘突出,其中从脊柱伸出的神经根部被相邻的盘物质压迫。尽管疼痛可能来源于受损的椎间盘本身,疼痛也将在被压迫神经达到的区域(例如,大腿、膝盖或脚)被感觉到。缓解神经根部的压力可能缓解牵涉性疼痛,只要永久性神经损伤还没有发生。心肌缺血(部分心肌组织血流的缺少)可能是被最熟知的牵涉性疼痛的实例;感觉可以发生在胸腔上部,受限的感觉(restricted feeling),或左肩、臂或甚至手的疼痛。
本发明所述的非细胞毒性蛋白酶组分是非细胞毒性的蛋白酶或其片段,所述蛋白酶或蛋白酶片段能够剪切以下三种底物蛋白的一种中存在的不同但特异的肽键,所述底物蛋白为疼痛感应传入器(nociceptive sensory afferent)中胞吐融合器(exocytic fusion apparatus)的小突触小泡蛋白(synaptobrevin)、突触融合蛋白(syntaxin)或SNAP-25。这些底物是神经分泌机制的重要组分。本发明所述的非细胞毒性蛋白酶组分优选地为奈瑟菌属IgA蛋白酶或其片段,或梭菌属神经毒素L-链或其片段。特别优选的非细胞毒性蛋白酶组分为肉毒菌神经毒素(BoNT)L-链或其片段。
本发明所述的转运组分使非细胞毒性蛋白酶(或其片段)能够转运进靶细胞,以便蛋白酶活性的功能表达发生在靶细胞的细胞溶胶中。转运组分优选地能够在低pH值的条件下,在脂膜上形成离子可渗透的孔。优选地,已经发现仅使用蛋白分子的那些部分能够在内涵体膜中形成孔。转运部分可能从微生物蛋白来源获得,特别地从细菌或病毒蛋白来源获得。因此,在一种实施方式中,转运组分是诸如细菌毒素或病毒蛋白的酶的转运区域。本发明所述的转运组分优选地为梭菌属神经毒素H-链或其片段。最优选地,它是区域HN(或其功能组分),其中HN表示梭菌属神经毒素H-链的部分或片段,其约等价于H-链氨基端的一半,或对应于完整H-链中该片段的区域。
本发明所述的TM组分负责将本发明所述的融合蛋白结合到靶细胞的结合位点(Binding Site)。因此,TM组分简单地是配体, 通过它本发明所述的融合蛋白结合到选定的靶细胞。
在本发明的文字中,靶细胞是疼痛感觉传入器,优选地是初级的疼痛传入器(例如A-纤维,如Aδ-纤维或C-纤维)。因此,本发明所述的融合蛋白能够抑制神经递质或神经调节物质[如,谷氨酰胺、P物质、降血钙素基因相关肽(calcitonin-gene related peptide(CGRP))和/或神经肽Y]从疼痛感受传入器神经元的分散群落中的释放。在使用中,融合蛋白降低或防止感觉传入器信号(如神经递质或神经调控物质)从外周向中枢疼痛纤维的传导;并因此具有作为治疗疼痛,特别是慢性疼痛的治疗分子的应用。
确定TM结合到疼痛感受传入器是常规。例如,简单的放射性位移实验可能被采用,其中代表疼痛感觉传入器的组织或细胞(如DRGs)在过量未标记配体存在的情况下被暴露给已经标记(如氚化)的配体。在这样的实验中,非特异和特异结合的相对比例可以被估计,由此允许确认配体结合到疼痛感觉传入器靶细胞。任选地,该测试可能包括一种或多种结合拮抗剂,并且该测试可能进一步包括观察配体结合的损失。这一类型实验的实例可以在Hulme,E.C.(1990),Receptor-binding studies,a brief outline,pp.303-311,In Receptorbiochemistry,A Practical Approach,Ed.E.C.Hulme,Oxford UniversityPress中找到。
当与相应的“游离(free)”TM比较时,本发明所述的融合蛋白通常显示出对疼痛感觉传入器靶细胞降低的结合亲和度(在达100倍的区间)。然而,尽管有这一观察结果,本发明所述的融合蛋白令人吃惊地显示出良好的效力。这可归因于两个主要的特征。第一,所述非细胞毒性蛋白酶组分是催化的——因此,若干这些分子的治疗效果被迅速扩大。第二,在疼痛感受传入器上存在的受体仅需要发挥用于治疗进入的通路作用,而非必须需要被刺激到要求的水平,以便达到配体-受体介导的药物反应。因此,本发明所述的融合蛋白可能以比其它类型的止痛分子,如NSAIDS、吗啡和加巴喷丁(Gabapentin)所使用低的多的剂量被给药。后者分子典型地以高微克到毫克(甚至到数百毫克)的量被给药,而本发明所述的融合蛋白可能以低得多的剂量给药,典型地至少低10倍,而更典型地至少低100倍。
TM优选地包含最多50个氨基酸残基,更优选地最多40个氨基酸残基,特别优选地最多30个氨基酸残基,和最优选地最多20个氨基酸残基。
阿片样物质(Opioids)代表优选的本发明所述的TM。在肽家族内包括脑啡肽(met和leu)、内源性吗啡(endomorphin)1和2、β-内啡肽和强啡肽。阿片样物质肽经常被用于临床,以修饰对疼痛感受器和疼痛反应中涉及的其它细胞的活性。如三级世界卫生组织止痛剂梯度(Analgesic Ladder),阿片样物质具有进入慢性癌症和非癌症性疼痛药物治疗的所有三个阶段的切入点,强调了它们对疼痛治疗的重要性。提到阿片样物质,包括其片段、变异体和衍生物,它们保留了结合疼痛感受传入器的能力。
本发明所述的TM也可以是在疼痛感受传入器上,更特别地在初级疼痛传入器上存在的一个或多个受体发挥“激动剂”作用的分子。传统地,激动剂已经被认为是能够在细胞内提高或降低活性的任何分子,即简单地引起细胞活性改变的任何分子。例如,传统方式的激动剂包括能够与细胞上受体结合病起始反应或活性的化学物质,或通过激活受体引起活性反应的药物,无论该反应是细胞活性的提高或降低。
然而,对于本发明的目的,激动剂更特异地被界定为能够刺激靶细胞内胞吐融合过程(exocytic fusion)的分子,该过程容易被能够剪切所述靶细胞中胞吐融合元件的蛋白的蛋白酶(或其片段)抑制。
因此,本发明特定激动剂的定义排除了传统上被认为是激动剂的多种分子。例如,在其通过结合到TrkA受体启动神经元分化的能力方面,神经生长因子(NGF)是激动剂。然而,当由上述条件评估时,NGF不是激动剂,因为它不是胞吐融合体的主要诱导剂。此外,NGF刺激的过程(即细胞分化)不易于被非细胞毒性毒素分子的蛋白酶活性抑制。
结合疼痛感受传入器上受体的TM的激动剂的性质可以用实施例10中所述的方法确认。
在本发明优选的实施方式中,所述TM的目标是ORL1受 体。该受体是G蛋白偶联类受体的一个成员,并且具有7个跨膜域结构。ORL1受体的性质在Mogil & Pasternak(2001),PharmacologicalReviews,Vol.53,No.3,pages 381-415中被详细讨论。
在一种实施方式中,TM是结合(优选地特异结合)ORL1受体的分子。更优选地,TM是ORL1受体的“激动剂”。术语“激动剂”在文中如上文定义。
结合ORL1受体的TM激动剂的性质可以用实施例10中所述的方法确认。这些方法基于前述实验(参见,Inoue et al.1998[Proc.Natl.Acad.Sci.,95,10949-10953]),其证实了受体的天然激动剂,伤害感受肽(或者孤啡肽)(nociceptin)),引发了P物质从疼痛感受初级传入器神经元释放的诱导。这被以下事实支持: 伤害感受肽诱导的反应通过特异受体(P物质受体)拮抗剂消除;和 用辣椒素(其耗尽小直径初级传入器神经元中的P物质)预处理细胞减弱了伤害感受肽诱导的反应。
相似地,Inoue等人证实了A类肉毒菌神经毒素的足底内注射消除了伤害感受肽诱导的反应。由于已知BoNT抑制P物质从初级传入器神经元的释放(Welch et al.,2000,Toxicon,38,245-258),这证实了伤害感受肽-ORL1相互作用与P物质的后续释放之间的关联。
因此,如果TM引起P物质从疼痛感觉传入器神经元释放的诱导,TM可以被称为在ORL1受体具有激动剂活性(参见实施例10)。
在本发明特别优选的实施方式中,所述TM是伤害感受肽——ORL1受体的天然配体。伤害感受肽靶向ORL1受体,具有高亲和度。其它优选TMs的实例包括:
编码 | 序列 | Ref. | SEQ ID No. |
伤害感受肽1-17 | FGGFTGARKSARKLANQ | [1] | 37,38 |
伤害感受肽1-11 | FGGFTGARKSA | [1] | 39,40 |
伤害感受肽[Y10]1-11 | FGGFTGARKYA | [1] | 41,42 |
伤害感受肽[Y14]1-17 | FGGFTGARKSARKYANQ | [1] | 45,46 |
伤害感受肽1-13 | FGGFTGARKSARK | [2] | 47,48 |
编码 | 序列 | Ref. | SEQ ID No. |
伤害感受肽[R14K15]1-17(在本说明书中也被称作“变异”伤害感受肽) | FGGFTGARKSARKRKNQ | [3,4] | 49,50 |
肽激动剂 | 来自重组文库方法的肽激动剂 | [5] | - |
[1]Mogil & Pasternak,2001,Pharmacol.Rev.,53,381-415[2]Maile et al.,2003,Neurosci.Lett.,350,190-192[3]Rizzi et al.,2002,J.Pharmacol.Exp.Therap.,300,57-63[4]Okada et al.,2000,Biochem.Biophys.Res.Commun.,278,493-498[5]Dooley et al.,1997,J Pharmacol Exp Ther.283(2),735-41.
上文识别的“变异”TM显示出对疼痛感觉传入器特别良好的结合亲和力(当与天然伤害感受肽比较时)。这是令人吃惊的,因为氨基酸修饰发生在远离TM的N-末端的位置。而且,修饰大多在TM的C-末端,其又被附着到大的多肽序列(即转运区域)。一般来说,含TM的融合蛋白将显示出相对于TM本身降低约100倍的结合能力。上述“变异”TM本身显示出疼痛感觉传入器对天然伤害感受肽提高了约3-10倍的结合能力(如,通过ORL1受体)。因此,含有“变异”TM的融合体被预期显示出疼痛感觉传入器对“游离的”伤害感受肽降低了约10倍的结合能力(如,通过ORL1受体)。然而,本发明人已经展示了:这些含有“变异”TM的融合蛋白显示出与“游离”伤害感受肽非常接近(最令人吃惊)的结合能力——参见图14。
在本发明的情形中,术语阿片样物质或ORL1受体激动剂(如伤害感受肽,或上表中所列的肽的任意一种)包括与所述阿片样物质或激动剂具有至少70%,优选地至少80%,更优选地至少90%,和最优选地至少95%同源性的分子。激动剂同源体保留了伤害感受肽在ORL1受体上的激动剂性质,其可使用实施例10中提供的方法测试。相似地,阿片样物质同源体基本上保持了与其显示高度同源性的阿片样物质的结合功能。
本发明也包括上述TMs中任一的片段、变异体和衍生物。这些片段、变异体和衍生物基本上保留了归因于所述TMs的性质。
除了上述阿片样物质和非阿片样物质类的TMs,多种其它多肽也适合靶向本发明所述的融合蛋白到疼痛感觉传入器(如,到伤害感受肽)。在这一方面,特别要提到甘丙肽(galanin)和甘丙肽的衍生物。甘丙肽受体在DRGs中突触前或突触后被发现(Liu & Hokfelt,(2002),Trends Pharm.Sci.,23(10),468-74),并且在神经病变疼痛状态过程中,表达被增强。蛋白酶激活的受体(proteinase-activated receptors(PARs))也是本发明所述的TMs的优选组,最特别地是PAR-2。已知PAR-2的激动剂诱导/引起急性炎症,部分通过神经元性的机理。PAR2由初级脊髓传入神经元表达,并且PAR2激动剂刺激P物质(substanceP(SP))和降血钙素基因相关肽(calcitonin gene-related peptide(CGRP))在外周组织中的释放。
本发明所述特别优选组的TMs包括:
配体 | 参考文献 |
伤害感受肽 | Guerrini,et al.,(1997)J.Med.Chem.,40,pp.1789-1793 |
β-内啡肽 | Blanc,et al.,(1983)J.Biol.Chem.,258(13),pp.8277-8284 |
内啡素-1;内啡素-2 | Zadina,et al.,(1997).Nature,386,pp.499-502 |
强啡肽 | Fields & Basbaum(2002)Chapter 11,In TheTextbook of Pain,Wall & Melzack eds. |
Met-脑啡肽 | Fields & Basbaum(2002)Chapter 11,In TheTextbook of Pain,Wall & Melzack eds. |
Leu-脑啡肽 | Fields & Basbaum(2002)Chapter 11,In TheTextbook of Pain,Wall & Melzack eds. |
甘丙肽 | Xu et al.,(2000)Neuropeptides,34(3 & 4),137-147 |
PAR-2肽 | Vergnolle et al.,(2001)Nat.Med.,7(7),821-826 |
本发明所述的蛋白酶剪切位点允许在非细胞毒性蛋白酶组分和TM组分之间的位置对融合蛋白进行剪切(优选地为可控剪切)。该剪切反应将融合蛋白从单链多肽转化为二硫键连接的双链多肽。
根据本发明优选的实施方式,TM通过位于该TM的C-端远端的区域或氨基酸序列结合。例如,相关的结合区域可能包括朝向所述TM中部(即线性肽序列)放置的内部区域或氨基酸序列。优选地,相关结合区域位于朝向该TM的N-末端,更优选地在或接近所述N-末端。
在一种实施方式中,单链多肽融合体可能包括一个以上蛋白水解剪切位点。然而,在两个或多个这样的位点存在之处,它们是不同的,借此基本上防止在单一蛋白酶存在的情况下发生多处剪切的事件。在另一实施方式中,优选的是单链多肽融合体具有单一蛋白酶剪切位点。
蛋白酶剪切序列可以通过传统的方法,例如通过位点定向诱变在DNA水平上引入(和/或任意内在剪切序列的去除)。确认剪切序列存在的筛选可手工进行或用计算机软件(如,DNASTAR,Inc公司的MapDraw程序)辅助进行。
尽管可采用任何蛋白酶剪切位点,以下是优选的:肠激酶 (DDDDK↓)Xa因子 (IEGR↓/IDGR↓)TEV(烟草蚀纹病毒) (ENLYFQ↓G)凝血酶 (LVPR↓GS)PreScission (LEVLFQ↓GP)
内含肽(intein)也被术语蛋白酶剪切位点包括,它是自剪切序列。自剪接反应是可控的,例如,通过改变存在的还原试剂的浓度。
在使用中,蛋白酶剪切位点被剪切,并且TM的N-末端区域(优选地为N-末端)成为暴露的。产生的多肽具有TM,其带有基本游离于融合蛋白其余部分的N-末端区域或内部区域。这一排列保证了该TM的N-末端组分(或内部区域)可直接与靶细胞上的结合位点 相互作用。
在优选的实施方式中,TM和蛋白酶剪切位点在该融合蛋白中由最多10个氨基酸残基分隔开,更优选地由最多5个氨基酸残基分隔,并且最优选地由0个氨基酸残基分隔。因此,蛋白酶剪切位点被剪切之后,向融合体提供具有N-末端区域的TM,所述N-末端区域基本游离于该融合体的其余部分。这一排列保证了靶向部分(TargetingMoiety)的N-末端组分可直接与靶细胞上的结合位点相互作用。
与上述激活步骤相关的一个好处在于,一旦融合蛋白的蛋白水解剪切已经发生,所述TM仅对N-末端降解易感。此外,特异蛋白酶剪切位点的选择允许多肽融合体的选择性激活,成为双链构型。
本发明所述的单链多肽融合体的构建将蛋白酶剪切位点置于TM和非细胞毒性蛋白酶组分之间。
优选的是:在单链融合体中,TM位于蛋白酶剪切位点和转运组分之间。这保证了TM被连接到转运区域(即,如原生梭菌全毒素所发生的),尽管在本发明的情况下,两种组分的顺序相对于原生全毒素被逆转。这一排列的另一优点在于,TM被置于融合蛋白暴露的环形区域中,这对融合蛋白的构型具有最小的结构影响。在这一方面,所述环被不同地称作接头、激活环、域间环或仅仅是表面暴露的环(Schiavo et al 2000,Phys.Rev.,80,717-766;Turton et al.,2002,TrendsBiochem.Sci.,27,552-558}。
在一种实施方式中,在单链多肽中,非细胞毒性蛋白酶组分和转运组分被二硫键连接在一起。因此,在蛋白酶剪切位点被剪切后,该多肽被认为是双链构型,其中所述蛋白酶和转运区域通过二硫键保持连接在一起。为此,优选的是蛋白酶和转运组分在单链融合蛋白中由最多100个氨基酸残基彼此分隔开,更优选地最多80个氨基酸残基,特别优选地最多60个氨基酸残基,和最优选地最多50个氨基酸残基彼此分隔开。
在一种实施方式中,非细胞毒性蛋白酶组分与融合蛋白的转运组分形成二硫键。例如,形成二硫键的蛋白酶组分的氨基酸残基位于蛋白酶组分最后20个,优选地最后10个C-末端氨基酸残基之内。相似地,在转运组分中形成二硫键第二部分的氨基酸残基位于转运组 分前20个,优选地前10个N-末端氨基酸残基之内。
可选地,在单链多肽中,非细胞毒性蛋白酶组分和TM可被二硫键连接在一起。在这一方面,TM中形成二硫键的氨基酸残基优选地位于该TM N-末端的远端,更优选地朝向该TM的C-末端。
在一种实施方式中,非细胞毒性蛋白酶组分与融合蛋白的TM组分形成二硫键。在这一方面,形成二硫键的蛋白酶组分的氨基酸残基优选地位于蛋白酶组分最后20个,优更选地最后10个C-末端氨基酸残基之内。相似地,在TM组分中形成二硫键第二部分的氨基酸残基优选地位于TM最后20个,更优选地最后10个C-末端氨基酸残基之内。
上述二硫键排列具有这样的优点:蛋白酶和转运组分以与原生梭菌神经毒素相似的方式排列。通过比较的方式,参考原生梭菌神经毒素的一级氨基酸序列,每个半胱氨酸氨基酸残基由8到27个氨基酸残基分隔——摘自Popoff,MR & Marvaud,J-C,1999,Structural &genomic features of clostridial neurotoxins,Chapter 9,in TheComprehensive Sourcebook of Bacterial Protein Toxins.Ed.Alouf &Freer:
血清型1 | 序列 | C-C之间的“原生”长度 |
BoNT/A1 | CVRGIITSKTKS----LDKGYNKALNDLC | 23 |
BoNT/A2 | CVRGIIPFKTKS----LDEGYNKALNDLC | 23 |
BoNT/B | CKSVKAPG-------------------IC | 8 |
BoNT/C | CHKAIDGRS----------LYNKTLDC | 15 |
BoNT/D | CLRLTK---------------NSRDDSTC | 12 |
BoNT/E | CKN-IVSVK----------GIRK---SIC | 13 |
BoNT/F | CKS-VIPRK----------GTKAPP-RLC | 15 |
BoNT/G | CKPVMYKNT----------GKSE----QC | 13 |
TeNT | CKKIIPPTNIRENLYNRTASLTDLGGELC | 27 |
1仅来自蛋白水解菌株的信息
融合蛋白可以包含一个或多个纯化标记,它们位于蛋白酶组分的N-末端和/或转运组分的C-末端。
尽管可采用任何纯化标记,以下是优选的:His-标记(如6个组氨酸),优选地作为C-末端和/或N-末端标记MBP-标记(麦芽糖结合蛋白),优选地作为N-末端标记GST-标记(谷胱甘肽-S-转移酶),优选地作为N-末端标记His-MBP-标记,优选地作为N-末端标记GST-MBP-标记,优选地作为N-末端标记硫氧还蛋白-标记,优选地作为N-末端标记CBD-标记(几丁质结合域),优选地作为N-末端标记
根据本发明进一步的实施方式,一个或多个肽间隔分子可被包含在融合蛋白中。例如,肽间隔分子可在纯化标记和融合蛋白分子的剩余部分之间使用(例如,在N-末端纯化标记和本发明的蛋白酶组分之间;和/或在C-末端纯化标记和本发明的转运组分之间)。肽间隔分子也可在本发明的TM和转运组分之间使用。
多种不同的间隔分子可被用于本发明所述的任意融合蛋白中。这些间隔分子的实例包括图28和29所示的那些。本文特别提到了GS15、GS20、GS25和Hx27——参见图28和29。
本发明人出乎意料地发现:当间隔分子的大小被选择,以便(在使用中)TM的C-末端与转运组分的N-末端彼此分开40-105埃,优选地50-100埃,且更优选地50-90埃时,本发明所述的融合蛋白(如CPNv/A)可显示出对疼痛感觉传入器提高的结合活性。在另一实施方式中,优选的间隔分子具有11-29个氨基酸残基,优选地15-27个氨基酸残基,并且更优选地20-27个氨基酸残基的氨基酸序列。合适的间隔分子可根据Crasto,C.J.and Feng,J.A.(2000)May,13(5),pp.309-312常规地识别和获得——也参见http://www.fccc./edu/research/labs/feng/limker.html。
根据本发明的第二方面,提供了编码上述单链多肽的DNA序列。在本发明优选的方面,该DNA序列作为DNA载体的一部分被制备,其中该载体包含启动子和终止子。
在优选的实施方式中,该载体具有选自以下的启动子: 启动子 诱导试剂 典型的诱导条件Tac(杂交体) IPTG 0.2mM(0.05-2.0mM)AraBAD L-阿拉伯糖 0.2%(0.002-0.4%)T7-lac操纵子 IPTG 0.2mM(0.05-2.0mM)
本发明所述的DNA构建体优选地用计算机模拟(in silico)设计,并随后通过传统的DNA合成技术合成。
上述DNA序列信息根据采用的最终宿主细胞(如,大肠杆菌)表达系统被任选地针对密码子偏好而修饰。
DNA骨架优选地针对任何内在的核酸序列被筛选,当被转录和翻译时,所述核酸序列可产生对应于蛋白酶剪切位点的氨基酸序列,所述剪切位点由第二肽编码序列编码。所述筛选可手工进行或用计算机软件(如,DNASTAR,Inc公司的MapDraw程序)辅助进行。
根据本发明进一步的实施方式,提供了制备非细胞毒性试剂的方法,包括:a.使本发明所述的单链多肽融合蛋白与能够剪切蛋白酶剪切位点的蛋白酶接触;b.剪切所述蛋白酶剪切位点,并由此形成双链融合蛋白。
这方面提供了双链多肽,其通常模拟梭菌全毒素的结构。更详细地,产生的双链多肽典型地具有这样的结构,其中:a.第一条链包含非细胞毒性的蛋白酶或其片段,所述蛋白酶或蛋白酶片段能够剪切疼痛感应传入器(nociceptive sensory afferent)中胞吐融合器(apparatus)的蛋白;b.第二条链包含TM和转运区域,其能够将蛋白酶或蛋白酶片段从内涵体中跨内涵体膜转运进入疼痛感应传入器的细胞溶胶中;并且第一和第二条链被二硫键连接在一起。
在使用中,本发明所述的单链或双链多肽治疗、预防或缓解疼痛。
在使用中,治疗有效量的本发明所述单链或双链多肽被给 予患者。
本发明解决了广泛的疼痛症状,特别地慢性疼痛症状。优选的病症包括癌症性和非癌症性疼痛,炎症性疼痛和神经病变性疼痛。本申请所述的阿片样物质-融合体特别适合解除炎症性疼痛,尽管其可能适合解除神经病变性疼痛的能力较差。甘丙肽-融合体更适合解除神经病变性疼痛。
在使用中,本发明所述的多肽典型地以联合药物载体、稀释剂和/或赋形剂的药物组合物的形式被使用,尽管组合物确切的形式可根据给药模式改变。给药优选地给予哺乳动物,更优选地给予人类。
该多肽可以,例如,以用于关节内给药或颅骨内给药的无菌溶液的形式被使用。脊柱注射(如,硬膜外或髓鞘内)是优选的。
本发明所述多肽给药的剂量范围是产生期望的治疗效果的那些。应该认识到,需要的剂量范围取决于所述组分精确的性质;给药的途径;制剂的特征;患者的年龄;患者病症的特征、程度或严重性;是否有任何禁忌症;和诊断医生的判断。
合适的每日剂量在0.0001-1mg/kg范围内,优选地0.0001-0.5mg/kg,更优选地0.002-0.5mg/kg,和特别优选地0.004-0.5mg/kg。单位剂量可以从小于1毫克到30毫克变化,但是典型地在每剂0.01到1mg的范围内,这可被每天给药或优选地更不频繁地给药,如每周或每6个月。
特别优选的给药方案是基于2.5ng融合蛋白(如CPNv/A)作为1×药剂。在这方面,优选的剂量在1×-100×(即2.5-250ng)范围内。这一剂量范围明显低于(即,至少低10倍,典型地低100倍)其它类型止痛剂分子,如NSAIDS、吗啡和加巴喷丁(Gabapentin)采用的剂量。而且,当在摩尔的基础上进行相同比较时,上述差异被显著增大——这是因为本发明所述的融合蛋白具有比传统“小”分子疗法大得多的分子量(Mw)。
然而,在所要求剂量中的多种变化被预期,其取决于所述组分的精确性质和各种给药途径不同的效率。
这些剂量水平中的变化可以使用用于优化的标准经验途径调整,它们在本领域内被公知。
适合注射的组合物可以是溶液、悬液或乳剂、或干燥粉末的形式,所述粉末在使用前溶解或悬浮在适当载体中。
液态单位剂量形式典型地使用无致热物(pyrogen-free)的无菌载体制备。取决于载体和使用的浓度,活性成分可以溶解或悬浮在载体中。
在制备可给药溶液时,多肽可以被溶解在载体中,如果必要,该溶液通过加入氯化钠被制成等渗的,并在灌入合适的无菌小瓶或安瓿和封装前,使用无菌技术通过经由无菌过滤器过滤而灭菌。可选地,如果溶液的稳定性足够,该溶液在其密封容器中可通过高压灭菌被灭菌。
有利的添加剂,如缓冲液、增溶剂、稳定剂、防腐剂或杀菌剂、悬浮剂或乳化剂可被溶解在载体中。
使用前溶解或悬浮在适当载体中的干燥粉末可在无菌区域中使用无菌技术,通过向无菌容器中灌入预先灭菌的药物物质和其它成分制备。
可选地,多肽和其它成分可被溶解在水性载体中,该溶液通过过滤灭菌,并在灭菌区域中使用无菌技术分装进合适的容器。产品随后被冷冻干燥并且容器被无菌封装。
非口服(肠胃外)悬液,适合用于肌肉内、皮下或真皮内注射,以基本相同的方式制备,除了无菌组分悬浮在无菌载体中替代了被溶解,且灭菌不能通过过滤完成。所述组分可在无菌状态下分离,或可选地,其可在分离后灭菌,例如通过γ辐射。
有利地,诸如聚乙烯吡咯烷酮的悬浮剂可被包含在组合物中,以促进所述组分的均一分布。
定义部分
靶向部分(Targeting Moiety(TM))表示与试剂相关的任何化学结构,所述试剂与结合位点功能上相互作用,引起所述试剂与靶细胞表面的物理联系。在本发明的文字中,靶细胞是疼痛感觉传入器(nociceptive sensory afferent)。术语TM包括能够结合靶细胞上结合位点的任何分子(即,天然发生的分子,或其化学/物理修饰的变异体), 所述结合位点能够内化(internalisation)(如,内涵体的形成)——也被称为受体介导的细胞内吞。TM可能具有内涵体膜转运功能,在这种情况下,分离的TM和转运区域(Translocation Domain)组分不需要存在于本发明的试剂中。
本发明所述的TM结合(优选地特异结合)疼痛感觉传入器(如初级疼痛传入器)。在这一方面,特异结合表示TM以比其结合诸如非疼痛传入器的其它神经元和/或运动神经元(即,梭菌神经毒素全毒素的天然目标)更大的亲和力,结合到疼痛感觉传入器(如,初级疼痛传入器)。术语“特异结合”也可以表示给定的TM以106M-1或更高,优选地107M-1或更高,更优选地108M-1或更高,和最优选地109M-1或更高的结合亲和力(Ka)结合到给定受体,例如ORL1受体。
出于本发明的目的,激动剂被定义为能够刺激靶细胞内胞吐(exocytic)融合过程的分子,该过程容易被能够剪切所述靶细胞中胞吐融合元件的蛋白的蛋白酶(或其片段)抑制。
因此,本发明特定激动剂的定义排除了传统上被认为是激动剂的多种分子。
例如,在其通过结合到TrkA受体启动神经元分化的能力方面,神经生长因子(nerve growth factor(NGF))是激动剂。然而,当由上述条件评估时,NGF不是激动剂,因为它不是胞吐融合体的主要诱导剂。此外,NGF刺激的过程(即细胞分化)不易于被非细胞毒性毒素分子的蛋白酶活性抑制。
术语“片段”,当用于蛋白时,表示具有至少35个,优选地至少25个,更优选地至少20个,和最优选地至少10个所述蛋白的氨基酸残基的肽。
术语“变异体”,当用于蛋白时,表示含有一个或多个氨基酸类似物(如,非天然氨基酸)或替代的连接的蛋白的肽或肽片段。
术语“衍生物”,当用于蛋白时,表示含有所述蛋白和其它肽序列的蛋白。所述其它肽序列应该优选地不干扰基本折叠和由此产生的初始蛋白的构型结构。两个或多个肽(或片段,或变异体)可能被连接在一起形成衍生物。可选地,肽(或片段,或变异体)可与不相关分子(如第二个不相关的肽)连接。衍生物可被化学合成,但典 型地通过重组核酸的方法被制备。其它组分,如脂质、和/或多糖、和/或聚酮组分可被包括。
在本说明书中,提到“ORL1受体”包括所有ORL1受体家族的成员。ORL1受体家族的成员典型地具有7个跨膜域结构,并与Gi和G0家族的G蛋白偶联。确定ORL1受体的配体的G-蛋白刺激活性的方法在实施例12中给出。测量ORL1激活后细胞cAMP水平的降低的方法在实施例11中给出。ORL1受体家族成员的进一步的特征在于,它们典型地能够结合伤害感受肽(ORL1的天然配体)。举例来说,所有ORL1受体的选择性剪接变异体是ORL1受体家族的成员。
术语“非细胞毒性的”表示讨论议题中的所述蛋白酶分子不杀死其重新靶向的靶细胞。
本发明所述的蛋白酶包括所有天然发生的非细胞毒性蛋白酶,其能够剪切真核细胞中胞吐融合器的一个或多个蛋白。
本发明所述的蛋白酶优选地为细菌蛋白酶(或其片段)。更优选地,所述细菌蛋白酶选自梭菌属(Clostridium)或奈瑟菌属(Neisseria)(例如,梭菌L-链,或优选地来自淋球菌(N.gonorrhoeae)的奈瑟菌IgA蛋白酶)。
本发明也包括修饰的非细胞毒性蛋白酶,其包含非天然发生的氨基酸序列和/或合成的氨基酸残基,只要修饰的蛋白酶仍显示出上述蛋白酶活性。
本发明所述的蛋白酶优选地显示出丝氨酸或金属蛋白酶活性(如,肽链内切酶活性)。蛋白酶优选地对SNARE蛋白(如SNAP-25、小突触泡蛋白/VAMP或突触融合蛋白)具有特异性。
特别提及的是神经毒素的蛋白酶区域,例如细菌神经毒素的蛋白酶区域。因此,本发明包含天然发生的神经毒素区域的使用,以及所述天然发生的神经毒素的重组制备版本的使用。
示例性的神经毒素通过梭菌产生,并且术语“梭菌神经毒素”包括由破伤风梭菌(C.tetani)(TeNT)和由肉毒梭菌(C.botulinum)(BoNT)血清型A-G产生的神经毒素,以及与由巴氏梭菌(C.baratii)和丁酸梭菌(C.butyricum)产生的、紧密相关的BoNT样神经毒素。上述缩写贯穿本说明书使用。例如,命名法BoNT/A表示神经毒素的 来源为BoNT(血清型A)。相应的命名法也适用于其它BoNT血清型。
术语“L-链片段”表示神经毒素L-链的组分,该片段显示出金属蛋白酶的活性并能够蛋白水解地剪切细胞胞吐中涉及的囊泡和/或质膜相关蛋白。
转运区域是使蛋白酶(或其片段)能够转运进靶细胞、以便蛋白酶活性的功能表达发生在靶细胞的细胞溶胶中的分子。任何分子(如,蛋白或肽)是否具有本发明所述必须的转运功能可通过多种传统测试中任一确认。
例如,Shone C.(1987)描述了采用脂质体的体外测试,其使用测试分子刺激。必须转运功能的存在通过K+和/或标记的NAD从脂质体中的释放确定,这可被容易地检测[参见Shone C.(1987)Eur.J.Biochem;vol.167(1):pp.175-180]。
Blaustein R.(1987)提供了另一实例,其描述了采用平面磷脂双层膜简单的体外测试。该膜用测试分子刺激,并且必须的转运功能通过跨所述膜传导性的提高确认[参见Blaustein(1987)FEBS Letts;vol.226,no.1:pp.115-120]。
能够评估膜融合体,并由此识别适合用于本发明的转运区域的其它方法由Methods in Enzymology Vol 220 and 221,MembraneFusion Techniques,Parts A and B,Academic Press 1993提供。
转运区域优选地能够在低pH值的条件下,在脂膜上形成离子可渗透的孔。优选地,已经发现仅使用蛋白分子的那些部分能够在内涵体膜中形成孔。
转运区域可以从微生物蛋白来源获得,特别地从细菌或病毒蛋白来源获得。因此,在一种实施方式中,转运区域是诸如细菌毒素或病毒蛋白的酶的转运区域。
已经有充分记载:细菌毒素分子的某些区域能够形成这样的孔。也已知:在病毒内表达的膜融合蛋白的某些转运区域能够形成这样的孔。这些区域可被用在本发明中。
所述转运区域可能是梭菌源的,即HN区域(或其功能组分)。HN表示梭菌属神经毒素H-链的部分或片段,其约等价于H-链氨基端的一半,或对应于完整H-链中的片段的区域。优选的是H-链基本 上缺少H-链的HC组分天然的结合功能。在这一方面,HC功能可通过HC氨基酸序列的删除(通过核酸酶或蛋白酶处理,或者在DNA合成水平,或者在合成后水平)而被除去。可选地,HC功能可通过化学或生物处理而失活。因此,H-链优选地不能结合靶细胞上的结合位点,而原生梭菌神经毒素(即全毒素)结合该位点。
在一种实施方式中,转运区域是梭菌神经毒素的HN区域(或其片段)。合适的梭菌转运区域的实例包括:肉毒菌A型神经毒素 -氨基酸残基(449-871)肉毒菌B型神经毒素 -氨基酸残基(441-858)肉毒菌C型神经毒素 -氨基酸残基(442-866)肉毒菌D型神经毒素 -氨基酸残基(446-862)肉毒菌E型神经毒素 -氨基酸残基(423-845)肉毒菌F型神经毒素 -氨基酸残基(440-864)肉毒菌G型神经毒素 -氨基酸残基(442-863)破伤风神经毒素 -氨基酸残基(458-879)
对于在肉毒梭菌和破伤风梭菌中产生毒素的遗传基础的细节,我们参考Henderson et al(1997)in The Clostridia:Molecular Biologyand Pathogenesis,Academic press。
术语“HN”包括天然发生的神经毒素的HN部分和修饰的HN部分,其具有非天然发生的氨基酸序列和/或合成的氨基酸残基,只要修饰的HN部分仍显示出上述转运功能。
可选地,转运区域可能是非梭菌源的(参见表4)。非梭菌转运区域源的实例包括,但不限制于白喉毒素的转运区域[O=Keefe etal.,Proc.Natl.Acad.Sci.USA(1992)89,6202-6206;Silverman et al.,J.Biol.Chem.(1993)269,22524-22532;和London,E.(1992)Biochem.Biophys.Acta.,1112,pp.25-51],假单胞菌外毒素A类型的转运区域[Prioret al.Biochemistry(1992)31,3555-3559],炭疽病毒素的转运区域[Blanke et al.Proc.Natl.Acad.Sci.USA(1996)93,8437-8442],多种具有转运功能的融合或疏水肽[Plank et al.J.Biol.Chem.(1994)269, 12918-12924;和Wagner et al(1992)PNAS,89,pp.7934-7938],及两亲肽[Murata et al(1992)Biochem.,31,pp.1986-1992]。所述转运区域可模拟天然生成的蛋白中的转运区域,或可能包括氨基酸变异,只要该变异不破坏该转运区域的转运能力。
适合用于本发明的病毒转运区域的特定实例包括病毒表达的膜融合蛋白的某些转运区域。例如,Wagner et al.(1992)和Murata et al.(1992)描述了从流感病毒血凝素的N-末端区域衍生的多个融合和两亲肽的转运(即,膜融合和囊泡形成)功能。已知具有期望转运活性的其它病毒表达的膜融合蛋白是塞姆利基森林病毒(Semliki Forest Virus(SFV))融合肽的转运区域,水泡性口炎病毒(vesicular stomatitis virus(VSV))糖蛋白G的转运区域,SER病毒F蛋白的转运区域和泡沫病毒包膜糖蛋白的转运区域。病毒编码的刺突(Aspike)蛋白在本发明的背景下具有特定的应用,例如,SFV的E1蛋白和VSV的G蛋白。
表(下文)中所列的转运区域的用途包括其序列变异体的用途。变异体可能包含一个或多个保守核酸置换和/或核酸删除或插入,条件是该变异体具有必须的转运功能。变异体也可能包含一个或多个氨基酸置换和/或氨基酸删除或插入,只要该变异体具有必须的转运功能。
转运区域来源 | 氨基酸残基 | 参考文献 |
白喉毒素 | 194-380 | Silverman et al.,1994,J.Biol.Chem.269,22524-22532London E.,1992,Biochem.Biophys.Acta.,1113,25-51 |
假单胞菌外毒素的区域II | 405-613 | Prior et al.,1992,Biochemistry31,3555-3559Kihara & Pastan,1994,Bioconj Chem.5,532-538 |
转运区域来源 | 氨基酸残基 | 参考文献 |
流感病毒血凝素 | GLFGAIAGFIENGWEGMIDGWYG及其变异体 | Plank et al.,1994,J.Biol.Chem.269,12918-12924Wagner et al.,1992,PNAS,89,7934-7938Murata et al.,1992,Biochemistry 31,1986-1992 |
塞姆利基森林病毒融合蛋白 | 转运区域 | Kielian et al.,1996,J Cell Biol.134(4),863-872 |
水泡性口炎病毒糖蛋白G | 118-139 | Yao et al.,2003,Virology310(2),319-332 |
SER病毒F蛋白 | 转运区域 | Seth et al.,2003,J Virol 77(11)6520-6527 |
泡沫病毒包膜糖蛋白 | 转运区域 | Picard-Maureau et al.,2003,JVirol.77(8),4722-4730 |
附图图1LC/A-伤害感受肽-HN/A融合蛋白的纯化图2伤害感受肽-LC/A-HN/A融合蛋白的纯化图3LC/C-伤害感受肽-HN/C融合蛋白的纯化图4LC/A-met脑啡肽-HN/A融合蛋白的纯化图5LC/A-伤害感受肽-HN/A融合蛋白和伤害感受肽-LC/A-HN/A融合蛋白的结合效力的比较图6LC/A-伤害感受肽-HN/A融合蛋白的体外催化活性图7LC/A-伤害感受肽变异体-HN/A融合蛋白的纯化 图8LC/A-伤害感受肽-HN/A融合蛋白和LC/A-伤害感受肽变异体-HN/A融合蛋白融的结合效力的比较图9表达/纯化的具有可变间隔长度产物的LC/A-伤害感受肽-HN/A融合蛋白家族图10SP释放和SNAP-25被CPN-A剪切的抑制图11DRG暴露于CPN-A后,SP释放和SNAP-25的剪切的在延长的时间段内的抑制图12SNAP-25被CPNv-A的剪切图13DRG暴露于CPNv-A后,NAP-25在延长的时间段内的剪切图14CPNv-A融合体介导的[3H]-伤害感受肽结合的替换图15表达/纯化的CPNv(Ek)-A产物图16SNAP-25被CPNv(Ek)-A的剪切图17表达/纯化的CPNv-C产物图18突触融合蛋白被CPNv-C的剪切图19CPN-A在急性辣椒素诱导的机械痛觉异常模型中的效力图20CPN-A在链脲霉素(STZ)诱导的外周糖尿病神经病变(神经病变性疼痛)模型中的效力图21CPNv-A在急性辣椒素诱导的机械痛觉异常模型中的效力图22表达/纯化的LC/A-CPLE-HN/A产物图23表达/纯化的LC/A-CPBE-HN/A产物图24表达/纯化的CPOP-A产物图25表达/纯化的CPOPv-A产物图26DRG细胞模型中SNAP-25的体外剪切图27表达/纯化的CPNv-A-FXa-HT(可去除his-标记)图28具有可变间隔长度的LC/A-伤害感受肽-HN/A融合蛋白的 体外效力,由配体竞争测试评估图29具有可变间隔长度的LC/A-伤害感受肽-HN/A融合蛋白的体外效力,由体外SNAP-25剪切评估在
附图现在被更详细地描述。图1-LC/A-伤害感受肽-HN/A融合蛋白的纯化
使用实施例9所概括描述的方法,LC/A-伤害感受肽-HN/A融合蛋白从大肠杆菌BL21细胞中被纯化。简单地说,细胞破碎后获得的可溶产物被加样到装有镍的亲和捕获柱上。结合的蛋白用100mM咪唑洗脱,用因子Xa处理以激活融合蛋白并除去麦芽糖结合蛋白(maltose-binding protein(MBP))标记,随后重加样到第二个装有镍的亲和捕获柱上。来自纯化步骤的样品通过SDS-PAGE(图A)和蛋白质印迹(图B)评估。抗伤害感受肽的抗血清(从Abcam获得)被用作蛋白质印迹蛋白质印迹的一抗。在还原剂不存在和存在下,最终纯化的材料分别在标记有[-]和[+]的泳道中被识别。图2-伤害感受肽-LC/A-HN/A融合蛋白的纯化
使用实施例9所述的方法,伤害感受肽-LC/A-HN/A融合蛋白从大肠杆菌BL21细胞中被纯化。简单地说,细胞破碎后获得的可溶产物被加样到装有镍的亲和捕获柱上。结合的蛋白用100mM咪唑洗脱,用因子Xa处理以激活融合蛋白并除去麦芽糖结合蛋白(MBP)标记,随后重加样到第二个装有镍的亲和捕获柱上。来自纯化步骤的样品通过SDS-PAGE(图A)和蛋白质印迹蛋白质印迹(图B)评估。抗伤害感受肽的抗血清(从Abcam获得)被用作蛋白质印迹蛋白质印迹的一抗。在还原剂不存在和存在下,最终纯化的材料分别在标记[-]和[+]的泳道中被识别。图3-LC/C-伤害感受肽-HN/C融合蛋白的纯化
使用实施例9所述的方法,LC/C-伤害感受肽-HN/C融合蛋白从大肠杆菌BL21细胞中被纯化。简单地说,细胞破碎后获得的可溶 产物被加样到装有镍的亲和捕获柱上。结合的蛋白用100mM咪唑洗脱,用因子Xa处理以激活融合蛋白并除去麦芽糖结合蛋白(MBP)标记,随后重加样到第二个装有镍的亲和捕获柱上。来自纯化步骤的样品通过SDS-PAGE(图A)和蛋白质印迹(图B)评估。抗伤害感受肽的抗血清(从Abcam获得)被用作蛋白质印迹的一抗。在还原试剂不存在和存在下,最终纯化的材料分别在标记[-]和[+]的泳道中被识别。图4-LC/A-met脑啡肽-HN/A融合蛋白的纯化
使用实施例9所述的方法,LC/A-met脑啡肽-HN/A融合蛋白从大肠杆菌BL21细胞中被纯化。简单地说,细胞破碎后获得的可溶产物被加样到装有镍的亲和捕获柱上。结合的蛋白用100mM咪唑洗脱,用因子Xa处理以激活融合蛋白并除去麦芽糖结合蛋白(MBP)标记,随后重加样到第二个装有镍的亲和捕获柱上。来自纯化步骤的样品通过SDS-PAGE评估。在还原剂不存在和存在下,最终纯化的材料分别在标记[-]和[+]的泳道中被识别。图5-LC/A-伤害感受肽-HN/A融合蛋白和伤害感受肽-LC/A-HN/A融合蛋白的结合效力的比较
伤害感受肽融合体结合ORL1受体的能力使用简单的基于竞争的测试评估。背根神经节(dorsal root ganglia(DRG))的原始培养物在1nM的[3H]-伤害感受肽存在的情况下被暴露于各种浓度的测试材料。放射性标记配体的特异结合的降低通过闪烁计数评估,并且与未标记配体(Tocris伤害感受肽)的效力比较绘图。清楚的是LC/A-伤害感受肽-HN/A融合体在与ORL1受体相互作用方面远比伤害感受肽-LC/A-HN/A融合体出众。图6-LC/A-伤害感受肽-HN/A融合蛋白的体外催化活性
纯化的LC/A-伤害感受肽-HN/A融合蛋白的体外肽链内切酶活性本质上根据Chaddock et al 2002,Prot.Express Purif.25,219-228所述确定。简单地说,固定在ELISA平板上的SNAP-25肽在37℃被暴露于多种浓度的融合蛋白1小时。一系列的洗涤之后,被剪切的 SNAP-25肽的量通过用与特定抗血清的反应性进行定量。图7-LC/A-伤害感受肽变异体-HN/A融合蛋白的纯化
使用实施例9所述的方法,LC/A-伤害感受肽变异体-HN/A融合蛋白从大肠杆菌BL21细胞中被纯化。简单地说,细胞破碎后获得的可溶产物被加样到装有镍的亲和捕获柱上。结合的蛋白用100mM咪唑洗脱,用因子Xa处理以激活融合蛋白并除去麦芽糖结合蛋白(MBP)标记,随后重加样到第二个装有镍的亲和捕获柱上。来自纯化步骤的样品通过SDS-PAGE评估。在还原剂不存在和存在下,最终纯化的材料分别在标记[-]和[+]的泳道中被识别。图8-LC/A-伤害感受肽-HN/A融合蛋白和LC/A-伤害感受肽变异体-HN/A融合蛋白的结合效力的比较
伤害感受肽融合体结合ORL1受体的能力使用简单的基于竞争的测试评估。背根神经节(DRG)的原始培养物在1nM的[3H]-伤害感受肽存在的情况下被暴露于各种浓度的测试材料。放射性标记配体的特异结合的降低通过闪烁计数评估,并且与未标记配体(Tocris伤害感受肽)的效力比较绘图。清楚的是LC/A-伤害感受肽变异体-HN/A融合体(CPNv-LHA)在与ORL1受体相互作用方面远比LC/A-伤害感受肽变异体-HN/A融合体(CPN-LHA)出众。图9-表达/纯化具有可变间隔长度产物的LC/A-伤害感受肽-HN/A融合蛋白家族
使用实施例9所述的方法,含有GS10、GS30和HX27的LC/A-CPN-HN/A融合蛋白从大肠杆菌细胞浆(cell paste)中被纯化。来自LC/A-CPN(GS10)-HN/A、LC/A-CPN(GS15)-HN/A、LC/A-CPN(GS25)-HN/A、LC/A-CPN(GS30)-HN/A和LC/A-CPN(HX27)-HN/A纯化的样品在用考马斯蓝(Coomassie Blue)染色前,通过SDS-PAGE评估。电泳图样表明CPBE-A预期分子量的二硫键双链种类的纯化。上部图面:M=标准分子量标记;S=大肠杆菌总蛋白可溶部分;FT=不结合Ni2+-装载的琼脂糖柱的蛋白; FUSION=通过加入咪唑洗脱的融合蛋白。底图:泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白的可溶部分;泳道3=在Ni2+-装载的琼脂糖上初始捕获后纯化的材料;泳道4=在Ni2+-装载琼脂糖上最终捕获前用因子Xa处理的材料;泳道5=用因子Xa(5μl)激活后纯化的最终材料;泳道6=用因子Xa(10μl)激活后纯化的最终材料;泳道7=用因子Xa(20μl)激活后纯化的最终材料;泳道8=用因子Xa+DTT(5μl)激活后纯化的最终材料;泳道9=用因子Xa+DTT(10μl)激活后纯化的最终材料;泳道10=用因子Xa+DTT(20μl)激活后纯化的最终材料。图10-SP释放和SNAP-25被CPN-A剪切的抑制
简单地说,背根神经节(DRG)的原始培养物被暴露于各种浓度的CPN-A中24小时。细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计量分析计算,并相对融合体浓度绘图(短划线)。也被回收,用于使用特定EIA试剂盒进行P物质含量的分析。P物质释放的抑制由实线显示。达到50%最大SNAP-25剪切所需的融合体浓度估计为6.30±2.48nM。图11-DRG暴露于CPN-A后,SP释放和SNAP-25的剪切在延长的时间段内的抑制
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPN-A中24小时。肉毒菌神经毒素(BoNT/A)被用作对照。初始的暴露后,细胞外物质通过清洗被除去,并且细胞在37℃下培养不同的时间段。在特定的时间点,细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计分析计算并由虚线显示。材料也被回收,用于使用特定EIA试剂盒进行的P物质含量的分析。P物质释放的抑制由实线显示。 图12-SNAP-25被CPNv-A的剪切
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPNv-A中24小时。细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计分析计算。达到50%最大SNAP--25剪切所需的融合体浓度估计为1.38±0.36nM。图13-DRG暴露于CPNv-A后,NAP-25在延长的时间段内的剪切
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPNv-A中24小时。CPN-A被用作对照。初始的暴露后,细胞外物质通过清洗被除去,并且细胞在37℃培养不同的时间段。在特定的时间点,细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计分析计算。图14-CPNv-A融合体介导的[3H]-伤害感受肽结合的替代
伤害感受肽融合体结合ORL1受体的能力使用简单的基于竞争的测试评估。背根神经节(DRG)的原始培养物在1nM的[3H]-伤害感受肽存在的情况下被暴露于各种浓度的测试材料。放射性标记配体的特异结合的降低通过闪烁计数评估,并且与未标记配体(Tocris伤害感受肽)的效力比较绘图。清楚的是LC/A-伤害感受肽变异体-HN/A融合体(标记为CPNv-LHnA)在与ORL1受体相互作用方面比LC/A-伤害感受肽-HN/A融合体(标记为CPN-LHnA)出众。图15-表达/纯化CPNv(Ek)-A产物
蛋白在用考马斯蓝染色前接受SDS-PAGE。电泳图谱表明预期分子量的CPNv(Ek)-A二硫键结合的双链种类的纯化。泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白可溶部分;泳道3=在Ni2+-装载的琼脂糖上初始捕获后纯化的物质;泳道4=用肠激酶(5μl)激活后纯化的最终物质;泳道5=用肠激酶(10μl)激活后纯化的最终物质;泳道6=用肠激酶(20μl)激活后纯化的最终物质;泳道7=用肠激酶+DTT(5μl)激活后纯化的最终物质;泳道8=用肠激酶+DTT(10μl)激活后纯化的最终物质;泳道9=用肠激酶+DTT(20μl)激活后纯化的最终物质。图16-SNAP-25被CPNv(Ek)-A的剪切
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPNv(Ek)-A中24小时。细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计分析计算。实施例9中制备的CPNv-A被用作比较的目的。SNAP-25被CPNv(Ek)-A(标记为En激活的)和CPNv-A(标记为Xa激活的)剪切的百分比被显示出。图17-表达/纯化CPNv-C产物
蛋白在用考马斯蓝染色前进行SDS-PAGE。电泳图谱表明预期分子量的CPNv-C的二硫键连接双链种类的纯化。泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白可溶部分;泳道3=在Ni2+-装载的琼脂糖上初始捕获后纯化的物质;泳道4=Ni2+-装载的琼脂糖上最终捕获前因子Xa处理的物质;泳道5=在Ni2+-装载的琼脂糖上第二次捕获后纯化的物质;泳道6=最终纯化的物质;泳道7=最终纯化的物质+DTT;泳道8=标准分子量标记。 图18-突触融合蛋白被CPNv-C的剪切
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPNv-C中24小时。细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-突触融合蛋白标记,以促进SNAP-25剪切的评估。被剪切的突触融合蛋白的百分比通过密度计分析计算。达到50%最大突触融合蛋白的剪切所需的融合体浓度估计为3.13±1.96nM。图19-CPN-A在急性辣椒素诱导的机械痛觉异常模型中的效力
LC/A-伤害感受肽-HN/A融合体(CPN/A)抑制急性辣椒素诱导的机械痛觉异常的能力在大鼠后爪的皮下足底内注射后被评估。在招入本研究之前(预处理),在用CPN/A皮下足底内注射后、但在辣椒素刺激之前(Pre-CAP),和在CPN/A注射后且用辣椒素刺激后(平均反应为15′和30′;CAP),实验动物被评估爪在对10g Von Frey纤丝刺激系列(10刺激×3次试验)的爪回缩频度(paw withdrawal frequency(PWF%))。辣椒素刺激通过10μL的0.3%溶液的注射完成。样品稀释物在0.5%的BSA/盐水中制备。图20-CPN-A在链脲霉素(Streptozotocin(STZ))诱导的外周糖尿病神经病变(神经病变性疼痛)模型中的效力
雄性Sprague-Dawley大鼠(250-300g)用65mg/kg溶解在柠檬酸盐缓冲液中的STZ处理(I.V.),并且血糖和脂质被每周测量以确定该模型的准备状态。爪回缩阈值(Paw Withdrawal Threshold(PWT))根据一段时间内响应于Von Frey纤丝刺激系列的反应被测量。当两个连续测量日(间隔1周)的PWT测量在尺度上低于6g时,疼痛异常被称为已建立。在这时,大鼠被随机分配到盐水组(阴性效力对照)、加巴喷丁(Gabapentin)组(阳性效力对照)或测试组(CPN/A)。测 试物质(20-25μl)作为单一注射剂被皮下注射(不包括加巴喷丁),并且PWT在治疗1天后被测量,并在这之后的两周时间内定期测量。加巴喷丁(30mg/kg i.p.,3ml/kg注射体积)在开始PWT测试之前2小时,被每天注射。图21-CPNv-A在急性辣椒素诱导的机械痛觉异常模型中的效力
LC/A-伤害感受肽变异体-HN/A融合体(CPNv/A)抑制辣椒素诱导的机械性疼痛异常的能力在大鼠后爪皮下足底内注射后被评估。在招入研究之前(预处理),在用CPNv/A皮下足底内注射后但在辣椒素刺激之前(Pre-CAP),和在CPN/A注射后且用辣椒素刺激后(平均反应为15′和30′;CAP),实验动物被评估爪在对10g Von Frey纤丝刺激系列(10刺激×3次试验)反应的爪回缩频度(PWF%)。辣椒素刺激通过10μL的0.3%溶液的注射完成。样品稀释物在0.5%的BSA/盐水中制备。这些数据被表示为标准化的爪回缩频度差异,其中峰值反应(辣椒素之后)和基线反应(辣椒素之前)之间的差异被表示为百分比。用该分析,可以看出CPNv/A比CPN/A更有效,因为达到应用CPN/A所看到的相似止痛效果需要较低剂量的CPNv/A。图22-表达/纯化LC/A-CPLE-HN/A产物
蛋白在用考马斯蓝染色前接受SDS-PAGE。电泳图谱表明预期分子量的CPLE-A的二硫键连接双链种类的纯化。泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白可溶部分;泳道3=在Ni2+-装载的琼脂糖上初始捕获后纯化的物质;泳道4=Ni2+-装载的琼脂糖上最终捕获前因子Xa处理的物质;泳道5=在Ni2+-装载的琼脂糖上第二次捕获后纯化的物质;泳道6=最终纯化的物质;泳道7=最终纯化的物质+DTT。 图23-表达/纯化LC/A-CPBE-HN/A产物
蛋白在用考马斯蓝染色前接受SDS-PAGE。电泳图谱表明预期分子量的CPBE-A的二硫键连接的双链种类的纯化。泳道1=大肠杆菌总蛋白的可溶部分;泳道2=在Ni2+-装载的琼脂糖上初始捕获后纯化的材料;泳道3=在Ni2+-装载琼脂糖上最终捕获前用因子Xa处理的材料;泳道4=用因子Xa(5μl)激活后纯化的最终材料;泳道5=用因子Xa(10μl)激活后纯化的最终材料;泳道6=用因子Xa(20μl)激活后纯化的最终材料;泳道7=用因子Xa+DTT(5μl)激活后纯化的最终材料;泳道8=用因子Xa+DTT(10μl)激活后纯化的最终材料;泳道9=用因子Xa+DTT(20μl)激活后纯化的最终材料;泳道10=标准分子量标记。图24-表达/纯化CPOP-A产物
蛋白在用考马斯蓝染色前进行SDS-PAGE。电泳图谱表明预期分子量的CPOP-A的二硫键连接的双链种类的纯化。泳道1=标准分子量标记;泳道2=在Ni2+-装载的琼脂糖上初始捕获后纯化的材料;泳道3=在Ni2+-装载琼脂糖上最终捕获前用因子Xa处理的材料;泳道4=在Ni2+-装载琼脂糖上第二次捕获后纯化的材料;泳道5=用因子Xa(5μl)激活后纯化的最终材料;泳道6=用因子Xa(10μl)激活后纯化的最终材料;泳道7=用因子Xa(20μl)激活后纯化的最终材料;泳道8=用因子Xa+DTT(5μl)激活后纯化的最终材料;泳道9=用因子Xa+DTT(10μl)激活后纯化的最终材料;泳道10=用因子Xa+DTT(20μl)激活后纯化的最终材料。图25-表达/纯化CPOPv-A产物
蛋白在用考马斯蓝染色前进行SDS-PAGE。电泳图谱表明预期分子量的CPOPv-A的二硫键连接的双链种类的纯化。泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白的可溶部分;泳道3=在Ni2+-装载的琼脂糖上初始捕获后纯化的材料;泳道4=在Ni2+-装载琼脂糖上最终捕获前用因子Xa处理的材料;泳道5=用因子Xa(5μl)激活后纯化的最终材料;泳道6=用因子Xa(10μl)激活后纯化的最终材料;泳道7=用因子Xa(20μl)激活后纯化的最终材料;泳道8=用因子Xa+DTT(5μl)激活后纯化的最终材料;泳道9=用因子Xa+DTT(10μl)激活后纯化的最终材料;泳道10=用因子Xa+DTT(20μl)激活后纯化的最终材料。图26-DRG细胞模型中SNAP-25的体外剪切
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPOPv-A中24小时。细胞蛋白质通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计量分析计算。图27-表达/纯化CPNv-A-FXa-HT(可去除his-标记)
蛋白在用考马斯蓝染色前进行SDS-PAGE。电泳图样表明预期分子量的CPNv-A-FXa-HT的二硫键双链种类的纯化。泳道1=标准分子量标记;泳道2=大肠杆菌总蛋白的可溶部分;泳道3=在Ni2+-装载琼脂糖上最终捕获前用因子Xa处理的材料;泳道4=用因子Xa激活后纯化的最终材料;泳道5=用因子Xa+DTT激活后纯化的最终材料。图28-具有可变间隔长度的LC/A-伤害感受肽-HN/A融合蛋白的体外 效力,由配体竞争测试评估
可变间隔分子长度的LC/A-伤害感受肽-HN/A融合体结合ORL1受体的能力使用简单的基于竞争的测试评估。背根神经节(DRG)的原始培养物在1nM的[3H]-伤害感受肽存在的情况下被暴露于各种浓度的测试材料。放射性标记配体的特异结合的降低通过闪烁计数评估,并且与未标记配体(Tocris伤害感受肽)的效力比较绘图。上图显示了GS0、GS20、GS30和Hx27间隔分子的替换特性,而下图显示了由GS10、GS15和GS25间隔的融合蛋白达到的移位。结论是:在伤害感受肽替换ORL1受体方面,GS0和GS30间隔分子是无效的,且GS10是较不有效的。图29-具有可变间隔长度的LC/A-伤害感受肽-HN/A融合蛋白的体外效力,由体外SNAP-25剪切评估
背根神经节(DRG)的原始培养物被暴露于各种浓度的CPN-A(具有可变间隔分子长度)中24小时。细胞蛋白通过SDS-PAGE、蛋白质印迹分离,并用抗-SNAP-25标记,以促进SNAP-25剪切的评估。被剪切的SNAP-25的百分比通过密度计量分析计算。GS10间隔的融合蛋白的较不有效的结合特性(参见图28)反映为需要较高浓度融合体,以达到细胞内SNAP-25的剪切。GS0和GS30间隔的融合蛋白完全无效(数据未显示)。GS15、20和25间隔的融合蛋白差不多一样有效。 SEQ ID NOsSEQ ID1 LC/A的DNA序列SEQ ID2 HN/A的DNA序列SEQ ID3 LC/B的DNA序列SEQ ID4 HN/B的DNA序列 SEQ ID5 LC/C的DNA序列SEQ ID6 HN/C的DNA序列SEQ ID7 CPN-A接头的DNA序列SEQ ID8 A接头的DNA序列SEQ ID9 N-末端呈递伤害感受肽插入体的DNA序列SEQ ID10 CPN-C接头的DNA序列SEQ ID11 CPBE-A接头的DNA序列SEQ ID12 CPNvar-A接头的DNA序列SEQ ID13 LC/A-CPN-HN/A融合体的DNA序列SEQ ID14 LC/A-CPN-HN/A融合体的蛋白序列SEQ ID15 N-LC/A-HN/A融合体的DNA序列SEQ ID16 N-LC/A-HN/A融合体的蛋白序列SEQ ID17 LC/C-CPN-HN/C融合体的DNA序列SEQ ID18 LC/C-CPN-HN/C融合体的蛋白序列SEQ ID19 LC/C-CPN-HN/C(A-接头)融合体的DNA序列SEQ ID20 LC/C-CPN-HN/C(A-接头)融合体的蛋白序列SEQ ID21 LC/A-CPME-HN/A融合体的DNA序列SEQ ID22 LC/A-CPME-HN/A融合体的蛋白序列SEQ ID23 LC/A-CPBE-HN/A融合体的DNA序列SEQ ID24 LC/A-CPBE-HN/A融合体的蛋白序列SEQ ID25 LC/A-CPNv-HN/A融合体的DNA序列SEQ ID26 LC/A-CPNv-HN/A融合体的蛋白序列SEQ ID27 LC/A-CPN[1-11]-HN/A融合体的DNA序列SEQ ID28 LC/A-CPN[1-11]-HN/A融合体的蛋白序列SEQ ID29 LC/A-CPN[[Y10]1-11]-HN/A融合体的DNA序列SEQ ID30 LC/A-CPN[[Y10]1-11]-HN/A融合体的蛋白序列 SEQ ID31 LC/A-CPN[[Y11]1-11]-HN/A融合体的DNA序列SEQ ID32 LC/A-CPN[[Y11]1-11]-HN/A融合体的蛋白序列SEQ ID33 LC/A-CPN[[Y14]1-17]-HN/A融合体的DNA序列SEQ ID34 LC/A-CPN[[Y14]1-17]-HN/A融合体的蛋白序列SEQ ID35 LC/A-CPN[1-13]-HN/A融合体的DNA序列SEQ ID36 LC/A-CPN[1-13]-HN/A融合体的蛋白序列SEQ ID37 CPN[1-17]的DNA序列SEQ ID38 CPN[1-17]的蛋白序列SEQ ID39 CPN[1-11]的DNA序列SEQ ID40 CPN[1-11]的蛋白序列SEQ ID41 CPN[[Y10]1-11]的DNA序列SEQ ID42 CPN[[Y10]1-11]的蛋白序列SEQ ID43 CPN[[Y11]1-11]的DNA序列SEQ ID44 CPN[[Y11]1-11]的蛋白序列SEQ ID45 CPN[[Y14]1-17]的DNA序列SEQ ID46 CPN[[Y14]1-17]的蛋白序列SEQ ID47 CPN[1-13]的DNA序列SEQ ID48 CPN[1-13]的蛋白序列SEQ ID49 CPNv(也称作N[[R14K15]1-17])的DNA序列SEQ ID50 CPNv(也称作N[[R14K15]1-17])的蛋白序列SEQ ID51 伤害感受肽-间隔分子-LC/A-HN/A融合体的DNA序列SEQ ID52 伤害感受肽-间隔分子-LC/A-HN/A融合体的蛋白序列SEQ ID53 CPN-A GS10接头的DNA序列SEQ ID54 CPN-A GS15接头的DNA序列SEQ ID55 CPN-A GS25接头的DNA序列SEQ ID56 CPN-A GS30接头的DNA序列 SEQ ID57 CPN-A HX27接头的DNA序列SEQ ID58 LC/A-CPN(GS15)-HN/A融合体的DNA序列SEQ ID59 LC/A-CPN(GS15)-HN/A融合体的蛋白序列SEQ ID60 LC/A-CPN(GS25)-HN/A融合体的DNA序列SEQ ID61 LC/A-CPN(GS25)-HN/A融合体的蛋白序列SEQ ID62 CPNvar-A肠激酶可激活接头的DNA序列SEQ ID63 LC/A-CPNv(Ek)-HN/A融合体的DNA序列SEQ ID64 LC/A-CPNv(Ek)-HN/A融合体的蛋白序列SEQ ID65 CPNvar-A接头的DNA序列SEQ ID66 LC/C-CPNv-HN/C融合体(act.A)的DNA序列SEQ ID67 LC/C-CPNv-HN/C融合体(act.A)的蛋白序列SEQ ID68 LC/A-CPLE-HN/A融合体的DNA序列SEQ ID69 LC/A-CPLE-HN/A融合体的蛋白序列SEQ ID70 LC/A-CPOP-HN/A融合体的DNA序列SEQ ID71 LC/A-CPOP-HN/A融合体的蛋白序列SEQ ID72 LC/A-CPOPv-HN/A融合体的DNA序列SEQ ID73 LC/A-CPOPv-HN/A融合体的蛋白序列SEQ ID74 IgA蛋白酶的DNA序列SEQ ID75 IgA-CPNv-HN/A融合体的DNA序列SEQ ID76 gA-CPNv-HN/A融合体的蛋白序列SEQ ID77 FXa-HT的DNA序列SEQ ID78 CPNv-A-FXa-HT的DNA序列SEQ ID79 CPNv-A-FXa-HT融合体的蛋白序列SEQ ID80 DT转运区域的DNA序列SEQ ID81 CPLE-DT-A的DNA序列SEQ ID82 CPLE-DT-A融合体的蛋白序列 SEQ ID83 TeNT LC的DNA序列SEQ ID84 CPNv-TENT LC的DNA序列SEQ ID85 CPNV-TeNT LC融合体的蛋白序列SEQ ID86 CPNvar-C接头的DNA序列SEQ ID87 LC/C-CPNv-HN/C融合体(act.C)的DNA序列SEQ ID88 LC/C-CPNv-HN/C融合体(act.C)的蛋白序列
实施例
实施例1-LC/A和HN/A骨架克隆的制备
以下步骤产生了用作多区域融合表达物组分骨架的LC和HN片段。本实施例基于血清型A基克隆(SEQ ID1和SEQ ID2)的制备,虽然该过程和方法可以同等地应用于其它血清型[由血清型B(SEQID3和SEQ ID4)和血清型C(SEQ ID5和SEQ ID6)的序列表所示例说明]。克隆和表达载体的制备pCR 4(Invitrogen)被选为标准克隆载体,其被选择是由于在载体和相邻的测序引物位点内缺少限制性序列,以便用于构建体容易确认。表达载体基于pMAL(NEB)表达载体,其在多克隆位点内具有正确顺序的期望限制性序列,用以构建体插入(BamHI-SalI-PstI-HindIII)。表达载体的片段已经被移除,以产生不可移动的质粒,并且多种不同的融合标签已经被插入,以增加纯化的选择方案。 蛋白酶(如LC/A)插入体的制备
LC/A(SEQ ID1)通过以下两种方式之一产生:该DNA序列通过LC/A氨基酸序列[从免费可用的数据库来源,如GenBank(登录号P10845)或Swissprot(登陆基因座BXA1_CLOBO)获得,使用多种反向翻译软件工具之一(例如,EditSeq best E.coli reversetranslation(DNASTAR Inc.)或Backtranslation tool v2.0(Entelechon))]的反向翻译设计。BamHI/SalI识别序列分别被插入该序列的5′和3′端, 保持正确的读码框。DNA序列针对反向翻译过程中被插入的限制性酶剪切序列被筛选(使用诸如MapDraw,DNASTAR Inc.的软件)。被发现对克隆系统要求的那些常见的任意剪切序列,从提议的编码序列中被手工移除,所述编码序列保证了常见大肠杆菌密码子选择(使用)被保持。大肠杆菌密码子选择通过软件程序,如Graphical Codon UsageAnalyser(Geneart)被评估,并且%GC含量和密码子使用比例通过参考公开的密码子使用表(例如,GenBank Release 143,2004年9月13日)来评估。含有LC/A开放读码框的,优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体中被提供。
可选的方法是使用BamHI和SalI限制性酶序列分别插入5′和3′端的PCR引物,对已存在的DNA序列使用PCR扩增。互补的寡核苷酸引物由供应商(如MWG或Sigma-Genosys)化学合成,以便每个引物具有与梭菌目标DNA伸展侧翼的相反链(其3′端彼此“相对”)杂交的能力,一个寡核苷酸对应两条DNA链的每一个。要产生PCR产物,一对特异针对梭菌DNA序列的短寡核苷酸引物与梭菌DNA模板和其它反应组分混合,并被置于能够自动改变反应试管温育温度的仪器中(“PCR仪”),该仪器的温度在约94℃(用于变性)、55℃(用于寡核苷酸退火)和72℃(用于合成)之间循环。用于PCR产物扩增要求的其它试剂包括DNA聚合酶(如Taq或Pfu聚合酶),等摩尔量(50-200μM)的四种核苷酸dNTP——DNA构建单元,和适合该酶、对Mg2+浓度(0.5-5mM)优化的缓冲液。
扩增产物被克隆进pCR 4,使用用于Taq PCR产物的TOPOTA克隆,或用于Pfu PCR产物的Zero Blunt TOPO克隆(两种试剂盒都可从Invitrogen购买)。产生的克隆通过测序检查。与该克隆系统不相容的任意其它限制性序列随后使用位点定向诱变[例如,使用Quickchange(Stratagene Inc.)]被除去。 转运(如HN)插入物的制备
HN/A(SEQ ID2)通过以下两种方式之一产生:该DNA序列通过HN/A氨基酸序列[从免费可用的数据库来源,如 GenBank(登录号P10845)或Swissprot(登陆基因座BXA1_CLOBO)获得,使用多种反向翻译软件工具之一(例如,EditSeq best E.coli reversetranslation(DNASTAR Inc.)或Backtranslation tool v2.0(Entelechon))]的反向翻译设计。PstI限制性序列被加入N-末端,并且XbaI-终止子-HindIII被加入C-末端以保证正确的读码框被保持。DNA序列针对反向翻译过程中被插入的限制性酶剪切序列被筛选(使用诸如MapDraw,DNASTAR Inc.的软件)。被发现对克隆系统要求的那些常见的任意序列,从提议的编码序列中被手工移除,所述编码序列保证了常见大肠杆菌密码子使用被保持。大肠杆菌密码子使用通过软件程序,如Graphical Codon Usage Analyser(Geneart)被评估,并且%GC含量和密码子使用比例通过参阅公开的密码子使用表(例如,GenBank Release143,2004年9月13日)来评估。优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体中被提供。
可选的方法是对已存在的DNA序列使用PCR扩增,并以PstI和XbaI-终止子-HindIII限制性酶序列分别插入到5′和3′端的PCR引物中。PCR扩增按上文所述进行。PCR产物被插入pCR4载体并通过测序检查。与该克隆系统不相容的任意其它限制性序列随后使用位点定向诱变[例如,使用Quickchange(Stratagene Inc.)]被除去。实施例2-LC/A-伤害感受肽-HN/A融合蛋白的制备(伤害感受肽是HN-链的N-末端)接头-伤害感受肽-间隔分子插入物的制备
LC-HN接头可以根据第一原则,使用已存在的用于接头作为模板的序列信息被设计。例如,血清型A接头(在这种情况下,被定义为存在于LC和HN之间的二硫键桥的半胱氨酸之间的区域间的多肽区域)是23个氨基酸的长度,并且具有序列VRGIITSKTKSLDKGYNKALNDL。在该序列中,应该理解,天然的蛋白水解激活产生了具有N-末端序列ALNDL的HN区域。这一序列信息可免费地从可用数据库资源获得,如GenBank(登录号P10845)或 Swissprot(登陆基因座BXA1 CLOBO)。在该接头内,插入了因子Xa位点、伤害感受肽和间隔分子;并使用多种反向翻译软件工具[例如,EditSeq best E.coli reverse translation(DNASTAR Inc.)或Backtranslationtool v2.0(Entelechon)],确定编码接头-配体-间隔分子区域的DNA序列。限制性位点随后被插入DNA序列,并能够被排列为BamHI-SalI-接头-蛋白酶位点-伤害感受肽-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID7)。重要的是确保用于间隔分子、伤害感受肽和限制性序列的正确读码框被保持,和XbaI序列前面没有碱基,TC;如果这样的话,可能导致DAM甲基化。DNA序列针对限制性序列的插入被筛选,并且任何其它序列从剩余的序列中被手工移除,以保证了常见大肠杆菌密码子使用被保持。大肠杆菌密码子使用通过软件程序,如Graphical Codon Usage Analyser(Geneart)被评估,并且%GC含量和密码子使用比例通过参考公开的密码子使用表(例如,GenBank Release143,2004年9月13日)来评估。优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体中被提供。LC/A-伤害感受肽-HN/A融合体的制备
为了产生LC-接头-伤害感受肽-间隔分子-HN构建体(SEQID13),编码接头(SEQ ID7)的pCR 4载体用BamHI+SalI限制性酶剪切。剪切的载体随后作为接受载体,用于被BamHI+SalI剪切的LC/ADNA(SEQ ID1)的插入和连接。产生的质粒DNA随后用PstI+XbaI限制性酶剪切,并作为接受载体,用于被PstI+XbaI剪切的HN/A DNA(SEQ ID2)的插入和连接。最终的构建体包含LC-接头-伤害感受肽-间隔分子-HN ORF(SEQ ID13),用于转染进表达载体进行表达,以产生SEQ ID14所示序列的融合蛋白。实施例3-伤害感受肽-LC/A-HN/A融合蛋白的制备(伤害感受肽是LC-链的N-末端)
LC/A-HN/A骨架按照实施例2所述,使用带有用于激活的因子Xa加入的合成的A血清型接头被构建,排列为BamHI-SalI-接头- 蛋白酶位点-接头-PstI-XbaI-终止子-HindIII(SEQ ID8)。LC/A-HN/A骨架及合成的N-末端呈递伤害感受肽插入体(SEQ ID9)用BamHI+HindIII限制性酶剪切,其被凝胶纯化并连接到一起,以产生伤害感受肽-间隔分子-LC-接头-HN。该ORF(SEQ ID15)随后用限制性酶AvaI+XbaI切出,用于转染进表达载体中表达,以产生SEQ ID16所示序列的融合蛋白。实施例4-LC/C-伤害感受肽-HN/C融合蛋白的制备
按照实施例1和2中使用的方法,LC/C(SEQ ID5)和HN/C(SEQ ID6)被产生并被插入C血清型接头,排列为BamHI-SalI-接头-蛋白酶位点-伤害感受肽-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID10)。最终的构建体包含LC-接头-伤害感受肽-间隔分子-HNORF(SEQ ID17),用于转染进表达载体表达,以产生SEQ ID18所示序列的融合蛋白。实施例5-带有血清型A激活序列的LC/C-伤害感受肽-HN/C融合蛋白的制备
按照实施例1和2中使用的方法,LC/C(SEQ ID5)和HN/C(SEQ ID6)被产生并被插入A血清型接头,排列为BamHI-SalI-接头-蛋白酶位点-伤害感受肽-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID7)。最终的构建体包含LC-接头-伤害感受肽-间隔分子-HNORF(SEQ ID19),用于转染进表达载体表达,以产生SEQ ID20所示序列的融合蛋白。实施例6-LC/A-met脑啡肽-HN/A融合蛋白的纯化
由于小的,5个氨基酸的,met-脑啡肽配体的尺寸,LC/A-met脑啡肽-HN/A融合体通过位点定向诱变[例如,使用 Quickchange(Stratagene Inc.)],使用LC/A-伤害感受肽-HN/A融合体(SEQ ID13)作为模板产生。编码YGGFM met-脑啡肽的肽的寡核苷酸被设计,保证标准大肠杆菌密码子的使用被保持,并且没有其它限制性酶位点被插入,由与LC/A-伤害感受肽-HN/A融合体任意一侧上伤害感受肽部分的接头区域互补的序列在其侧翼。SDM产物通过测序检查,并且最终的构建体包含LC-接头-met脑啡肽-间隔分子-HN ORF(SEQ ID21)用以表达SEQ ID22所示序列的蛋白。实施例7-LC/A-β内啡肽-HN/A融合蛋白的制备
按照实施例1和2中使用的方法,LC/A(SEQ ID1)和HN/A(SEQ ID2)被产生并被插入A血清型β内啡肽接头,排列为BamHI-SalI-接头-蛋白酶位点-β内啡肽-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID11)。最终的构建体包含LC-接头-β内啡肽-间隔分子-HN ORF(SEQ ID23),用以表达SEQ ID24所示序列的蛋白。实施例8-LC/A-伤害感受肽变异体-HN/A融合蛋白的制备
按照实施例1和2中使用的方法,LC/A(SEQ ID1)和HN/A(SEQ ID2)被产生并被插入A血清型伤害感受肽变异体接头,排列为BamHI-SalI-接头-蛋白酶位点-伤害感受肽变异体-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID 12)。最终的构建体包含LC-接头-伤害感受肽变异体-间隔分子-HN ORF(SEQ ID25),用以表达SEQID26所示序列的蛋白。实施例9-LC/A-伤害感受肽-HN/A融合蛋白的纯化方法
解冻装有25ml 50mM HEPES pH 7.2、200mM NaCl和大约10g大肠杆菌BL21细胞浆(cell paste)的falcon管。用50mM的HEPES pH 7.2、200mM的NaCl将融解的细胞浆补充到80ml,并在以22微米的功率冰上超声波处理,30秒开,30秒关,10个循环,以保证样品保持冷冻。在4℃,18000rpm下,离心裂解的细胞30分钟。将上清液加样到用50mM HEPES pH 7.2、200mM NaCl平衡的,装有0.1MNiSO4的螯合柱上(20-30ml的柱是足够的)。使用10到40mM咪唑的浓度梯度洗去非特异结合的蛋白,并用100mM咪唑洗脱融合蛋白。用5L的50mM HEPES pH 7.2、200mM NaCl在4℃渗析洗脱的融合蛋白过夜,并测量渗析的融合蛋白的OD。每100μg融合蛋白中加入1个单位的因子Xa,并在25℃稳定温育过夜。加样到用50mM HEPES pH7.2、200mM NaCl平衡的,装有0.1 M NiSO4的螯合柱上(20-30ml的柱足够)。用50mM HEPES pH 7.2、200mM NaCl清洗该柱到基线。使用10到40mM咪唑的浓度梯度洗去非特异结合的蛋白,并用100mM咪唑洗脱融合蛋白。用5L的50mM HEPES pH 7.2、200mM NaCl在4℃透析洗脱的融合蛋白过夜,并浓缩该融合体到约2mg/ml,将样品分成等量小样并在-20℃冷冻。用OD、BCA、纯度分析和SNAP-25评估测试纯化的蛋白。实施例10-通过测量P物质从神经元细胞培养物中的释放确定TM激动剂的活性材料P物质EIA从R&D Systems,UK获得。方法
eDRG的原代神经元培养物按前述(Duggan et al.,2002)建立。P物质从培养物中的释放通过EIA,基本根据前述(Duggan et al.,2002)评估。目标TM被加入神经元培养物(处理前至少2周建立); 对照培养物通过加入载体代替TM平行进行。对照和TM处理的培养物的P物质的刺激(100mM KCl)和基线释放,与总细胞裂解物含量一起获得。P物质的免疫反应性使用P物质酶免疫测试试剂盒(Substance P Enzyme Immunoassay Kits)(Cayman Chemical Company,USA or R&D Systems,UK),根据制造商的说明测量。
神经元细胞在目标TM存在的情况下释放P物质的量,与存在和不存在100mM KCl的情况下获得的释放比较。由上述目标TM刺激产生的P物质释放与基线释放表明,目标TM是如本说明书中定义的“激动剂配体”。如果希望,由目标TM刺激产生的P物质释放可以与用天然ORL-1受体配体,伤害感受肽(Tocris)产生的标准P物质释放曲线比较。实施例11-通过测量福斯高林(forskolin)刺激的cAMP生产确认ORL1受体激活
通过以下测试提供了给定TM通过ORL1受体被激活的确认,其中TMs抑制福斯高林刺激的cAMP生产的能力被评估。材料
[3H]腺嘌呤和[14C]cAMP从GE Healthcare获得方法
测试基本上按照Meunier et al.[Isolation and structure of theendogenous agonist of opioid receptor-like ORL1 receptor.Nature 377:532-535,1995]的先前所述予以进行,是在完整的,在24孔塑料盘中接种的,被转染的CHO细胞中进行。
向所述细胞中以0.4ml培养基的形式加入[3H]腺嘌呤(1.0μCi)。细胞在37℃保存2小时,以允许腺嘌呤进入细胞内ATP池。2小时后,细胞用温育缓冲液清洗一次,该缓冲液含有:130mM NaCl、4.8mM KCl、1.2mM KH2PO4、1.3mM CaCl2、1.2mM MgSO4、10mM葡萄糖、1mg/ml牛血清白蛋白和25mM HEPES pH 7.4,并用含有福斯高林(10μM)和异丁基甲基黄嘌呤(50μM)在含有和不含目标TM的 情况下进行替换。10分钟后,培养基被吸出并用0.5ml的0.2 M HCl代替。大约1000cpm的[14C]cAMP被加入每个孔,并被用作内部标准。孔中的内含物随后被转移到0.65g干燥铝粉的柱中。该柱用4ml的5mMHCl、0.5ml的0.1M醋酸铵,随后额外2毫升的醋酸铵洗脱。最终的洗脱物被收集到闪烁管中并对14C和氚计数。收集的量针对[14C]cAMP的恢复被修正。ORL1受体激动剂的TMs引起由福斯高林反应产生的cAMP水平的降低。实施例12-使用GTPγS结合功能测试确认ORL1受体激活
给定TM通过ORL1受体作用的确认也由以下测试,GTPγS结合功能测试提供。材料
[35S]GTPγS从GE Healthcare获得小麦芽凝集素包被(Wheatgerm agglutinin-coated(SPA))的珠从GE Healthcare获得方法
本测试基本上根据Traynor和Nahorski[Modulation byμ-opioid agonists of guanosine-5-O-(3-[35S]thio)triphosphate binding tomembranes from human neuroblastoma SH-SY5Y cells.Mol.Pharmacol.47:848-854,1995]所述进行。
细胞从组织培养盘中被刮入20mM HEPES、1mM乙二胺四乙酸中,随后500×g离心10分钟。细胞被重悬浮在该缓冲液中,并用Polytron匀质器(Homogenizer)均一化。
匀浆在27,000×g离心15分钟,并且沉淀物在缓冲液A中重悬浮,该缓冲液含有:20mM HEPES、10mM MgCl2、100mM NaCl,pH7.4。悬液在20,000×g离心并再次被悬浮在缓冲液A中。对于结合测试,膜(8-15μg蛋白)与[35S]GTP S(50pM)、GDP(10μM),在含有和不含目标TM的情况下,在总体积1.0ml中25℃温育60分钟。样品在玻璃纤维过滤器中被过滤,并根据结合测试中所述计数。 实施例13-LC/A-伤害感受肽-HN/A融合蛋白的制备(伤害感受肽是HN-链的N-末端)
接头-伤害感受肽-间隔分子插入体按实施例2所述制备。LC/A-伤害感受肽-HN/A融合体的制备
为了产生LC-接头-伤害感受肽-间隔分子-HN构建体(SEQID13),编码接头(SEQ ID7)的pCR 4载体用BamHI+SalI限制性酶剪切。剪切的载体随后作为接受体,用于被BamHI+SalI剪切的LC/ADNA(SEQ ID1)的插入和连接。产生的质粒DNA随后被BamHI+HindIII限制性酶剪切,并且LC/A-接头片段被插入到被相似剪切的载体中,该载体包含BamHI、SalI、PstI和HindIII的独特多克隆位点,如pMAL载体(NEB)。HN/A DNA(SEQ ID2)随后被PstI+HindIII限制性酶剪切,并被插入被相似剪切的pMAL-LC/A-接头构建体。最终的构建体包含LC-接头-伤害感受肽-间隔分子-HN ORF(SEQ ID13),用于转染进表达载体表达,以产生SEQ ID14所示序列的蛋白。 实施例14-伤害感受肽-LC/A-HN/A融合蛋白的制备(伤害感受肽是LC-链的N-末端)
为了产生伤害感受肽-间隔分子-LC/A-HN/A构建体,使用带有用于激活的因子Xa加入的A血清型接头,排列为BamHI-SalI-接头-蛋白酶位点-接头-PstI-XbaI-终止子-HindIII(SEQ ID8),按实施例13所述被合成。编码该接头的pCR 4载体用BamHI+SalI限制性酶剪切。剪切的载体随后作为接受体,用于被BamHI+SalI剪切的LC/A DNA(SEQ ID1)的插入和连接。产生的质粒DNA随后被BamHI+HindIII限制性酶剪切,并且LC/A-接头片段被插入被相似剪切的载体,该载体包含合成的N-末端呈递的伤害感受肽插入体(SEQ ID9)。该构建体随后用AvaI+HindIII剪切,并被插入表达载体,如pMAL质粒(NEB)。HN/ADNA(SEQ ID2)随后被PstI+HindIII限制性酶剪切,并被插入被相似剪切的pMAL-伤害感受肽-LC/A-接头构建体。最终的构建体包含伤害感受肽-间隔分子-LC/A-HN/A ORF(SEQ ID51),用于转染进表达载体表 达,以产生SEQ ID52所示序列的蛋白质。 实施例15-具有可变间隔长度产物的LC/A-伤害感受肽-HN/A融合蛋白家族的表达和纯化
使用如实施例2中采用的策略,一系列编码伤害感受肽和间隔分子的DNA接头被制备。使用多种反向翻译软件工具之一[例如,EditSeq best E.coli reverse translation(DNASTAR Inc.)或Backtranslationtool v2.0(Entelechon)],编码接头-配体-间隔分子区域的DNA序列被确定。限制性位点随后被插入DNA序列,并能够被排列为BamHI-SalI-接头-蛋白酶位点-伤害感受肽-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID53到SEQ ID57)。重要的是确保用于间隔分子、伤害感受肽和限制性序列的正确读码框被保持,和XbaI序列的前面没有碱基TC;如果有碱基TC的话,可能导致DAM甲基化。DNA序列针对限制性序列的插入被筛选,并且任何其它序列从剩余的序列中被手工移除,以保证了常见大肠杆菌密码子使用被保持。大肠杆菌密码子使用通过软件程序,如Graphical Codon Usage Analyser(Geneart)被评估,并且%GC含量和密码子使用比例通过参考公开的密码子使用表(例如,GenBank Release 143,2004年9月13日)来评估。优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体中被提供。 所产生的间隔分子包括:
编码 | 接头的蛋白序列 | 接头DNA的SEQ ID |
GS10 | ALAGGGGSALVLQ | 53 |
GS15 | ALAGGGGSGGGGSALVLQ | 54 |
GS25 | ALAGGGGSGGGGSGGGGSGGGGSALVLQ | 55 |
GS30 | ALAGGGGSGGGGSGGGGSGGGGSGGGGSALVLQ | 56 |
HX27 | ALAAEAAAKEAAAKEAAAKAGGGGSALVLQ | 57 |
表1
通过实施例的方式,为了产生LC/A-CPN(GS15)-HN/A融合构建体(SEQ ID58),编码接头(SEQ ID54)的pCR 4载体用BamHI+SalI限制性酶剪切。剪切的载体随后作为接受体,用于被BamHI+SalI剪切的LC/A DNA(SEQ ID1)的插入和连接。产生的质粒DNA随后被BamHI+HindIII限制性酶剪切,并且LC/A-接头片段被插入被相似剪切的载体,该载体包含BamHI、SalI、PstI和HindIII独特的多克隆位点,如pMAL载体(NEB)。HN/A DNA(SEQ ID2)随后被PstI+HindIII限制性酶剪切,并被插入被相似剪切的pMAL-LC/A-接头构建体。最终的构建体包含LC/A-CPN(GS15)-HN/A ORF(SEQ ID58),用于表达SEQ ID59所示序列的蛋白。
作为一个进一步的实例,要产生LC/A-CPN(GS25)-HN/A融合构建体(SEQ ID60),编码接头(SEQ ID55)的pCR 4载体用BamHI+SalI限制性酶剪切。剪切的载体随后作为接受载体,用于被BamHI+SalI剪切的LC/A DNA(SEQ ID1)的插入和连接。产生的质粒DNA随后被BamHI+HindIII限制性酶剪切,并且LC/A-接头片段被插入被相似剪切的载体,该载体包含BamHI、SalI、PstI和HindIII独特的多克隆位点,如pMAL载体(NEB)。HN/A DNA(SEQ ID2)随后被PstI+HindIII限制性酶剪切,并被插入被相似剪切的pMAL-LC/A-接头构建体。最终的构建体包含LC/A-CPN(GS25)-HN/A ORF(SEQ ID60),用于表达SEQ ID61所示序列的蛋白。
含有GS10、GS30和HX27的LC/A-CPN-HN/A融合体的变异体被相似地构建。使用实施例9所述的纯化方法,融合蛋白从大肠杆菌细胞浆中被纯化。图9显示了在LC/A-CPN(GS10)-HN/A、LC/A-CPN(GS15)-HN/A、LC/A-CPN(GS25)-HN/A、LC/A-CPN(GS30)-HN/A和LC/A-CPN(HX27)-HN/A情况下获得的纯化产品。 实施例16-LC/A-伤害感受肽-HN/A融合体的体外活性的评估
根据实施例2和9制备的融合蛋白在eDRG神经元细胞模型中被评估。
P物质释放和SNAP-25剪切抑制的评估已经在此前报告(Duggan et al.,2002,J.Biol.Chem.,277,34846-34852)。简单地说,背根神经节神经元从15天大的胎儿Sprague-Dawley大鼠中收集,并且分离的细胞以1×106细胞/孔的密度在Matrigel包被的24孔板中接种。接种一天后,细胞用10μM胞嘧啶β-D-呋喃阿拉伯糖苷(arabinofuranoside)处理48小时。细胞被保存在补充有5%热失活的胎牛血清、5mM L-谷氨酰胺、0.6%D-葡萄糖、2%B27补充剂和100ng/ml 2.5S小鼠神经生长因子的Dulbecco’s基本必须培养基中。加入测试物质前,培养被保持在37℃,95%空气/5%CO2的环境中2周。
P物质从eDRG的释放由酶联免疫吸收测试(enzyme-linkedimmunosorbent assay)评估。简单地说,eDRG细胞用低钾平衡的盐溶液(BSS:5mM KCl、137mM NaCl、1.2mM MgCl2、5mM葡萄糖、0.44mMKH2PO4、20mM HEPES,pH 7.4、2mM CaCl2)冲洗两次。基线样品通过用1ml的低钾BBS温育每个孔5分钟获得。去除该缓冲液后,细胞通过与1ml高钾缓冲液(如上述BBS,修改为包括用NaCl等渗平衡的100mM KCl)温育被刺激以释放。稀释的样品被评估P物质的含量。P物质的免疫反应性使用P物质酶免疫测试试剂盒(Substance P EnzymeImmunoassay Kits)(Cayman Chemical Company或R&D Systems),根据制造商的说明测量。P物质被表示为相对于平行进行的标准P物质曲线的pg/ml。
SDS-PAGE和蛋白质印迹分析使用标准的步骤(Novex)进行。SNAP-25蛋白在12%的Tris/甘氨酸聚丙烯酰胺凝胶(Novex)上分离并随后被转移到硝酸纤维素膜上。该膜用识别受剪切的和完整的SNAP-25的单克隆抗体(SMI-81)检测。特异结合使用过氧化物酶偶联的二抗和化学荧光检测系统观察。SNAP-25的剪切通过扫描密度计(Molecular Dynamics Personal SI,ImageQuant数据分析软件)量化。SNAP-25剪切的百分比根据下式计算:(剪切的SNAP-25/(剪切的+完整的SNAP-25))x100。
eDRG神经元暴露于LC/A-伤害感受肽-HN/A融合体(称作CPN-A)后,P物质释放和SNAP-25的剪切的抑制均被观察到(图10)。暴露于融合体24小时后,最大SNAP-25剪切的50%通过融合体浓度 为6.3±2.5nM而达到。
该融合体的效果也在eDRG暴露于CPN-A 16小时后在确定的时间点评估。图11显示了CFN-A融合蛋白延长的作用时间,可测量活性在暴露后28天仍可被观察到。 实施例17-LC/A-伤害感受肽变异体-HN/A融合体的体外活性的评估
根据实施例8和9制备的融合蛋白使用实施例16所述的方法,在eDRG神经元细胞模型中被评估。
eDRG神经元暴露于LC/A-伤害感受肽变异体-HN/A融合体(称作CPNv-A)后,P物质释放和SNAP-25的剪切之抑制均被观察到。暴露于融合体24小时后,最大SNAP-25剪切的50%通过融合体浓度1.4±0.4nM达到(图12)。
该融合体的效果也在eDRG暴露于CPN-A 16小时后在确定的时间点评估。图13显示了CPN-A融合蛋白延长的作用时间,可测量活性在暴露后24天仍可被观察到。
CPNv-A融合蛋白的结合能力也与CPN-A融合体比较评估。图14显示了竞争实验确定在ORL-1受体结合效力的结果。CPNv-A被显示替代了[3H]-伤害感受肽,由此确定了用中央呈递形式的配体可能到达该受体。 实施例18-通过肠激酶处理激活的LC/A-伤害感受肽变异体-HN/A融合蛋白的制备
按照实施例1和2中使用的方法,LC/A(SEQ ID1)和HN/A(SEQ ID2)被产生并被插入A血清型伤害感受肽变异体接头,排列为BamHI-SalI-接头-肠激酶蛋白酶位点-伤害感受肽变异体-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID62)。最终的构建体包含LC-接头-伤害感受肽变异体-间隔分子-HN ORF序列(SEQ ID63),用以表达SEQ ID64所示序列的蛋白。该融合蛋白被称为CPNv(Ek)-A。图15显示了根据实施例9中使用的方法,但使用每100μg融合蛋白0.00064μg肠激酶激活,从大肠杆菌中纯化CPNv(Ek)-A。 实施例19-已经通过肠激酶处理激活的LC/A-伤害感受肽变异体-HN/A融合体体外效力的评估
实施例18中制备的CPNv(Ek)-A以纯化的形式获得,并且被加样到eDRG细胞模型以评估SNAP-25的剪切(使用实施例16的方法)。图16显示了eDRG暴露于CPNv(Ek)-A24小时后SNAP-25的剪切。剪切效率据观察与实施例17中记载的,使用因子Xa剪切物质所达到的效率相似。实施例20-带有从血清型A衍生的因子Xa激活接头的LC/C-伤害感受肽变异体-HN/C融合蛋白的制备
按照实施例4中使用的方法,LC/C(SEQ ID5)和HN/C(SEQID6)被产生并被插入A血清型股啡肽变异体接头,排列为BamHI-SalI-接头-伤害感受肽变异体-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID65)。最终的构建体包含LC-接头-伤害感受肽变异体-间隔分子-HN ORF序列(SEQ ID66),用以表达SEQ ID67所示序列的蛋白。该融合蛋白被称为CPNv-C(act.A)。图17显示了CPNv-C产物(act.A)按照实施例9中使用的方法从大肠杆菌中纯化。 实施例21-LC/C-伤害感受肽变异体-HN/C融合蛋白体外效力的评估
根据实施例9使用的方法,实施例20中制备的CPNv-C(act.A)以纯化的形式获得,并且被加样到eDRG细胞模型以评估SNAP-25的剪切(使用实施例16的方法)。暴露于融合体24小时后,最大SNAP-25剪切的50%通过融合体浓度3.1±2.0nM达到。图18显示了eDRG暴露于CPNv-C(act.A)24小时后,突触融合蛋白的剪切。 实施例22-LC/A-伤害感受肽-HN/A融合体的体内活性的评估
LC/A-伤害感受肽-HN/A融合体(CPN/A)抑制急性辣椒素诱导的机械痛觉异常的能力,在大鼠后爪的皮下足底内注射后被评估。在招入研究之前(预处理),在用CPN/A皮下足底内注射后但在辣椒素刺激之前(Pre-CAP),和在CPN/A注射后且用辣椒素刺激后(平均反应为15′和30′;CAP),实验动物被评估对10g Von Frey纤丝刺激系列 (10刺激×3次试验)的爪回缩频度(PWF%)。辣椒素刺激通过10μL的0.3%溶液的注射完成。样品稀释物在0.5%的BSA/盐水中制备。图19显示了通过用一系列浓度的LC/A-伤害感受肽-HN/A融合体对动物预处理达到的机械性痛觉异常的逆转。
LC/A-伤害感受肽-HN/A融合体(CPN/A)抑制链脲酶素(STZ)在大鼠中诱导的机械性痛觉异常的能力,被评估。STZ-诱导的大鼠机械性痛觉异常通过链脲酶素的注射(i.p.或i.v.)达到,链脲酶素导致胰腺β细胞的解体和伴随的代谢压力(高血糖症和高血脂症),β细胞的解体导致胰岛素产生的缺失。因此,STZ诱导I型糖尿病。此外,STZ处理导致神经病变的逐步发展,其发挥带有痛觉过敏和痛觉异常的慢性疼痛的模型,其可能反映了糖尿病患者中观察到的标志(外周糖尿病神经痛)。
雄性Sprague-Dawley大鼠(250-300g)用65mg/kg溶解在柠檬酸盐缓冲液中的STZ处理(I.V.),并且血糖和脂质被每周测量以确定该模型的准备状态。爪回缩阈值(PWT)根据一段时间内响应于VonFrey纤丝刺激系列的反应被测量。当两个连续测量日(间隔1周)的PWT测量在尺度上低于6g时,疼痛异常被称为已建立。在这时,大鼠被随机分配到盐水组(阴性效力对照)、加巴喷丁(Gabapentin)组(阳性效力对照)或测试组(CPN/A)。测试物质(20-25μl)作为单一注射剂被皮下注射(不包括加巴喷丁),并且PWT在治疗1天后被测量,并在这之后的两周时间内定期测量。加巴喷丁(30mg/kg i.p.3ml/kg注射体积)在开始PWT测试之前2小时,被每天注射。图20显示了通过用750ng的CPN/A对动物进行预处理达到的痛觉异常的逆转。数据是在CPN/A单次注射后2周的时间段内获得。 实施例23-LC/A-伤害感受肽变异体-HN/A融合体的体内效力的评估
LC/A-伤害感受肽变异体-HN/A融合体(CPNv/A)抑制辣椒素诱导的机械性疼痛异常的能力,在大鼠后爪皮下足底内注射后被评估。在招入研究之前(预处理),在用CPNv/A皮下足底内注射后但在辣椒素刺激之前(Pre-CAP),和在CPNv/A注射后且用辣椒素刺激后(平均反应为15′和30′;CAP),实验动物被评估在对10g Von Frey纤丝刺激 系列(10刺激x 3次试验)的爪回缩频度(PWF%)。辣椒素刺激通过10μL的0.3%溶液的注射完成。样品稀释物在0.5%的BSA/盐溶液中制备。
图21显示了通过用一系列浓度的LC/A-伤害感受肽变异体-HN/A融合体对动物预处理达到的机械性痛觉异常的逆转,与通过加入LC/A-伤害感受肽-HN/A融合体达到的逆转的比较。这些数据被表示为标准化的爪回缩频度差异,其中峰值反应(辣椒素之后)和基线反应(辣椒素之前)之间的差异被表示为百分比。用该分析,可以看出CPNv/A比CPN/A更有效,因为达到相似止痛效果需要比CPN/A低剂量的CPNv/A。 实施例24-LC/A-leu脑啡肽-HN/A融合蛋白的制备
由于小的、5个氨基酸的、leu-脑啡肽配体的尺寸,则LC/A-leu脑啡肽-HN/A融合体通过位点定向诱变[例如,使用Quickchange(Stratagene Inc.)],使用LC/A-伤害感受肽-HN/A融合体(SEQ ID13)作为模板产生。编码YGGFM leu-脑啡肽的肽的寡核苷酸被设计,保证标准大肠杆菌密码子的使用被保持,并且没有其它限制性酶位点被插入,由与LC/A-伤害感受肽-HN/A融合体(SEQ ID13)任意一侧上伤害感受肽部分的接头区域互补的序列在其侧翼。SDM产物通过测序检查,并且最终的构建体包含LC-接头-leu脑啡肽-间隔分子-HNORF(SEQ ID68)用以表达SEQ ID69所示序列的蛋白。该融合蛋白被称为CPLE-A。图22显示了根据实施例9中使用的方法,从大肠杆菌中纯化CPLE-A。 实施例25-LC/A-β内啡肽-HN/A融合蛋白的表达和纯化
使用实施例9所述的方法,并使用实施例7中产生的LC/A-β内啡肽-HN/A融合蛋白(被称为CPBE-A),CPBE-A从大肠杆菌中被纯化。图23显示了通过SDS-PAGE分析的纯化蛋白。 实施例26-LC/A-伤害感受肽变异体-HN/A融合蛋白的制备
由于单一氨基酸改变对将伤害感受肽序列第1位置的Phe 诱变为Tyr是必要的,LC/A-伤害感受肽变异体-HN/A融合体通过位点定向诱变[例如,使用Quickchange(Stratagene Inc.)],使用LC/A-伤害感受肽-HN/A融合体(SEQ ID13)作为模板产生。编码伤害感受肽序列中第1位酪氨酸的寡核苷酸被设计,保证标准大肠杆菌密码子的使用被保持,并且没有其它限制性酶位点被插入,由与LC/A-伤害感受肽-HN/A融合体(SEQ ID13)任意一侧上伤害感受肽部分的接头区域互补的序列在其侧翼。SDM产物通过测序检查,并且最终的构建体包含LC/A-伤害感受肽诱变体-间隔分子-HN/A融合体ORF(SEQ ID70)用以表达SEQID71所示序列的蛋白。该融合蛋白被称为CPOP-A。图24显示了根据实施例9中使用的方法,从大肠杆菌中纯化CPOP-A。 实施例27-LC/A-伤害感受肽变异诱变体-HN/A融合蛋白的制备和评估
由于单一氨基酸改变对将伤害感受肽序列第1位置的Phe诱变为Tyr是必要的,LC/A-伤害感受肽变异诱变体-HN/A融合体通过位点定向诱变[例如,使用Quickchange(Stratagene Inc.)],使用LC/A-伤害感受肽变异体-HN/A融合体(SEQ ID25)作为模板产生。编码伤害感受肽序列中第1位酪氨酸的寡核苷酸被设计,保证标准大肠杆菌密码子的使用被保持,并且没有其它限制性酶位点被插入,由与LC/A-伤害感受肽变异体-HN/A融合体(SEQ ID25)任意一侧上伤害感受肽部分的接头区域互补的序列在其侧翼。SDM产物通过测序检查,并且最终的构建体包含LC/A-伤害感受肽诱变体-间隔分子-HN/A融合体ORF(SEQID72)用以表达SEQ ID73所示序列的蛋白。该融合蛋白被称为CPOPv-A。图25显示了根据实施例9中使用的方法,从大肠杆菌中纯化CPOPv-A。
使用实施例16所述的方法,CPOPv-A被评估其在eDRG细胞模型中剪切SNAP-25的能力。图26显示了CPOPv-A能够在eDRG模型中剪切SNAP-25,细胞暴露于约5.9nM融合体24小时后,达到50%的最大SNAP-25剪切。 实施例28-IgA蛋白酶-伤害感受肽变异体-HN/A融合蛋白的制备
IgA蛋白酶的氨基酸序列从免费可用的数据库资源,如GenBank(登录号P09790)获得。关于淋球菌IgA蛋白酶基因结构的信息在文献(Pohlner et al.,Gene structure and extracellular secretion ofNeisseria gonorrhoeae IgA protease,Nature,1987,325(6103),458-62)中可找到。使用Backtranslation tool v2.0(Entelechon),编码为大肠杆菌表达所修饰的IgA蛋白酶的DNA序列被确定。BamHI识别序列被插入5′端,并且编码半胱氨酸氨基酸的密码子和SalI识别序列被插入IgADNA的3′端。DNA序列针对反向翻译过程中被插入的限制性酶剪切序列使用诸如MapDraw(DNASTAR Inc.)被筛选。被发现对克隆系统要求的那些常见的任意剪切序列从提议的编码序列中被手工移除,以保证常见大肠杆菌密码子选择被保持。大肠杆菌密码子选择通过软件程序,如图像密码子使用分析仪(Graphical Codon Usage Analyser(Geneart))被评估,并且%GC含量和密码子使用比例通过公开的密码子使用表来评估。含有IgA开放读码框(ORF)的优化的DNA序列(SEQID74)随后被商业合成。
IgA(SEQ ID74)使用BamHI和SalI限制性酶被插入LC-接头-伤害感受肽变异体-间隔分子-HN ORF(SEQ ID25),以用IgA蛋白酶DNA代替LC。最终的构建体包含IgA-接头-伤害感受肽变异体-间隔分子-HN ORF(SEQ ID75),用以表达SEQ ID76所示序列的蛋白。 实施例29-靶向带有可去除组氨酸纯化标记的肽链内切酶融合蛋白的伤害感受肽的制备和评估
编码因子Xa可去除his-标记(his-6)的DNA被制备,虽然明显的是可选的蛋白酶位点,如肠激酶,和可选的纯化标记,如更长的组氨酸标记,也是可能的。使用多种反向翻译软件工具之一[例如,EditSeq best E.coli reverse translation(DNASTAR Inc.)或Backtranslationtool v2.0(Entelechon)],编码因子Xa可去除his-标记区域的DNA序列被确定。限制性位点随后被插入DNA序列,并能够被排列为NheI-接头-SpeI-PstI-HN/A-XbaI-LEIEGRSGHHHHHH终止子-HindIII(SEQID77)。DNA序列针对限制性序列的插入被筛选,并且任何其它序列从剩余的序列中被手工移除,以保证了常见大肠杆菌密码子使用被保持。 大肠杆菌密码子使用通过软件程序,如图像密码子使用分析仪(Graphical Codon Usage Analyser(Geneart))被评估,并且%GC含量和密码子使用比例通过参考已经公开的密码子使用表(例如,GenBankRelease 143,2004年9月13日)来评估。优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体中被提供。为了产生CPNv-A-FXa-HT(SEQ ID78,可去除his-标记的构建体),编码可去除his-标记的pCR 4载体用NheI和HindIII剪切。NheI-HindIII片段随后被插入也已经用NheI和HindIII剪切的LC/A-CPNv-HN/A载体(SEQ ID25)。最终的构建体包含LC/A-接头-伤害感受肽变异体-间隔分子-HN-FXa-His标记-HindIII ORF序列(SEQID78),用以表达SEQ ID79所示序列的蛋白。图27显示了按照实施例9中使用的方法从大肠杆菌中纯化的CPNv-A-FXa-HT。 实施例30-靶向含有从白喉毒素衍生的转运区域的肽链内切酶融合蛋白的leu-脑啡肽的制备
该DNA序列通过白喉毒素转运区域的氨基酸序列(从免费可用的数据库来源,如GenBank(登录号1XDTT)获得),使用多种反向翻译软件工具之一(例如,EditSeq best E.coli reverse translation(DNASTAR Inc.)或Backtranslation tool v2.0(Entelechon))]的反向翻译设计。限制性位点随后被插入DNA序列,并能够被排列为NheI-接头-SpeI-PstI-白喉转运区域-XbaI-终止子-HindIII(SEQ ID80)。PstI/XbaI识别序列分别被插入转运区域的5′和3′端,保持正确的读码框。DNA序列针对反向翻译过程中被插入的限制性酶剪切序列被筛选(使用诸如MapDraw,DNASTAR Inc.的软件)。被发现对克隆系统要求的那些常见的任意剪切序列,从提议的编码序列中被手工移除,所述编码序列保证了常见大肠杆菌密码子选择被保持。大肠杆菌密码子选择通过软件程序,如图像密码子使用分析仪(Graphical Codon Usage Analyser(Geneart))被评估,并且%GC含量和密码子使用比例通过参考公开的密码子使用表(例如,GenBank Release 143,2004年9月13日)来评估。含有白喉转运区域的优化的DNA序列随后被商业合成为NheI-接头-SpeI-PstI-白喉转运区域-XbaI-终止子-HindIII(例如,通过Entelechon, Geneart或Sigma-Genosys),并在pCR4载体中被提供。编码白喉转运区域的pCR 4载体用NheI和XbaI剪切。NheI-XbaI片段随后被插入也已经用NheI和XbaI剪切的LC/A-CPLE-HN/A载体(SEQ ID68)。最终的构建体包含LC/A-leu-脑啡肽-间隔分子-白喉转运区域ORF序列(SEQ ID81),用以表达SEQ ID82所示序列的蛋白。 实施例31-靶向含有从破伤风毒素衍生的LC区域的肽链内切酶融合蛋白的伤害感受肽变异体的制备
该DNA序列通过破伤风毒素LC氨基酸序列(从免费可用的数据库来源,如GenBank(登录号X04436)获得),使用多种反向翻译软件工具之一(例如,EditSeq best E.coli reverse translation(DNASTAR Inc.)或Backtranslation tool v2.0(Entelechon))]的反向翻译设计。BamHI/SalI识别序列分别被插入该序列的5′和3′端,保持正确的读码框(SEQ ID83)。DNA序列针对反向翻译过程中被插入的限制性酶剪切序列被筛选(使用诸如MapDraw,DNASTAR Inc.的软件)。被发现对克隆系统要求的那些常见的任意剪切序列,从提议的编码序列中被手工移除,所述编码序列保证了常见大肠杆菌密码子选择被保持。大肠杆菌密码子选择通过软件程序,如图像密码子使用分析仪(Graphical Codon Usage Analyser(Geneart))被评估,并且%GC含量和密码子使用比例通过公开的密码子使用表(例如,GenBank Release143,2004年9月13日)来评估。含有破伤风毒素LC开放读码框的,优化的DNA序列随后被商业合成(例如,通过Entelechon,Geneart或Sigma-Genosys),并在pCR4载体(invitrogen)中被提供。编码TeNT LC的pCR 4载体用BamHI和SalI剪切。BamHI-SalI片段随后被插入也已经用BamHI和SalI剪切的LC/A-CPNv-HN/A载体(SEQ ID25)。最终的构建体包含TeNT LC-接头-伤害感受肽变异体-间隔分子-HN ORF序列(SEQ ID84),用以表达SEQ ID85所示序列的蛋白。 实施例32-带有对因子Xa剪切易感的原生血清型C接头的LC/C-伤害感受肽变异体-HN/C融合蛋白的制备
按照实施例4中使用的方法,LC/C(SEQ ID5)和HN/C(SEQ ID6)被产生并被插入C血清型股啡肽变异体接头,排列为BamHI-SalI-接头-伤害感受肽变异体-NheI-间隔分子-SpeI-PstI-XbaI-终止子-HindIII(SEQ ID86)。最终的构建体包含LC-接头-伤害感受肽变异体-间隔分子-HN ORF序列(SEQ ID87),用以表达SEQ ID88所示序列的蛋白。该融合蛋白被称为CPNv-C(act.C)。
序列列表
<110>赛恩泰新公司
爱力根公司
J·查多克
K·福斯特
P·马科斯
P·斯坦库姆
K·R·奥基
J·弗朗西斯
L·斯图尔德
<120>疼痛的治疗
<130>P29323GB/MRM
<160>88
<170>PatentIn version 3.3
<210>1
<211>1302
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>1
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg ac 1302
<210>2
<211>1257
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>2
ctgcagtgta tcaaggttaa caactgggat ttattcttca gcccgagtga agacaacttc 60
accaacgacc tgaacaaagg tgaagaaatc acctcagata ctaacatcga agcagccgaa 120
gaaaacatct cgctggacct gatccagcag tactacctga cctttaattt cgacaacgag 180
ccggaaaaca tttctatcga aaacctgagc tctgatatca tcggccagct ggaactgatg 240
ccgaacatcg aacgtttccc aaacggtaaa aagtacgagc tggacaaata taccatgttc 300
cactacctgc gcgcgcagga atttgaacac ggcaaatccc gtatcgcact gactaactcc 360
gttaacgaag ctctgctcaa cccgtcccgt gtatacacct tcttctctag cgactacgtg 420
aaaaaggtca acaaagcgac tgaagctgca atgttcttgg gttgggttga acagcttgtt 480
tatgatttta ccgacgagac gtccgaagta tctactaccg acaaaattgc ggatatcact 540
atcatcatcc cgtacatcgg tccggctctg aacattggca acatgctgta caaagacgac 600
ttcgttggcg cactgatctt ctccggtgcg gtgatcctgc tggagttcat cccggaaatc 660
gccatcccgg tactgggcac ctttgctctg gtttcttaca ttgcaaacaa ggttctgact 720
gtacaaacca tcgacaacgc gctgagcaaa cgtaacgaaa aatgggatga agtttacaaa 780
tatatcgtga ccaactggct ggctaaggtt aatactcaga tcgacctcat ccgcaaaaaa 840
atgaaagaag cactggaaaa ccaggcggaa gctaccaagg caatcattaa ctaccagtac 900
aaccagtaca ccgaggaaga aaaaaacaac atcaacttca acatcgacga tctgtcctct 960
aaactgaacg aatccatcaa caaagctatg atcaacatca acaagttcct gaaccagtgc 1020
tctgtaagct atctgatgaa ctccatgatc ccgtacggtg ttaaacgtct ggaggacttc 1080
gatgcgtctc tgaaagacgc cctgctgaaa tacatttacg acaaccgtgg cactctgatc 1140
ggtcaggttg atcgtctgaa ggacaaagtg aacaatacct tatcgaccga catccctttt 1200
cagctcagta aatatgtcga taaccaacgc cttttgtcca ctctagacta gaagctt 1257
<210>3
<211>1323
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>3
ggatccatgc cggttaccat caacaacttc aactacaacg acccgatcga caacaacaac 60
atcattatga tggaaccgcc gttcgcacgt ggtaccggac gttactacaa ggcttttaag 120
atcaccgacc gtatctggat catcccggaa cgttacacct tcggttacaa acctgaggac 180
ttcaacaaga gtagcgggat tttcaatcgt gacgtctgcg agtactatga tccagattat 240
ctgaatacca acgataagaa gaacatattc cttcagacta tgattaaact cttcaaccgt 300
atcaaaagca aaccgctcgg tgaaaaactc ctcgaaatga ttatcaacgg tatcccgtac 360
ctcggtgacc gtcgtgtccc gcttgaagag ttcaacacca acatcgcaag cgtcaccgtc 420
aacaaactca tcagcaaccc aggtgaagtc gaacgtaaaa aaggtatctt cgcaaacctc 480
atcatcttcg gtccgggtcc ggtcctcaac gaaaacgaaa ccatcgacat cggtatccag 540
aaccacttcg caagccgtga aggtttcggt ggtatcatgc agatgaaatt ctgcccggaa 600
tacgtcagtg tcttcaacaa cgtccaggaa aacaaaggtg caagcatctt caaccgtcgt 660
ggttacttca gcgacccggc actcatcctc atgcatgaac tcatccacgt cctccacggt 720
ctctacggta tcaaagttga cgacctcccg atcgtcccga acgagaagaa attcttcatg 780
cagagcaccg acgcaatcca ggctgaggaa ctctacacct tcggtggcca agacccaagt 840
atcataaccc cgtccaccga caaaagcatc tacgacaaag tcctccagaa cttcaggggt 900
atcgtggaca gactcaacaa agtcctcgtc tgcatcagcg acccgaacat caatatcaac 960
atatacaaga acaagttcaa agacaagtac aaattcgtcg aggacagcga aggcaaatac 1020
agcatcgacg tagaaagttt cgacaagctc tacaaaagcc tcatgttcgg tttcaccgaa 1080
accaacatcg ccgagaacta caagatcaag acaagggcaa gttacttcag cgacagcctc 1140
ccgcctgtca aaatcaagaa cctcttagac aacgagattt acacaattga agagggcttc 1200
aacatcagtg acaaagacat ggagaaggaa tacagaggtc agaacaaggc tatcaacaaa 1260
caggcatacg aggagatcag caaagaacac ctcgcagtct acaagatcca gatgtgcgtc 1320
gac 1323
<210>4
<211>1260
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>4
ctgcagtgca tcgacgttga caacgaagac ctgttcttca tcgctgacaa aaacagcttc 60
agtgacgacc tgagcaaaaa cgaacgtatc gaatacaaca cccagagcaa ctacatcgaa 120
aacgacttcc cgatcaacga actgatcctg gacaccgacc tgataagtaa aatcgaactg 180
ccgagcgaaa acaccgaaag tctgaccgac ttcaacgttg acgttccggt ttacgaaaaa 240
cagccggcta tcaagaaaat cttcaccgac gaaaacacca tcttccagta cctgtacagc 300
cagaccttcc cgctggacat ccgtgacatc agtctgacca gcagtttcga cgacgctctg 360
ctgttcagca acaaagttta cagtttcttc agcatggact acatcaaaac cgctaacaaa 420
gttgttgaag cagggctgtt cgctggttgg gttaaacaga tcgttaacga cttcgttatc 480
gaagctaaca aaagcaacac tatggacaaa atcgctgaca tcagtctgat cgttccgtac 540
atcggtctgg ctctgaacgt tggtaacgaa accgctaaag gtaactttga aaacgctttc 600
gagatcgctg gtgcaagcat cctgctggag ttcatcccgg aactgctgat cccggttgtt 660
ggtgctttcc tgctggaaag ttacatcgac aacaaaaaca agatcatcaa aaccatcgac 720
aacgctctga ccaaacgtaa cgaaaaatgg agtgatatgt acggtctgat cgttgctcag 780
tggctgagca ccgtcaacac ccagttctac accatcaaag aaggtatgta caaagctctg 840
aactaccagg ctcaggctct ggaagagatc atcaaatacc gttacaacat ctacagtgag 900
aaggaaaaga gtaacatcaa catcgacttc aacgacatca acagcaaact gaacgaaggt 960
atcaaccagg ctatcgacaa catcaacaac ttcatcaacg gttgcagtgt tagctacctg 1020
atgaagaaga tgatcccgct ggctgttgaa aaactgctgg acttcgacaa caccctgaaa 1080
aagaacctgc tgaactacat cgacgaaaac aagctgtacc tgatcggtag tgctgaatac 1140
gaaaaaagta aagtgaacaa atacctgaag accatcatgc cgttcgacct gagtatctac 1200
accaacgaca ccatcctgat cgaaatgttc aacaaataca actctctaga ctagaagctt 1260
<210>5
<211>1329
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>5
ggatccgaat tcatgccgat caccatcaac aacttcaact acagcgatcc ggtggataac 60
aaaaacatcc tgtacctgga tacccatctg aataccctgg cgaacgaacc ggaaaaagcg 120
tttcgtatca ccggcaacat ttgggttatt ccggatcgtt ttagccgtaa cagcaacccg 180
aatctgaata aaccgccgcg tgttaccagc ccgaaaagcg gttattacga tccgaactat 240
ctgagcaccg atagcgataa agataccttc ctgaaagaaa tcatcaaact gttcaaacgc 300
atcaacagcc gtgaaattgg cgaagaactg atctatcgcc tgagcaccga tattccgttt 360
ccgggcaaca acaacacccc gatcaacacc tttgatttcg atgtggattt caacagcgtt 420
gatgttaaaa cccgccaggg taacaattgg gtgaaaaccg gcagcattaa cccgagcgtg 480
attattaccg gtccgcgcga aaacattatt gatccggaaa ccagcacctt taaactgacc 540
aacaacacct ttgcggcgca ggaaggtttt ggcgcgctga gcattattag cattagcccg 600
cgctttatgc tgacctatag caacgcgacc aacgatgttg gtgaaggccg tttcagcaaa 660
agcgaatttt gcatggaccc gatcctgatc ctgatgcatg aactgaacca tgcgatgcat 720
aacctgtatg gcatcgcgat tccgaacgat cagaccatta gcagcgtgac cagcaacatc 780
ttttacagcc agtacaacgt gaaactggaa tatgcggaaa tctatgcgtt tggcggtccg 840
accattgatc tgattccgaa aagcgcgcgc aaatacttcg aagaaaaagc gctggattac 900
tatcgcagca ttgcgaaacg tctgaacagc attaccaccg cgaatccgag cagcttcaac 960
aaatatatcg gcgaatataa acagaaactg atccgcaaat atcgctttgt ggtggaaagc 1020
agcggcgaag ttaccgttaa ccgcaataaa ttcgtggaac tgtacaacga actgacccag 1080
atcttcaccg aatttaacta tgcgaaaatc tataacgtgc agaaccgtaa aatctacctg 1140
agcaacgtgt ataccccggt gaccgcgaat attctggatg ataacgtgta cgatatccag 1200
aacggcttta acatcccgaa aagcaacctg aacgttctgt ttatgggcca gaacctgagc 1260
cgtaatccgg cgctgcgtaa agtgaacccg gaaaacatgc tgtacctgtt caccaaattt 1320
tgcgtcgac 1329
<210>6
<211>1263
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>6
ctgcagtgtc gtgaactgct ggtgaaaaac accgatctgc cgtttattgg cgatatcagc 60
gatgtgaaaa ccgatatctt cctgcgcaaa gatatcaacg aagaaaccga agtgatctac 120
tacccggata acgtgagcgt tgatcaggtg atcctgagca aaaacaccag cgaacatggt 180
cagctggatc tgctgtatcc gagcattgat agcgaaagcg aaattctgcc gggcgaaaac 240
caggtgtttt acgataaccg tacccagaac gtggattacc tgaacagcta ttactacctg 300
gaaagccaga aactgagcga taacgtggaa gattttacct ttacccgcag cattgaagaa 360
gcgctggata acagcgcgaa agtttacacc tattttccga ccctggcgaa caaagttaat 420
gcgggtgttc agggcggtct gtttctgatg tgggcgaacg atgtggtgga agatttcacc 480
accaacatcc tgcgtaaaga taccctggat aaaatcagcg atgttagcgc gattattccg 540
tatattggtc cggcgctgaa cattagcaat agcgtgcgtc gtggcaattt taccgaagcg 600
tttgcggtta ccggtgtgac cattctgctg gaagcgtttc cggaatttac cattccggcg 660
ctgggtgcgt ttgtgatcta tagcaaagtg caggaacgca acgaaatcat caaaaccatc 720
gataactgcc tggaacagcg tattaaacgc tggaaagata gctatgaatg gatgatgggc 780
acctggctga gccgtattat cacccagttc aacaacatca gctaccagat gtacgatagc 840
ctgaactatc aggcgggtgc gattaaagcg aaaatcgatc tggaatacaa aaaatacagc 900
ggcagcgata aagaaaacat caaaagccag gttgaaaacc tgaaaaacag cctggatgtg 960
aaaattagcg aagcgatgaa taacatcaac aaattcatcc gcgaatgcag cgtgacctac 1020
ctgttcaaaa acatgctgcc gaaagtgatc gatgaactga acgaatttga tcgcaacacc 1080
aaagcgaaac tgatcaacct gatcgatagc cacaacatta ttctggtggg cgaagtggat 1140
aaactgaaag cgaaagttaa caacagcttc cagaacacca tcccgtttaa catcttcagc 1200
tataccaaca acagcctgct gaaagatatc atcaacgaat acttcaatct agactagaag 1260
ctt 1263
<210>7
<211>207
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>7
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat cgaaggtcgt 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
ggcggtggcg gtagcggcgg tggcggtagc ggcggtggcg gtagcgcact agtgctgcag 180
acgcacggtc tagaatgata aaagctt 207
<210>8
<211>108
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>8
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
aacaaagcgc tgaacctgca gacgcacggt ctagaatgat aaaagctt 108
<210>9
<211>186
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>9
catatgaata acctcgggat tgagggtcgt tttggcggtt tcacgggcgc acgcaaatca 60
gcgcgtaaat tagctaacca gactagtggc ggtgggggta gtggcggtgg cggttcgggc 120
gggggtggga gccctagggg atccgtcgac ctgcagggtc tagaagcgct agcgtgataa 180
aagctt 186
<210>10
<211>180
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>10
ggatccacgc acgtcgacgc gattgatggt cgttttggcg gtttcacggg cgcacgcaaa 60
tcagcgcgta aattagctaa ccaggcgcta gcgggcggtg gcggtagcgg cggtggcggt 120
agcggcggtg gcggtagcgc actagtgctg cagacgcacg gtctagaatg ataaaagctt 180
<210>11
<211>249
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>11
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat cgaaggtcgt 60
tacggtggtt tcatgacctc tgaaaaatct cagaccccgc tggttaccct gttcaaaaac 120
gctatcatca aaaacgctta caaaaaaggt gaagcgctag cgggtggtgg tggttctggt 180
ggtggtggtt ctggtggtgg tggttctgca ctagtgctgc agacgcacgg tctagaatga 240
taaaagctt 249
<210>12
<211>207
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>12
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat cgaaggtcgt 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaac gtaagaacca ggcgctagcg 120
ggcggtggcg gtagcggcgg tggcggtagc ggcggtggcg gtagcgcact agtgctgcag 180
acgcacggtc tagaatgata aaagctt 207
<210>13
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>13
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaattagcta accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>14
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>14
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Ash Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
450 455 460
Gln Ala Leu Ala GIy Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>15
<211>2736
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>15
ctcgggattg agggtcgttt tggcggtttc acgggcgcac gcaaatcagc gcgtaaatta 60
gctaaccaga ctagtggcgg tgggggtagt ggcggtggcg gttcgggcgg gggtgggagc 120
cctaggggat ccatggagtt cgttaacaaa cagttcaact ataaagaccc agttaacggt 180
gttgacattg cttacatcaa aatcccgaac gctggccaga tgcagccggt aaaggcattc 240
aaaatccaca acaaaatctg ggttatcccg gaacgtgata cctttactaa cccggaagaa 300
ggtgacctga acccgccacc ggaagcgaaa caggtgccgg tatcttacta tgactccacc 360
tacctgtcta ccgataacga aaaggacaac tacctgaaag gtgttactaa actgttcgag 420
cgtatttact ccaccgacct gggccgtatg ctgctgacta gcatcgttcg cggtatcccg 480
ttctggggcg gttctaccat cgataccgaa ctgaaagtaa tcgacactaa ctgcatcaac 540
gttattcagc cggacggttc ctatcgttcc gaagaactga acctggtgat catcggcccg 600
tctgctgata tcatccagtt cgagtgtaag agctttggtc acgaagttct gaacctcacc 660
cgtaacggct acggttccac tcagtacatc cgtttctctc cggacttcac cttcggtttt 720
gaagaatccc tggaagtaga cacgaaccca ctgctgggcg ctggtaaatt cgcaactgat 780
cctgcggtta ccctggctca cgaactgatt catgcaggcc accgcctgta cggtatcgcc 840
atcaatccga accgtgtctt caaagttaac accaacgcgt attacgagat gtccggtctg 900
gaagttagct tcgaagaact gcgtactttt ggcggtcacg acgctaaatt catcgactct 960
ctgcaagaaa acgagttccg tctgtactac tataacaagt tcaaagatat cgcatccacc 1020
ctgaacaaag cgaaatccat cgtgggtacc actgcttctc tccagtacat gaagaacgtt 1080
tttaaagaaa aatacctgct cagcgaagac acctccggca aattctctgt agacaagttg 1140
aaattcgata aactttacaa aatgctgact gaaatttaca ccgaagacaa cttcgttaag 1200
ttctttaaag ttctgaaccg caaaacctat ctgaacttcg acaaggcagt attcaaaatc 1260
aacatcgtgc cgaaagttaa ctacactatc tacgatggtt tcaacctgcg taacaccaac 1320
ctggctgcta attttaacgg ccagaacacg gaaatcaaca acatgaactt cacaaaactg 1380
aaaaacttca ctggtctgtt cgagttttac aagctgctgt gcgtcgacgg catcattacc 1440
tccaaaacta aatctctgat agaaggtaga aacaaagcgc tgaacgacct ctgtatcaag 1500
gttaacaact gggatttatt cttcagcccg agtgaagaca acttcaccaa cgacctgaac 1560
aaaggtgaag aaatcacctc agatactaac atcgaagcag ccgaagaaaa catctcgctg 1620
gacctgatcc agcagtacta cctgaccttt aatttcgaca acgagccgga aaacatttct 1680
atcgaaaacc tgagctctga tatcatcggc cagctggaac tgatgccgaa catcgaacgt 1740
ttcccaaacg gtaaaaagta cgagctggac aaatatacca tgttccacta cctgcgcgcg 1800
caggaatttg aacacggcaa atcccgtatc gcactgacta actccgttaa cgaagctctg 1860
ctcaacccgt cccgtgtata caccttcttc tctagcgact acgtgaaaaa ggtcaacaaa 1920
gcgactgaag ctgcaatgtt cttgggttgg gttgaacagc ttgtttatga ttttaccgac 1980
gagacgtccg aagtatctac taccgacaaa attgcggata tcactatcat catcccgtac 2040
atcggtccgg ctctgaacat tggcaacatg ctgtacaaag acgacttcgt tggcgcactg 2100
atcttctccg gtgcggtgat cctgctggag ttcatcccgg aaatcgccat cccggtactg 2160
ggcacctttg ctctggtttc ttacattgca aacaaggttc tgactgtaca aaccatcgac 2220
aacgcgctga gcaaacgtaa cgaaaaatgg gatgaagttt acaaatatat cgtgaccaac 2280
tggctggcta aggttaatac tcagatcgac ctcatccgca aaaaaatgaa agaagcactg 2340
gaaaaccagg cggaagctac caaggcaatc attaactacc agtacaacca gtacaccgag 2400
gaagaaaaaa acaacatcaa cttcaacatc gacgatctgt cctctaaact gaacgaatcc 2460
atcaacaaag ctatgatcaa catcaacaag ttcctgaacc agtgctctgt aagctatctg 2520
atgaactcca tgatcccgta cggtgttaaa cgtctggagg acttcgatgc gtctctgaaa 2580
gacgccctgc tgaaatacat ttacgacaac cgtggcactc tgatcggtca ggttgatcgt 2640
ctgaaggaca aagtgaacaa taccttatcg accgacatcc cttttcagct cagtaaatat 2700
gtcgataacc aacgcctttt gtccactcta gactag 2736
<210>16
<211>911
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>16
Leu Gly Ile Glu Gly Arg Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser
1 5 10 15
Ala Arg Lys Leu Ala Asn Gln Thr Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
Gly Gly Ser Gly Gly Gly Gly Ser Pro Arg Gly Ser Met Glu Phe Val
35 40 45
Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala
50 55 60
Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe
65 70 75 80
Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr
85 90 95
Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val
100 105 110
Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys
115 120 125
Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser
130 135 140
Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro
145 150 155 160
Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr
165 170 175
Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu
180 185 190
Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu
195 200 205
Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr
210 215 220
Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe
225 230 235 240
Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys
245 250 255
Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu Ile His Ala
260 265 270
Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys
275 280 285
Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe
290 295 300
Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser
305 310 315 320
Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp
325 330 335
Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala
340 345 350
Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser
355 360 365
Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys
370 375 380
Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys
385 390 395 400
Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala
405 410 415
Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp
420 425 430
Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln
435 440 445
Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr
450 455 460
Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly Ile Ile Thr
465 470 475 480
Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg Asn Lys Ala Leu Asn Asp
485 490 495
Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu
500 505 510
Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp
515 520 525
Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln
530 535 540
Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser
545 550 555 560
Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro
565 570 575
Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr
580 585 590
Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser
595 600 605
Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser
610 615 620
Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys
625 630 635 640
Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr
645 650 655
Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala
660 665 670
Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly
675 680 685
Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly
690 695 700
Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu
705 710 715 720
Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val
725 730 735
Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu
740 745 750
Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln
755 760 765
Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala
770 775 780
Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu
785 790 795 800
Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys
805 810 815
Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu
820 825 830
Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly
835 840 845
Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu
850 855 860
Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg
865 870 875 880
Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln
885 890 895
Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
900 905 910
<210>17
<211>2715
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>17
ggatccgaat tcatgccgat caccatcaac aacttcaact acagcgatcc ggtggataac 60
aaaaacatcc tgtacctgga tacccatctg aataccctgg cgaacgaacc ggaaaaagcg 120
tttcgtatca ccggcaacat ttgggttatt ccggatcgtt ttagccgtaa cagcaacccg 180
aatctgaata aaccgccgcg tgttaccagc ccgaaaagcg gttattacga tccgaactat 240
ctgagcaccg atagcgataa agataccttc ctgaaagaaa tcatcaaact gttcaaacgc 300
atcaacagcc gtgaaattgg cgaagaactg atctatcgcc tgagcaccga tattccgttt 360
ccgggcaaca acaacacccc gatcaacacc tttgatttcg atgtggattt caacagcgtt 420
gatgttaaaa cccgccaggg taacaattgg gtgaaaaccg gcagcattaa cccgagcgtg 480
attattaccg gtccgcgcga aaacattatt gatccggaaa ccagcacctt taaactgacc 540
aacaacacct ttgcggcgca ggaaggtttt ggcgcgctga gcattattag cattagcccg 600
cgctttatgc tgacctatag caacgcgacc aacgatgttg gtgaaggccg tttcagcaaa 660
agcgaatttt gcatggaccc gatcctgatc ctgatgcatg aactgaacca tgcgatgcat 720
aacctgtatg gcatcgcgat tccgaacgat cagaccatta gcagcgtgac cagcaacatc 780
ttttacagcc agtacaacgt gaaactggaa tatgcggaaa tctatgcgtt tggcggtccg 840
accattgatc tgattccgaa aagcgcgcgc aaatacttcg aagaaaaagc gctggattac 900
tatcgcagca ttgcgaaacg tctgaacagc attaccaccg cgaatccgag cagcttcaac 960
aaatatatcg gcgaatataa acagaaactg atccgcaaat atcgctttgt ggtggaaagc 1020
agcggcgaag ttaccgttaa ccgcaataaa ttcgtggaac tgtacaacga actgacccag 1080
atcttcaccg aatttaacta tgcgaaaatc tataacgtgc agaaccgtaa aatctacctg 1140
agcaacgtgt ataccccggt gaccgcgaat attctggatg ataacgtgta cgatatccag 1200
aacggcttta acatcccgaa aagcaacctg aacgttctgt ttatgggcca gaacctgagc 1260
cgtaatccgg cgctgcgtaa agtgaacccg gaaaacatgc tgtacctgtt caccaaattt 1320
tgcgtcgacg cgatagatgg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaattagcta accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtcgt gaactgctgg tgaaaaacac cgatctgccg 1500
tttattggcg atatcagcga tgtgaaaacc gatatcttcc tgcgcaaaga tatcaacgaa 1560
gaaaccgaag tgatctacta cccggataac gtgagcgttg atcaggtgat cctgagcaaa 1620
aacaccagcg aacatggtca gctggatctg ctgtatccga gcattgatag cgaaagcgaa 1680
attctgccgg gcgaaaacca ggtgttttac gataaccgta cccagaacgt ggattacctg 1740
aacagctatt actacctgga aagccagaaa ctgagcgata acgtggaaga ttttaccttt 1800
acccgcagca ttgaagaagc gctggataac agcgcgaaag tttacaccta ttttccgacc 1860
ctggcgaaca aagttaatgc gggtgttcag ggcggtctgt ttctgatgtg ggcgaacgat 1920
gtggtggaag atttcaccac caacatcctg cgtaaagata ccctggataa aatcagcgat 1980
gttagcgcga ttattccgta tattggtccg gcgctgaaca ttagcaatag cgtgcgtcgt 2040
ggcaatttta ccgaagcgtt tgcggttacc ggtgtgacca ttctgctgga agcgtttccg 2100
gaatttacca ttccggcgct gggtgcgttt gtgatctata gcaaagtgca ggaacgcaac 2160
gaaatcatca aaaccatcga taactgcctg gaacagcgta ttaaacgctg gaaagatagc 2220
tatgaatgga tgatgggcac ctggctgagc cgtattatca cccagttcaa caacatcagc 2280
taccagatgt acgatagcct gaactatcag gcgggtgcga ttaaagcgaa aatcgatctg 2340
gaatacaaaa aatacagcgg cagcgataaa gaaaacatca aaagccaggt tgaaaacctg 2400
aaaaacagcc tggatgtgaa aattagcgaa gcgatgaata acatcaacaa attcatccgc 2460
gaatgcagcg tgacctacct gttcaaaaac atgctgccga aagtgatcga tgaactgaac 2520
gaatttgatc gcaacaccaa agcgaaactg atcaacctga tcgatagcca caacattatt 2580
ctggtgggcg aagtggataa actgaaagcg aaagttaaca acagcttcca gaacaccatc 2640
ccgtttaaca tcttcagcta taccaacaac agcctgctga aagatatcat caacgaatac 2700
ttcaatctag actag 2715
<210>18
<211>904
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>18
Gly Ser Glu Phe Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp
1 5 10 15
Pro Val Asp Asn Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr
20 25 30
Leu Ala Asn Glu Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp
35 40 45
Val Ile Pro Asp Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys
50 55 60
Pro Pro Arg Val Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr
65 70 75 80
Leu Ser Thr Asp Ser Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys
85 90 95
Leu Phe Lys Arg Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr
100 105 110
Arg Leu Ser Thr Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile
115 120 125
Asn Thr Phe Asp Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr
130 135 140
Arg Gln Gly Asn Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val
145 150 155 160
Ile Ile Thr Gly Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr
165 170 175
Phe Lys Leu Thr Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala
180 185 190
Leu Ser Ile Ile Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn
195 200 205
Ala Thr Asn Asp Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys
210 215 220
Met Asp Pro Ile Leu Ile Leu Met His Glu Leu Asn His Ala Met His
225 230 235 240
Asn Leu Tyr Gly Ile Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val
245 250 255
Thr Ser Asn Ile Phe Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala
260 265 270
Glu Ile Tyr Ala Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser
275 280 285
Ala Arg Lys Tyr Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile
290 295 300
Ala Lys Arg Leu Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn
305 310 315 320
Lys Tyr Ile Gly Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe
325 330 335
Val Val Glu Ser Ser Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val
340 345 350
Glu Leu Tyr Asn Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala
355 360 365
Lys Ile Tyr Asn Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr
370 375 380
Thr Pro Val Thr Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln
385 390 395 400
Asn Gly Phe Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly
405 410 415
Gln Asn Leu Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn
420 425 430
Met Leu Tyr Leu Phe Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Arg Glu Leu Leu Val Lys Asn
485 490 495
Thr Asp Leu Pro Phe Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile
500 505 510
Phe Leu Arg Lys Asp Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro
515 520 525
Asp Asn Val Ser Val Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu
530 535 540
His Gly Gln Leu Asp Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu
545 550 555 560
Ile Leu Pro Gly Glu Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn
565 570 575
Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser
580 585 590
Asp Asn Val Glu Asp Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu
595 600 605
Asp Asn Ser Ala Lys Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys
610 615 620
Val Asn Ala Gly Val Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp
625 630 635 640
Val Val Glu Asp Phe Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp
645 650 655
Lys Ile Ser Asp Val Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu
660 665 670
Asn Ile Ser Asn Ser Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala
675 680 685
Val Thr Gly Val Thr Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile
690 695 700
Pro Ala Leu Gly Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn
705 710 715 720
Glu Ile Ile Lys Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg
725 730 735
Trp Lys Asp Ser Tyr Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile
740 745 750
Ile Thr Gln Phe Asn Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn
755 760 765
Tyr Gln Ala Gly Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys
770 775 780
Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu
785 790 795 800
Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn
805 810 815
Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu
820 825 830
Pro Lys Val Ile Asp Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala
835 840 845
Lys Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu
850 855 860
Val Asp Lys Leu Lys Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile
865 870 875 880
Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile
885 890 895
Ile Asn Glu Tyr Phe Asn Leu Asp
900
<210>19
<211>2742
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>19
ggatccgaat tcatgccgat caccatcaac aacttcaact acagcgatcc ggtggataac 60
aaaaacatcc tgtacctgga tacccatctg aataccctgg cgaacgaacc ggaaaaagcg 120
tttcgtatca ccggcaacat ttgggttatt ccggatcgtt ttagccgtaa cagcaacccg 180
aatctgaata aaccgccgcg tgttaccagc ccgaaaagcg gttattacga tccgaactat 240
ctgagcaccg atagcgataa agataccttc ctgaaagaaa tcatcaaact gttcaaacgc 300
atcaacagcc gtgaaattgg cgaagaactg atctatcgcc tgagcaccga tattccgttt 360
ccgggcaaca acaacacccc gatcaacacc tttgatttcg atgtggattt caacagcgtt 420
gatgttaaaa cccgccaggg taacaattgg gtgaaaaccg gcagcattaa cccgagcgtg 480
attattaccg gtccgcgcga aaacattatt gatccggaaa ccagcacctt taaactgacc 540
aacaacacct ttgcggcgca ggaaggtttt ggcgcgctga gcattattag cattagcccg 600
cgctttatgc tgacctatag caacgcgacc aacgatgttg gtgaaggccg tttcagcaaa 660
agcgaatttt gcatggaccc gatcctgatc ctgatgcatg aactgaacca tgcgatgcat 720
aacctgtatg gcatcgcgat tccgaacgat cagaccatta gcagcgtgac cagcaacatc 780
ttttacagcc agtacaacgt gaaactggaa tatgcggaaa tctatgcgtt tggcggtccg 840
accattgatc tgattccgaa aagcgcgcgc aaatacttcg aagaaaaagc gctggattac 900
tatcgcagca ttgcgaaacg tctgaacagc attaccaccg cgaatccgag cagcttcaac 960
aaatatatcg gcgaatataa acagaaactg atccgcaaat atcgctttgt ggtggaaagc 1020
agcggcgaag ttaccgttaa ccgcaataaa ttcgtggaac tgtacaacga actgacccag 1080
atcttcaccg aatttaacta tgcgaaaatc tataacgtgc agaaccgtaa aatctacctg 1140
agcaacgtgt ataccccggt gaccgcgaat attctggatg ataacgtgta cgatatccag 1200
aacggcttta acatcccgaa aagcaacctg aacgttctgt ttatgggcca gaacctgagc 1260
cgtaatccgg cgctgcgtaa agtgaacccg gaaaacatgc tgtacctgtt caccaaattt 1320
tgcgtcgacg gcatcattac ctccaaaact aaatctctga tagaaggtag atttggcggt 1380
ttcacgggcg cacgcaaatc agcgcgtaaa ttagctaacc aggcgctagc gggcggtggc 1440
ggtagcggcg gtggcggtag cggcggtggc ggtagcgcac tagtgctgca gtgtcgtgaa 1500
ctgctggtga aaaacaccga tctgccgttt attggcgata tcagcgatgt gaaaaccgat 1560
atcttcctgc gcaaagatat caacgaagaa accgaagtga tctactaccc ggataacgtg 1620
agcgttgatc aggtgatcct gagcaaaaac accagcgaac atggtcagct ggatctgctg 1680
tatccgagca ttgatagcga aagcgaaatt ctgccgggcg aaaaccaggt gttttacgat 1740
aaccgtaccc agaacgtgga ttacctgaac agctattact acctggaaag ccagaaactg 1800
agcgataacg tggaagattt tacctttacc cgcagcattg aagaagcgct ggataacagc 1860
gcgaaagttt acacctattt tccgaccctg gcgaacaaag ttaatgcggg tgttcagggc 1920
ggtctgtttc tgatgtgggc gaacgatgtg gtggaagatt tcaccaccaa catcctgcgt 1980
aaagataccc tggataaaat cagcgatgtt agcgcgatta ttccgtatat tggtccggcg 2040
ctgaacatta gcaatagcgt gcgtcgtggc aattttaccg aagcgtttgc ggttaccggt 2100
gtgaccattc tgctggaagc gtttccggaa tttaccattc cggcgctggg tgcgtttgtg 2160
atctatagca aagtgcagga acgcaacgaa atcatcaaaa ccatcgataa ctgcctggaa 2220
cagcgtatta aacgctggaa agatagctat gaatggatga tgggcacctg gctgagccgt 2280
attatcaccc agttcaacaa catcagctac cagatgtacg atagcctgaa ctatcaggcg 2340
ggtgcgatta aagcgaaaat cgatctggaa tacaaaaaat acagcggcag cgataaagaa 2400
aacatcaaaa gccaggttga aaacctgaaa aacagcctgg atgtgaaaat tagcgaagcg 2460
atgaataaca tcaacaaatt catccgcgaa tgcagcgtga cctacctgtt caaaaacatg 2520
ctgccgaaag tgatcgatga actgaacgaa tttgatcgca acaccaaagc gaaactgatc 2580
aacctgatcg atagccacaa cattattctg gtgggcgaag tggataaact gaaagcgaaa 2640
gttaacaaca gcttccagaa caccatcccg tttaacatct tcagctatac caacaacagc 2700
ctgctgaaag atatcatcaa cgaatacttc aatctagact ag 2742
<210>20
<211>913
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>20
Gly Ser Glu Phe Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp
1 5 10 15
Pro Val Asp Asn Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr
20 25 30
Leu Ala Asn Glu Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp
35 40 45
Val Ile Pro Asp Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys
50 55 60
Pro Pro Arg Val Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr
65 70 75 80
Leu Ser Thr Asp Ser Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys
85 90 95
Leu Phe Lys Arg Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr
100 105 110
Arg Leu Ser Thr Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile
115 120 125
Asn Thr Phe Asp Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr
130 135 140
Arg Gln Gly Asn Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val
145 150 155 160
Ile Ile Thr Gly Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr
165 170 175
Phe Lys Leu Thr Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala
180 185 190
Leu Ser Ile Ile Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn
195 200 205
Ala Thr Asn Asp Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys
210 215 220
Met Asp Pro Ile Leu Ile Leu Met His Glu Leu Asn His Ala Met His
225 230 235 240
Asn Leu Tyr Gly Ile Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val
245 250 255
Thr Ser Asn Ile Phe Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala
260 265 270
Glu Ile Tyr Ala Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser
275 280 285
Ala Arg Lys Tyr Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile
290 295 300
Ala Lys Arg Leu Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn
305 310 315 320
Lys Tyr Ile Gly Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe
325 330 335
Val Val Glu Ser Ser Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val
340 345 350
Glu Leu Tyr Asn Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala
355 360 365
Lys Ile Tyr Asn Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr
370 375 380
Thr Pro Val Thr Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln
385 390 395 400
Asn Gly Phe Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly
405 410 415
Gln Asn Leu Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn
420 425 430
Met Leu Tyr Leu Phe Thr Lys Phe Cys Val Asp Gly Ile Ile Thr Ser
435 440 445
Lys Thr Lys Ser Leu Ile Glu Gly Arg Phe Gly Gly Phe Thr Gly Ala
450 455 460
Arg Lys Ser Ala Arg Lys Leu Ala Asn Gln Ala Leu Ala Gly Gly Gly
465 470 475 480
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu
485 490 495
Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe Ile Gly
500 505 510
Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp Ile Asn
515 520 525
Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val Asp Gln
530 535 540
Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp Leu Leu
545 550 555 560
Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu Asn Gln
565 570 575
Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn Ser Tyr
580 585 590
Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp Phe Thr
595 600 605
Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys Val Tyr
610 615 620
Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val Gln Gly
625 630 635 640
Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe Thr Thr
645 650 655
Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Ala
660 665 670
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser Val Arg
675 680 685
Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr Ile Leu
690 695 700
Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala Phe Val
705 710 715 720
Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr Ile Asp
725 730 735
Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr Glu Trp
740 745 750
Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn Asn Ile
755 760 765
Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala Ile Lys
770 775 780
Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu
785 790 795 800
Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys
805 810 815
Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser
820 825 830
Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu
835 840 845
Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu Ile Asp
850 855 860
Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys Ala Lys
865 870 875 880
Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn I1e Phe Ser Tyr
885 890 895
Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn Leu
900 905 910
Asp
<210>21
<211>2673
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>21
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatacggt ggtttcatgg cgctagcggg cggtggcggt 1380
agcggcggtg gcggtagcgg cggtggcggt agcgcactag tgctgcagtg tatcaaggtt 1440
aacaactggg atttattctt cagcccgagt gaagacaact tcaccaacga cctgaacaaa 1500
ggtgaagaaa tcacctcaga tactaacatc gaagcagccg aagaaaacat ctcgctggac 1560
ctgatccagc agtactacct gacctttaat ttcgacaacg agccggaaaa catttctatc 1620
gaaaacctga gctctgatat catcggccag ctggaactga tgccgaacat cgaacgtttc 1680
ccaaacggta aaaagtacga gctggacaaa tataccatgt tccactacct gcgcgcgcag 1740
gaatttgaac acggcaaatc ccgtatcgca ctgactaact ccgttaacga agctctgctc 1800
aacccgtccc gtgtatacac cttcttctct agcgactacg tgaaaaaggt caacaaagcg 1860
actgaagctg caatgttctt gggttgggtt gaacagcttg tttatgattt taccgacgag 1920
acgtccgaag tatctactac cgacaaaatt gcggatatca ctatcatcat cccgtacatc 1980
ggtccggctc tgaacattgg caacatgctg tacaaagacg acttcgttgg cgcactgatc 2040
ttctccggtg cggtgatcct gctggagttc atcccggaaa tcgccatccc ggtactgggc 2100
acctttgctc tggtttctta cattgcaaac aaggttctga ctgtacaaac catcgacaac 2160
gcgctgagca aacgtaacga aaaatgggat gaagtttaca aatatatcgt gaccaactgg 2220
ctggctaagg ttaatactca gatcgacctc atccgcaaaa aaatgaaaga agcactggaa 2280
aaccaggcgg aagctaccaa ggcaatcatt aactaccagt acaaccagta caccgaggaa 2340
gaaaaaaaca acatcaactt caacatcgac gatctgtcct ctaaactgaa cgaatccatc 2400
aacaaagcta tgatcaacat caacaagttc ctgaaccagt gctctgtaag ctatctgatg 2460
aactccatga tcccgtacgg tgttaaacgt ctggaggact tcgatgcgtc tctgaaagac 2520
gccctgctga aatacattta cgacaaccgt ggcactctga tcggtcaggt tgatcgtctg 2580
aaggacaaag tgaacaatac cttatcgacc gacatccctt ttcagctcag taaatatgtc 2640
gataaccaac gccttttgtc cactctagac tag 2673
<210>22
<211>890
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>22
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Met Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly
450 455 460
Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val
465 470 475 480
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
485 490 495
Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
500 505 510
Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
515 520 525
Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
530 535 540
Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
545 550 555 560
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
565 570 575
Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
580 585 590
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
595 600 605
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
610 615 620
Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
625 630 635 640
Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
645 650 655
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
660 665 670
Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
675 680 685
Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
690 695 700
Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
705 710 715 720
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
725 730 735
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
740 745 750
Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
755 760 765
Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
770 775 780
Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
785 790 795 800
Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
805 810 815
Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
820 825 830
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
835 840 845
Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
850 855 860
Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
865 870 875 880
Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
885 890
<210>23
<211>2751
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>23
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatcgaagg tcgttacggt ggtttcatga cctctgaaaa atctcagacc 1380
ccgctggtta ccctgttcaa aaacgctatc atcaaaaacg cttacaaaaa aggtgaagcg 1440
ctagcgggtg gtggtggttc tggtggtggt ggttctggtg gtggtggttc tgcactagtg 1500
ctgcagtgta tcaaggttaa caactgggat ttattcttca gcccgagtga agacaacttc 1560
accaacgacc tgaacaaagg tgaagaaatc acctcagata ctaacatcga agcagccgaa 1620
gaaaacatct cgctggacct gatccagcag tactacctga cctttaattt cgacaacgag 1680
ccggaaaaca tttctatcga aaacctgagc tctgatatca tcggccagct ggaactgatg 1740
ccgaacatcg aacgtttccc aaacggtaaa aagtacgagc tggacaaata taccatgttc 1800
cactacctgc gcgcgcagga atttgaacac ggcaaatccc gtatcgcact gactaactcc 1860
gttaacgaag ctctgctcaa cccgtcccgt gtatacacct tcttctctag cgactacgtg 1920
aaaaaggtca acaaagcgac tgaagctgca atgttcttgg gttgggttga acagcttgtt 1980
tatgatttta ccgacgagac gtccgaagta tctactaccg acaaaattgc ggatatcact 2040
atcatcatcc cgtacatcgg tccggctctg aacattggca acatgctgta caaagacgac 2100
ttcgttggcg cactgatctt ctccggtgcg gtgatcctgc tggagttcat cccggaaatc 2150
gccatcccgg tactgggcac ctttgctctg gtttcttaca ttgcaaacaa ggttctgact 2220
gtacaaacca tcgacaacgc gctgagcaaa cgtaacgaaa aatgggatga agtttacaaa 2280
tatatcgtga ccaactggct ggctaaggtt aatactcaga tcgacctcat ccgcaaaaaa 2340
atgaaagaag cactggaaaa ccaggcggaa gctaccaagg caatcattaa ctaccagtac 2400
aaccagtaca ccgaggaaga aaaaaacaac atcaacttca acatcgacga tctgtcctct 2460
aaactgaacg aatccatcaa caaagctatg atcaacatca acaagttcct gaaccagtgc 2520
tctgtaagct atctgatgaa ctccatgatc ccgtacggtg ttaaacgtct ggaggacttc 2580
gatgcgtctc tgaaagacgc cctgctgaaa tacatttacg acaaccgtgg cactctgatc 2640
ggtcaggttg atcgtctgaa ggacaaagtg aacaatacct tatcgaccga catccctttt 2700
cagctcagta aatatgtcga taaccaacgc cttttgtcca ctctagacta g 2751
<210>24
<211>916
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>24
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Met Thr Ser Glu Lys Ser Gln Thr Pro Leu Val Thr
450 455 460
Leu Phe Lys Asn Ala Ile Ile Lys Asn Ala Tyr Lys Lys Gly Glu Ala
465 470 475 480
Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
485 490 495
Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe
500 505 510
Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu
515 520 525
Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser
530 535 540
Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu
545 550 555 560
Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln
565 570 575
Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr
580 585 590
Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe
595 600 605
Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala
610 615 620
Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val
625 630 635 640
Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val
645 650 655
Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr
660 665 670
Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro
675 680 685
Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala
690 695 700
Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile
705 710 715 720
Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn
725 730 735
Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn
740 745 750
Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala
755 760 765
Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala
770 775 780
Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr
785 790 795 800
Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp
805 810 815
Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn
820 825 830
Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser
835 840 845
Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu
850 855 860
Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile
865 870 875 880
Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr
885 890 895
Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu
900 905 910
Ser Thr Leu Asp
915
<210>25
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>25
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaacgtaaga accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>26
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>26
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>27
<211>2691
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>27
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcggcg 1380
ctagcgggcg gtggcggtag cggcggtggc ggtagcggcg gtggcggtag cgcactagtg 1440
ctgcagtgta tcaaggttaa caactgggat ttattcttca gcccgagtga agacaacttc 1500
accaacgacc tgaacaaagg tgaagaaatc acctcagata ctaacatcga agcagccgaa 1560
gaaaacatct cgctggacct gatccagcag tactacctga cctttaattt cgacaacgag 1620
ccggaaaaca tttctatcga aaacctgagc tctgatatca tcggccagct ggaactgatg 1680
ccgaacatcg aacgtttccc aaacggtaaa aagtacgagc tggacaaata taccatgttc 1740
cactacctgc gcgcgcagga atttgaacac ggcaaatccc gtatcgcact gactaactcc 1800
gttaacgaag ctctgctcaa cccgtcccgt gtatacacct tcttctctag cgactacgtg 1860
aaaaaggtca acaaagcgac tgaagctgca atgttcttgg gttgggttga acagcttgtt 1920
tatgatttta ccgacgagac gtccgaagta tctactaccg acaaaattgc ggatatcact 1980
atcatcatcc cgtacatcgg tccggctctg aacattggca acatgctgta caaagacgac 2040
ttcgttggcg cactgatctt ctccggtgcg gtgatcctgc tggagttcat cccggaaatc 2100
gccatcccgg tactgggcac ctttgctctg gtttcttaca ttgcaaacaa ggttctgact 2160
gtacaaacca tcgacaacgc gctgagcaaa cgtaacgaaa aatgggatga agtttacaaa 2220
tatatcgtga ccaactggct ggctaaggtt aatactcaga tcgacctcat ccgcaaaaaa 2280
atgaaagaag cactggaaaa ccaggcggaa gctaccaagg caatcattaa ctaccagtac 2340
aaccagtaca ccgaggaaga aaaaaacaac atcaacttca acatcgacga tctgtcctct 2400
aaactgaacg aatccatcaa caaagctatg atcaacatca acaagttcct gaaccagtgc 2460
tctgtaagct atctgatgaa ctccatgatc ccgtacggtg ttaaacgtct ggaggacttc 2520
gatgcgtctc tgaaagacgc cctgctgaaa tacatttacg acaaccgtgg cactctgatc 2580
ggtcaggttg atcgtctgaa ggacaaagtg aacaatacct tatcgaccga catccctttt 2640
cagctcagta aatatgtcga taaccaacgc cttttgtcca ctctagacta g 2691
<210>28
<211>896
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>28
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Ala Leu Ala Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val
465 470 475 480
Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser
485 490 495
Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser
500 505 510
Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile
515 520 525
Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile
530 535 540
Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met
545 550 555 560
Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys
565 570 575
Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys
580 585 590
Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro
595 600 605
Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn
610 615 620
Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val
625 630 635 640
Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile
645 650 655
Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
660 665 670
Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser
675 680 685
Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val
690 695 700
Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr
705 710 715 720
Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp
725 730 735
Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr
740 745 750
Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln
755 760 765
Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr
770 775 780
Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser
785 790 795 800
Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe
805 810 815
Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr
820 825 830
Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu
835 840 845
Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp
850 855 860
Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe
865 870 875 880
Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
885 890 895
<210>29
<211>2691
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>29
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atatgcggcg 1380
ctagcgggcg gtggcggtag cggcggtggc ggtagcggcg gtggcggtag cgcactagtg 1440
ctgcagtgta tcaaggttaa caactgggat ttattcttca gcccgagtga agacaacttc 1500
accaacgacc tgaacaaagg tgaagaaatc acctcagata ctaacatcga agcagccgaa 1560
gaaaacatct cgctggacct gatccagcag tactacctga cctttaattt cgacaacgag 1620
ccggaaaaca tttctatcga aaacctgagc tctgatatca tcggccagct ggaactgatg 1680
ccgaacatcg aacgtttccc aaacggtaaa aagtacgagc tggacaaata taccatgttc 1740
cactacctgc gcgcgcagga atttgaacac ggcaaatccc gtatcgcact gactaactcc 1800
gttaacgaag ctctgctcaa cccgtcccgt gtatacacct tcttctctag cgactacgtg 1860
aaaaaggtca acaaagcgac tgaagctgca atgttcttgg gttgggttga acagcttgtt 1920
tatgatttta ccgacgagac gtccgaagta tctactaccg acaaaattgc ggatatcact 1980
atcatcatcc cgtacatcgg tccggctctg aacattggca acatgctgta caaagacgac 2040
ttcgttggcg cactgatctt ctccggtgcg gtgatcctgc tggagttcat cccggaaatc 2100
gccatcccgg tactgggcac ctttgctctg gtttcttaca ttgcaaacaa ggttctgact 2160
gtacaaacca tcgacaacgc gctgagcaaa cgtaacgaaa aatgggatga agtttacaaa 2220
tatatcgtga ccaactggct ggctaaggtt aatactcaga tcgacctcat ccgcaaaaaa 2280
atgaaagaag cactggaaaa ccaggcggaa gctaccaagg caatcattaa ctaccagtac 2340
aaccagtaca ccgaggaaga aaaaaacaac atcaacttca acatcgacga tctgtcctct 2400
aaactgaacg aatccatcaa caaagctatg atcaacatca acaagttcct gaaccagtgc 2460
tctgtaagct atctgatgaa ctccatgatc ccgtacggtg ttaaacgtct ggaggacttc 2520
gatgcgtctc tgaaagacgc cctgctgaaa tacatttacg acaaccgtgg cactctgatc 2580
ggtcaggttg atcgtctgaa ggacaaagtg aacaatacct tatcgaccga catccctttt 2640
cagctcagta aatatgtcga taaccaacgc cttttgtcca ctctagacta g 2691
<210>30
<211>896
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>30
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Tyr Ala Ala Leu Ala Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val
465 470 475 480
Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser
485 490 495
Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser
500 505 510
Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile
515 520 525
Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile
530 535 540
Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met
545 550 555 560
Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys
565 570 575
Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys
580 585 590
Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro
595 600 605
Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn
610 615 620
Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val
625 630 635 640
Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile
645 650 655
Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
660 665 670
Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser
675 680 685
Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val
690 695 700
Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr
705 710 715 720
Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp
725 730 735
Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr
740 745 750
Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln
755 760 765
Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr
770 775 780
Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser
785 790 795 800
Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe
805 810 815
Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr
820 825 830
Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu
835 840 845
Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp
850 855 860
Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe
865 870 875 880
Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
885 890 895
<210>31
<211>2691
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>31
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcatatgcg 1380
ctagcgggcg gtggcggtag cggcggtggc ggtagcggcg gtggcggtag cgcactagtg 1440
ctgcagtgta tcaaggttaa caactgggat ttattcttca gcccgagtga agacaacttc 1500
accaacgacc tgaacaaagg tgaagaaatc acctcagata ctaacatcga agcagccgaa 1560
gaaaacatct cgctggacct gatccagcag tactacctga cctttaattt cgacaacgag 1620
ccggaaaaca tttctatcga aaacctgagc tctgatatca tcggccagct ggaactgatg 1680
ccgaacatcg aacgtttccc aaacggtaaa aagtacgagc tggacaaata taccatgttc 1740
cactacctgc gcgcgcagga atttgaacac ggcaaatccc gtatcgcact gactaactcc 1800
gttaacgaag ctctgctcaa cccgtcccgt gtatacacct tcttctctag cgactacgtg 1860
aaaaaggtca acaaagcgac tgaagctgca atgttcttgg gttgggttga acagcttgtt 1920
tatgatttta ccgacgagac gtccgaagta tctactaccg acaaaattgc ggatatcact 1980
atcatcatcc cgtacatcgg tccggctctg aacattggca acatgctgta caaagacgac 2040
ttcgttggcg cactgatctt ctccggtgcg gtgatcctgc tggagttcat cccggaaatc 2100
gccatcccgg tactgggcac ctttgctctg gtttcttaca ttgcaaacaa ggttctgact 2160
gtacaaacca tcgacaacgc gctgagcaaa cgtaacgaaa aatgggatga agtttacaaa 2220
tatatcgtga ccaactggct ggctaaggtt aatactcaga tcgacctcat ccgcaaaaaa 2280
atgaaagaag cactggaaaa ccaggcggaa gctaccaagg caatcattaa ctaccagtac 2340
aaccagtaca ccgaggaaga aaaaaacaac atcaacttca acatcgacga tctgtcctct 2400
aaactgaacg aatccatcaa caaagctatg atcaacatca acaagttcct gaaccagtgc 2460
tctgtaagct atctgatgaa ctccatgatc ccgtacggtg ttaaacgtct ggaggacttc 2520
gatgcgtctc tgaaagacgc cctgctgaaa tacatttacg acaaccgtgg cactctgatc 2580
ggtcaggttg atcgtctgaa ggacaaagtg aacaatacct tatcgaccga catccctttt 2640
cagctcagta aatatgtcga taaccaacgc cttttgtcca ctctagacta g 2691
<210>32
<211>896
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>32
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Tyr Ala Leu Ala Gly Gly
450 455 460
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val
465 470 475 480
Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser
485 490 495
Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser
500 505 510
Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile
515 520 525
Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile
530 535 540
Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met
545 550 555 560
Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys
565 570 575
Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys
580 585 590
Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro
595 600 605
Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn
610 615 620
Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val
625 630 635 640
Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile
645 650 655
Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile
660 665 670
Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser
675 680 685
Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val
690 695 700
Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr
705 710 715 720
Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp
725 730 735
Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr
740 745 750
Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln
755 760 765
Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr
770 775 780
Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser
785 790 795 800
Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe
805 810 815
Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr
820 825 830
Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu
835 840 845
Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp
850 855 860
Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe
865 870 875 880
Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
885 890 895
<210>33
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>33
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaatatgcta accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>34
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>34
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Tyr Ala Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>35
<211>2697
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>35
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaagcgctag cgggcggtgg cggtagcggc ggtggcggta gcggcggtgg cggtagcgca 1440
ctagtgctgc agtgtatcaa ggttaacaac tgggatttat tcttcagccc gagtgaagac 1500
aacttcacca acgacctgaa caaaggtgaa gaaatcacct cagatactaa catcgaagca 1560
gccgaagaaa acatctcgct ggacctgatc cagcagtact acctgacctt taatttcgac 1620
aacgagccgg aaaacatttc tatcgaaaac ctgagctctg atatcatcgg ccagctggaa 1680
ctgatgccga acatcgaacg tttcccaaac ggtaaaaagt acgagctgga caaatatacc 1740
atgttccact acctgcgcgc gcaggaattt gaacacggca aatcccgtat cgcactgact 1800
aactccgtta acgaagctct gctcaacccg tcccgtgtat acaccttctt ctctagcgac 1860
tacgtgaaaa aggtcaacaa agcgactgaa gctgcaatgt tcttgggttg ggttgaacag 1920
cttgtttatg attttaccga cgagacgtcc gaagtatcta ctaccgacaa aattgcggat 1980
atcactatca tcatcccgta catcggtccg gctctgaaca ttggcaacat gctgtacaaa 2040
gacgacttcg ttggcgcact gatcttctcc ggtgcggtga tcctgctgga gttcatcccg 2100
gaaatcgcca tcccggtact gggcaccttt gctctggttt cttacattgc aaacaaggtt 2160
ctgactgtac aaaccatcga caacgcgctg agcaaacgta acgaaaaatg ggatgaagtt 2220
tacaaatata tcgtgaccaa ctggctggct aaggttaata ctcagatcga cctcatccgc 2280
aaaaaaatga aagaagcact ggaaaaccag gcggaagcta ccaaggcaat cattaactac 2340
cagtacaacc agtacaccga ggaagaaaaa aacaacatca acttcaacat cgacgatctg 2400
tcctctaaac tgaacgaatc catcaacaaa gctatgatca acatcaacaa gttcctgaac 2460
cagtgctctg taagctatct gatgaactcc atgatcccgt acggtgttaa acgtctggag 2520
gacttcgatg cgtctctgaa agacgccctg ctgaaataca tttacgacaa ccgtggcact 2580
ctgatcggtc aggttgatcg tctgaaggac aaagtgaaca ataccttatc gaccgacatc 2640
ccttttcagc tcagtaaata tgtcgataac caacgccttt tgtccactct agactag 2697
<210>36
<211>898
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>36
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Ala Leu Ala
450 455 460
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala
465 470 475 480
Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser
485 490 495
Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile
500 505 510
Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp
515 520 525
Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu
530 535 540
Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu
545 550 555 560
Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu
565 570 575
Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His
580 585 590
Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu
595 600 605
Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys
610 615 620
Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
625 630 635 640
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp
645 650 655
Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu
660 665 670
Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile
675 680 685
Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile
690 695 700
Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val
705 710 715 720
Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys
725 730 735
Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val
740 745 750
Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu
755 760 765
Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln
770 775 780
Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu
785 790 795 800
Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn
805 810 815
Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile
820 825 830
Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp
835 840 845
Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln
850 855 860
Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
865 870 875 880
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr
885 890 895
Leu Asp
<210>37
<211>51
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>37
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca g 51
<210>38
<211>17
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>38
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
1 5 10 15
Gln
<210>39
<211>33
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>39
tttggcggtt tcacgggcgc acgcaaatca gcg 33
<210>40
<211>11
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>40
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala
1 5 10
<210>41
<211>33
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>41
tttggcggtt tcacgggcgc acgcaaatat gcg 33
<210>42
<211>11
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>42
Phe Gly Gly Phe Thr Gly Ala Arg Lys Tyr Ala
1 5 10
<210>43
<211>33
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>43
tttggcggtt tcacgggcgc acgcaaatca tat 33
<210>44
<211>11
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>44
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Tyr
1 5 10
<210>45
<211>51
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>45
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat atgctaacca g 51
<210>46
<211>17
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>46
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Tyr Ala Asn
1 5 10 15
Gln
<210>47
<211>39
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>47
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaa 39
<210>48
<211>13
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>48
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys
1 5 10
<210>49
<211>51
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>49
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaac gcaaaaacca g 51
<210>50
<211>17
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>50
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
1 5 10 15
Gln
<210>51
<211>2736
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>51
ctcgggattg agggtcgttt tggcggtttc acgggcgcac gcaaatcagc gcgtaaatta 60
gctaaccaga ctagtggcgg tgggggtagt ggcggtggcg gttcgggcgg gggtgggagc 120
cctaggggat ccatggagtt cgttaacaaa cagttcaact ataaagaccc agttaacggt 180
gttgacattg cttacatcaa aatcccgaac gctggccaga tgcagccggt aaaggcattc 240
aaaatccaca acaaaatctg ggttatcccg gaacgtgata cctttactaa cccggaagaa 300
ggtgacctga acccgccacc ggaagcgaaa caggtgccgg tatcttacta tgactccacc 360
tacctgtcta ccgataacga aaaggacaac tacctgaaag gtgttactaa actgttcgag 420
cgtatttact ccaccgacct gggccgtatg ctgctgacta gcatcgttcg cggtatcccg 480
ttctggggcg gttctaccat cgataccgaa ctgaaagtaa tcgacactaa ctgcatcaac 540
gttattcagc cggacggttc ctatcgttcc gaagaactga acctggtgat catcggcccg 600
tctgctgata tcatccagtt cgagtgtaag agctttggtc acgaagttct gaacctcacc 660
cgtaacggct acggttccac tcagtacatc cgtttctctc cggacttcac cttcggtttt 720
gaagaatccc tggaagtaga cacgaaccca ctgctgggcg ctggtaaatt cgcaactgat 780
cctgcggtta ccctggctca cgaactgatt catgcaggcc accgcctgta cggtatcgcc 840
atcaatccga accgtgtctt caaagttaac accaacgcgt attacgagat gtccggtctg 900
gaagttagct tcgaagaact gcgtactttt ggcggtcacg acgctaaatt catcgactct 960
ctgcaagaaa acgagttccg tctgtactac tataacaagt tcaaagatat cgcatccacc 1020
ctgaacaaag cgaaatccat cgtgggtacc actgcttctc tccagtacat gaagaacgtt 1080
tttaaagaaa aatacctgct cagcgaagac acctccggca aattctctgt agacaagttg 1140
aaattcgata aactttacaa aatgctgact gaaatttaca ccgaagacaa cttcgttaag 1200
ttctttaaag ttctgaaccg caaaacctat ctgaacttcg acaaggcagt attcaaaatc 1260
aacatcgtgc cgaaagttaa ctacactatc tacgatggtt tcaacctgcg taacaccaac 1320
ctggctgcta attttaacgg ccagaacacg gaaatcaaca acatgaactt cacaaaactg 1380
aaaaacttca ctggtctgtt cgagttttac aagctgctgt gcgtcgacgg catcattacc 1440
tccaaaacta aatctctgat agaaggtaga aacaaagcgc tgaacctgca gtgtatcaag 1500
gttaacaact gggatttatt cttcagcccg agtgaagaca acttcaccaa cgacctgaac 1560
aaaggtgaag aaatcacctc agatactaac atcgaagcag ccgaagaaaa catctcgctg 1620
gacctgatcc agcagtacta cctgaccttt aatttcgaca acgagccgga aaacatttct 1680
atcgaaaacc tgagctctga tatcatcggc cagctggaac tgatgccgaa catcgaacgt 1740
ttcccaaacg gtaaaaagta cgagctggac aaatatacca tgttccacta cctgcgcgcg 1800
caggaatttg aacacggcaa atcccgtatc gcactgacta actccgttaa cgaagctctg 1860
ctcaacccgt cccgtgtata caccttcttc tctagcgact acgtgaaaaa ggtcaacaaa 1920
gcgactgaag ctgcaatgtt cttgggttgg gttgaacagc ttgtttatga ttttaccgac 1980
gagacgtccg aagtatctac taccgacaaa attgcggata tcactatcat catcccgtac 2040
atcggtccgg ctctgaacat tggcaacatg ctgtacaaag acgacttcgt tggcgcactg 2100
atcttctccg gtgcggtgat cctgctggag ttcatcccgg aaatcgccat cccggtactg 2160
ggcacctttg ctctggtttc ttacattgca aacaaggttc tgactgtaca aaccatcgac 2220
aacgcgctga gcaaacgtaa cgaaaaatgg gatgaagttt acaaatatat cgtgaccaac 2280
tggctggcta aggttaatac tcagatcgac ctcatccgca aaaaaatgaa agaagcactg 2340
gaaaaccagg cggaagctac caaggcaatc attaactacc agtacaacca gtacaccgag 2400
gaagaaaaaa acaacatcaa cttcaacatc gacgatctgt cctctaaact gaacgaatcc 2460
atcaacaaag ctatgatcaa catcaacaag ttcctgaacc agtgctctgt aagctatctg 2520
atgaactcca tgatcccgta cggtgttaaa cgtctggagg acttcgatgc gtctctgaaa 2580
gacgccctgc tgaaatacat ttacgacaac cgtggcactc tgatcggtca ggttgatcgt 2640
ctgaaggaca aagtgaacaa taccttatcg accgacatcc cttttcagct cagtaaatat 2700
gtcgataacc aacgcctttt gtccactcta gactag 2736
<210>52
<211>911
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>52
Leu Gly Ile Glu Gly Arg Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser
1 5 10 15
Ala Arg Lys Leu Ala Asn Gln Thr Ser Gly Gly Gly Gly Ser Gly Gly
20 25 30
Gly Gly Ser Gly Gly Gly Gly Ser Pro Arg Gly Ser Met Glu Phe Val
35 40 45
Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly Val Asp Ile Ala
50 55 60
Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro Val Lys Ala Phe
65 70 75 80
Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg Asp Thr Phe Thr
85 90 95
Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu Ala Lys Gln Val
100 105 110
Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr Asp Asn Glu Lys
115 120 125
Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu Arg Ile Tyr Ser
130 135 140
Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val Arg Gly Ile Pro
145 150 155 160
Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys Val Ile Asp Thr
165 170 175
Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr Arg Ser Glu Glu
180 185 190
Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile Ile Gln Phe Glu
195 200 205
Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr Arg Asn Gly Tyr
210 215 220
Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe Thr Phe Gly Phe
225 230 235 240
Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu Gly Ala Gly Lys
245 250 255
Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu Leu Ile His Ala
260 265 270
Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn Arg Val Phe Lys
275 280 285
Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu Glu Val Ser Phe
290 295 300
Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys Phe Ile Asp Ser
305 310 315 320
Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn Lys Phe Lys Asp
325 330 335
Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val Gly Thr Thr Ala
340 345 350
Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys Tyr Leu Leu Ser
355 360 365
Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu Lys Phe Asp Lys
370 375 380
Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp Asn Phe Val Lys
385 390 395 400
Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn Phe Asp Lys Ala
405 410 415
Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr Thr Ile Tyr Asp
420 425 430
Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn Phe Asn Gly Gln
435 440 445
Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu Lys Asn Phe Thr
450 455 460
Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Asp Gly Ile Ile Thr
465 470 475 480
Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg Asn Lys Ala Leu Asn Leu
485 490 495
Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu
500 505 510
Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp
515 520 525
Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln
530 535 540
Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser
545 550 555 560
Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro
565 570 575
Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr
580 585 590
Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser
595 600 605
Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser
610 615 620
Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys
625 630 635 640
Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr
645 650 655
Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala
660 665 670
Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly
675 680 685
Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly
690 695 700
Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu
705 710 715 720
Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val
725 730 735
Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu
740 745 750
Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln
755 760 765
Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala
770 775 780
Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu
785 790 795 800
Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys
805 810 815
Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu
820 825 830
Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly
835 840 845
Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu
850 855 860
Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg
865 870 875 880
Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln
885 890 895
Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
900 905 910
<210>53
<211>177
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>53
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
ggtggtggtg gttctgcact agtgctgcag acgcacggtc tagaatgata aaagctt 177
<210>54
<211>192
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>54
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
ggtggtggtg gttctggtgg tggtggttct gcactagtgc tgcagacgca cggtctagaa 180
tgataaaagc tt 192
<210>55
<211>222
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>55
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
ggtggtggtg gttctggtgg tggtggttct ggtggtggtg gttctggtgg tggtggttct 180
gcactagtgc tgcagacgca cggtctagaa tgataaaagc tt 222
<210>56
<211>237
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>56
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
ggtggtggtg gttctggtgg tggtggttct ggtggtggtg gttctggtgg tggtggttct 180
ggtggtggtg gttctgcact agtgctgcag acgcacggtc tagaatgata aaagctt 237
<210>57
<211>228
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>57
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaat tagctaacca ggcgctagcg 120
gctgaagctg ctgctaaaga agctgctgct aaagaagctg ctgctaaagc tggtggcggt 180
ggttccgcac tagtgctgca gacgcacggt ctagaatgat aaaagctt 228
<210>58
<211>2694
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>58
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaattagcta accaggcgct agcgggtggt ggtggttctg gtggtggtgg ttctgcacta 1440
gtgctgcagt gtatcaaggt taacaactgg gatttattct tcagcccgag tgaagacaac 1500
ttcaccaacg acctgaacaa aggtgaagaa atcacctcag atactaacat cgaagcagcc 1560
gaagaaaaca tctcgctgga cctgatccag cagtactacc tgacctttaa tttcgacaac 1620
gagccggaaa acatttctat cgaaaacctg agctctgata tcatcggcca gctggaactg 1680
atgccgaaca tcgaacgttt cccaaacggt aaaaagtacg agctggacaa atataccatg 1740
ttccactacc tgcgcgcgca ggaatttgaa cacggcaaat cccgtatcgc actgactaac 1800
tccgttaacg aagctctgct caacccgtcc cgtgtataca ccttcttctc tagcgactac 1860
gtgaaaaagg tcaacaaagc gactgaagct gcaatgttct tgggttgggt tgaacagctt 1920
gtttatgatt ttaccgacga gacgtccgaa gtatctacta ccgacaaaat tgcggatatc 1980
actatcatca tcccgtacat cggtccggct ctgaacattg gcaacatgct gtacaaagac 2040
gacttcgttg gcgcactgat cttctccggt gcggtgatcc tgctggagtt catcccggaa 2100
atcgccatcc cggtactggg cacctttgct ctggtttctt acattgcaaa caaggttctg 2160
actgtacaaa ccatcgacaa cgcgctgagc aaacgtaacg aaaaatggga tgaagtttac 2220
aaatatatcg tgaccaactg gctggctaag gttaatactc agatcgacct catccgcaaa 2280
aaaatgaaag aagcactgga aaaccaggcg gaagctacca aggcaatcat taactaccag 2340
tacaaccagt acaccgagga agaaaaaaac aacatcaact tcaacatcga cgatctgtcc 2400
tctaaactga acgaatccat caacaaagct atgatcaaca tcaacaagtt cctgaaccag 2460
tgctctgtaa gctatctgat gaactccatg atcccgtacg gtgttaaacg tctggaggac 2520
ttcgatgcgt ctctgaaaga cgccctgctg aaatacattt acgacaaccg tggcactctg 2580
atcggtcagg ttgatcgtct gaaggacaaa gtgaacaata ccttatcgac cgacatccct 2640
tttcagctca gtaaatatgt cgataaccaa cgccttttgt ccactctaga ctag 2694
<210>59
<211>897
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>59
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu
465 470 475 480
Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro
485 490 495
Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr
500 505 510
Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu
515 520 525
Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn
530 535 540
Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu
545 550 555 560
Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp
565 570 575
Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly
580 585 590
Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn
595 600 605
Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val
610 615 620
Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu
625 630 635 640
Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys
645 650 655
Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn
660 665 670
Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe
675 680 685
Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro
690 695 700
Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu
705 710 715 720
Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp
725 730 735
Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn
740 745 750
Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn
755 760 765
Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr
770 775 780
Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser
785 790 795 800
Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys
805 810 815
Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro
820 825 830
Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala
835 840 845
Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val
850 855 860
Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro
865 870 875 880
Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu
885 890 895
Asp
<210>60
<211>2724
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>60
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaattagcta accaggcgct agcgggtggt ggtggttctg gtggtggtgg ttctggtggt 1440
ggtggttctg gtggtggtgg ttctgcacta gtgctgcagt gtatcaaggt taacaactgg 1500
gatttattct tcagcccgag tgaagacaac ttcaccaacg acctgaacaa aggtgaagaa 1560
atcacctcag atactaacat cgaagcagcc gaagaaaaca tctcgctgga cctgatccag 1620
cagtactacc tgacctttaa tttcgacaac gagccggaaa acatttctat cgaaaacctg 1680
agctctgata tcatcggcca gctggaactg atgccgaaca tcgaacgttt cccaaacggt 1740
aaaaagtacg agctggacaa atataccatg ttccactacc tgcgcgcgca ggaatttgaa 1800
cacggcaaat cccgtatcgc actgactaac tccgttaacg aagctctgct caacccgtcc 1860
cgtgtataca ccttcttctc tagcgactac gtgaaaaagg tcaacaaagc gactgaagct 1920
gcaatgttct tgggttgggt tgaacagctt gtttatgatt ttaccgacga gacgtccgaa 1980
gtatctacta ccgacaaaat tgcggatatc actatcatca tcccgtacat cggtccggct 2040
ctgaacattg gcaacatgct gtacaaagac gacttcgttg gcgcactgat cttctccggt 2100
gcggtgatcc tgctggagtt catcccggaa atcgccatcc cggtactggg cacctttgct 2160
ctggtttctt acattgcaaa caaggttctg actgtacaaa ccatcgacaa cgcgctgagc 2220
aaacgtaacg aaaaatggga tgaagtttac aaatatatcg tgaccaactg gctggctaag 2280
gttaatactc agatcgacct catccgcaaa aaaatgaaag aagcactgga aaaccaggcg 2340
gaagctacca aggcaatcat taactaccag tacaaccagt acaccgagga agaaaaaaac 2400
aacatcaact tcaacatcga cgatctgtcc tctaaactga acgaatccat caacaaagct 2460
atgatcaaca tcaacaagtt cctgaaccag tgctctgtaa gctatctgat gaactccatg 2520
atcccgtacg gtgttaaacg tctggaggac ttcgatgcgt ctctgaaaga cgccctgctg 2580
aaatacattt acgacaaccg tggcactctg atcggtcagg ttgatcgtct gaaggacaaa 2640
gtgaacaata ccttatcgac cgacatccct tttcagctca gtaaatatgt cgataaccaa 2700
cgccttttgt ccactctaga ctag 2724
<210>61
<211>907
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>61
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys
485 490 495
Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr
500 505 510
Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu
515 520 525
Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu
530 535 540
Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu
545 550 555 560
Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg
565 570 575
Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His
580 585 590
Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu
595 600 605
Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr
610 615 620
Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala
625 630 635 640
Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp
645 650 655
Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile
660 665 670
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr
675 680 685
Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu
690 695 700
Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala
705 710 715 720
Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp
725 730 735
Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr
740 745 750
Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile
755 760 765
Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys
770 775 780
Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn
785 790 795 800
Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser
805 810 815
Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser
820 825 830
Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu
835 840 845
Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr
850 855 860
Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys
865 870 875 880
Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr
885 890 895
Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
900 905
<210>62
<211>207
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>62
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctgacga tgacgataaa 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaac gtaagaacca ggcgctagcg 120
ggcggtggcg gtagcggcgg tggcggtagc ggcggtggcg gtagcgcact agtgctgcag 180
acgcacggtc tagaatgata aaagctt 207
<210>63
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>63
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctg acgatgacga taaatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaacgtaaga accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>64
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>64
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Asp Asp Asp Asp Lys
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>65
<211>207
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>65
ggatccacgc acgtcgacgg catcattacc tccaaaacta aatctctgat agaaggtaga 60
tttggcggtt tcacgggcgc acgcaaatca gcgcgtaaac gtaagaacca ggcgctagcg 120
ggcggtggcg gtagcggcgg tggcggtagc ggcggtggcg gtagcgcact agtgctgcag 180
acgcacggtc tagaatgata aaagctt 207
<210>66
<211>2742
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>66
ggatccgaat tcatgccgat caccatcaac aacttcaact acagcgatcc ggtggataac 60
aaaaacatcc tgtacctgga tacccatctg aataccctgg cgaacgaacc ggaaaaagcg 120
tttcgtatca ccggcaacat ttgggttatt ccggatcgtt ttagccgtaa cagcaacccg 180
aatctgaata aaccgccgcg tgttaccagc ccgaaaagcg gttattacga tccgaactat 240
ctgagcaccg atagcgataa agataccttc ctgaaagaaa tcatcaaact gttcaaacgc 300
atcaacagcc gtgaaattgg cgaagaactg atctatcgcc tgagcaccga tattccgttt 360
ccgggcaaca acaacacccc gatcaacacc tttgatttcg atgtggattt caacagcgtt 420
gatgttaaaa cccgccaggg taacaattgg gtgaaaaccg gcagcattaa cccgagcgtg 480
attattaccg gtccgcgcga aaacattatt gatccggaaa ccagcacctt taaactgacc 540
aacaacacct ttgcggcgca ggaaggtttt ggcgcgctga gcattattag cattagcccg 600
cgctttatgc tgacctatag caacgcgacc aacgatgttg gtgaaggccg tttcagcaaa 660
agcgaatttt gcatggaccc gatcctgatc ctgatgcatg aactgaacca tgcgatgcat 720
aacctgtatg gcatcgcgat tccgaacgat cagaccatta gcagcgtgac cagcaacatc 780
ttttacagcc agtacaacgt gaaactggaa tatgcggaaa tctatgcgtt tggcggtccg 840
accattgatc tgattccgaa aagcgcgcgc aaatacttcg aagaaaaagc gctggattac 900
tatcgcagca ttgcgaaacg tctgaacagc attaccaccg cgaatccgag cagcttcaac 960
aaatatatcg gcgaatataa acagaaactg atccgcaaat atcgctttgt ggtggaaagc 1020
agcggcgaag ttaccgttaa ccgcaataaa ttcgtggaac tgtacaacga actgacccag 1080
atcttcaccg aatttaacta tgcgaaaatc tataacgtgc agaaccgtaa aatctacctg 1140
agcaacgtgt ataccccggt gaccgcgaat attctggatg ataacgtgta cgatatccag 1200
aacggcttta acatcccgaa aagcaacctg aacgttctgt ttatgggcca gaacctgagc 1260
cgtaatccgg cgctgcgtaa agtgaacccg gaaaacatgc tgtacctgtt caccaaattt 1320
tgcgtcgacg gcatcattac ctccaaaact aaatctctga tagaaggtag atttggcggt 1380
ttcacgggcg cacgcaaatc agcgcgtaaa cgtaagaacc aggcgctagc gggcggtggc 1440
ggtagcggcg gtggcggtag cggcggtggc ggtagcgcac tagtgctgca gtgtcgtgaa 1500
ctgctggtga aaaacaccga tctgccgttt attggcgata tcagcgatgt gaaaaccgat 1560
atcttcctgc gcaaagatat caacgaagaa accgaagtga tctactaccc ggataacgtg 1620
agcgttgatc aggtgatcct gagcaaaaac accagcgaac atggtcagct ggatctgctg 1680
tatccgagca ttgatagcga aagcgaaatt ctgccgggcg aaaaccaggt gttttacgat 1740
aaccgtaccc agaacgtgga ttacctgaac agctattact acctggaaag ccagaaactg 1800
agcgataacg tggaagattt tacctttacc cgcagcattg aagaagcgct ggataacagc 1860
gcgaaagttt acacctattt tccgaccctg gcgaacaaag ttaatgcggg tgttcagggc 1920
ggtctgtttc tgatgtgggc gaacgatgtg gtggaagatt tcaccaccaa catcctgcgt 1980
aaagataccc tggataaaat cagcgatgtt agcgcgatta ttccgtatat tggtccggcg 2040
ctgaacatta gcaatagcgt gcgtcgtggc aattttaccg aagcgtttgc ggttaccggt 2100
gtgaccattc tgctggaagc gtttccggaa tttaccattc cggcgctggg tgcgtttgtg 2160
atctatagca aagtgcagga acgcaacgaa atcatcaaaa ccatcgataa ctgcctggaa 2220
cagcgtatta aacgctggaa agatagctat gaatggatga tgggcacctg gctgagccgt 2280
attatcaccc agttcaacaa catcagctac cagatgtacg atagcctgaa ctatcaggcg 2340
ggtgcgatta aagcgaaaat cgatctggaa tacaaaaaat acagcggcag cgataaagaa 2400
aacatcaaaa gccaggttga aaacctgaaa aacagcctgg atgtgaaaat tagcgaagcg 2460
atgaataaca tcaacaaatt catccgcgaa tgcagcgtga cctacctgtt caaaaacatg 2520
ctgccgaaag tgatcgatga actgaacgaa tttgatcgca acaccaaagc gaaactgatc 2580
aacctgatcg atagccacaa cattattctg gtgggcgaag tggataaact gaaagcgaaa 2640
gttaacaaca gcttccagaa caccatcccg tttaacatct tcagctatac caacaacagc 2700
ctgctgaaag atatcatcaa cgaatacttc aatctagact ag 2742
<210>67
<211>913
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>67
Gly Ser Glu Phe Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp
1 5 10 15
Pro Val Asp Asn Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr
20 25 30
Leu Ala Asn Glu Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp
35 40 45
Val Ile Pro Asp Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys
50 55 60
Pro Pro Arg Val Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr
65 70 75 80
Leu Ser Thr Asp Ser Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys
85 90 95
Leu Phe Lys Arg Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr
100 105 110
Arg Leu Ser Thr Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile
115 120 125
Asn Thr Phe Asp Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr
130 135 140
Arg Gln Gly Asn Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val
145 150 155 160
Ile Ile Thr Gly Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr
165 170 175
Phe Lys Leu Thr Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala
180 185 190
Leu Ser Ile Ile Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn
195 200 205
Ala Thr Asn Asp Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys
210 215 220
Met Asp Pro Ile Leu Ile Leu Met His Glu Leu Asn His Ala Met His
225 230 235 240
Asn Leu Tyr Gly Ile Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val
245 250 255
Thr Ser Asn Ile Phe Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala
260 265 270
Glu Ile Tyr Ala Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser
275 280 285
Ala Arg Lys Tyr Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile
290 295 300
Ala Lys Arg Leu Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn
305 310 315 320
Lys Tyr Ile Gly Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe
325 330 335
Val Val Glu Ser Ser Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val
340 345 350
Glu Leu Tyr Asn Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala
355 360 365
Lys Ile Tyr Asn Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr
370 375 380
Thr Pro Val Thr Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln
385 390 395 400
Asn Gly Phe Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly
405 410 415
Gln Asn Leu Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn
420 425 430
Met Leu Tyr Leu Phe Thr Lys Phe Cys Val Asp Gly Ile Ile Thr Ser
435 440 445
Lys Thr Lys Ser Leu Ile Glu Gly Arg Phe Gly Gly Phe Thr Gly Ala
450 455 460
Arg Lys Ser Ala Arg Lys Arg Lys Asn Gln Ala Leu Ala Gly Gly Gly
465 470 475 480
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu
485 490 495
Gln Cys Arg Glu Leu Leu Val Lys Asn Thr Asp Leu Pro Phe Ile Gly
500 505 510
Asp Ile Ser Asp Val Lys Thr Asp Ile Phe Leu Arg Lys Asp Ile Asn
515 520 525
Glu Glu Thr Glu Val Ile Tyr Tyr Pro Asp Asn Val Ser Val Asp Gln
530 535 540
Val Ile Leu Ser Lys Asn Thr Ser Glu His Gly Gln Leu Asp Leu Leu
545 550 555 560
Tyr Pro Ser Ile Asp Ser Glu Ser Glu Ile Leu Pro Gly Glu Asn Gln
565 570 575
Val Phe Tyr Asp Asn Arg Thr Gln Asn Val Asp Tyr Leu Asn Ser Tyr
580 585 590
Tyr Tyr Leu Glu Ser Gln Lys Leu Ser Asp Asn Val Glu Asp Phe Thr
595 600 605
Phe Thr Arg Ser Ile Glu Glu Ala Leu Asp Asn Ser Ala Lys Val Tyr
610 615 620
Thr Tyr Phe Pro Thr Leu Ala Asn Lys Val Asn Ala Gly Val Gln Gly
625 630 635 640
Gly Leu Phe Leu Met Trp Ala Asn Asp Val Val Glu Asp Phe Thr Thr
645 650 655
Asn Ile Leu Arg Lys Asp Thr Leu Asp Lys Ile Ser Asp Val Ser Ala
660 665 670
Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ser Asn Ser Val Arg
675 680 685
Arg Gly Asn Phe Thr Glu Ala Phe Ala Val Thr Gly Val Thr Ile Leu
690 695 700
Leu Glu Ala Phe Pro Glu Phe Thr Ile Pro Ala Leu Gly Ala Phe Val
705 710 715 720
Ile Tyr Ser Lys Val Gln Glu Arg Asn Glu Ile Ile Lys Thr Ile Asp
725 730 735
Asn Cys Leu Glu Gln Arg Ile Lys Arg Trp Lys Asp Ser Tyr Glu Trp
740 745 750
Met Met Gly Thr Trp Leu Ser Arg Ile Ile Thr Gln Phe Asn Asn Ile
755 760 765
Ser Tyr Gln Met Tyr Asp Ser Leu Asn Tyr Gln Ala Gly Ala Ile Lys
770 775 780
Ala Lys Ile Asp Leu Glu Tyr Lys Lys Tyr Ser Gly Ser Asp Lys Glu
785 790 795 800
Asn Ile Lys Ser Gln Val Glu Asn Leu Lys Asn Ser Leu Asp Val Lys
805 810 815
Ile Ser Glu Ala Met Asn Asn Ile Asn Lys Phe Ile Arg Glu Cys Ser
820 825 830
Val Thr Tyr Leu Phe Lys Asn Met Leu Pro Lys Val Ile Asp Glu Leu
835 840 845
Asn Glu Phe Asp Arg Asn Thr Lys Ala Lys Leu Ile Asn Leu Ile Asp
850 855 860
Ser His Asn Ile Ile Leu Val Gly Glu Val Asp Lys Leu Lys Ala Lys
865 870 875 880
Val Asn Asn Ser Phe Gln Asn Thr Ile Pro Phe Asn Ile Phe Ser Tyr
885 890 895
Thr Asn Asn Ser Leu Leu Lys Asp Ile Ile Asn Glu Tyr Phe Asn Leu
900 905 910
Asp
<210>68
<211>2673
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>68
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatacggt ggtttcctgg cgctagcggg cggtggcggt 1380
agcggcggtg gcggtagcgg cggtggcggt agcgcactag tgctgcagtg tatcaaggtt 1440
aacaactggg atttattctt cagcccgagt gaagacaact tcaccaacga cctgaacaaa 1500
ggtgaagaaa tcacctcaga tactaacatc gaagcagccg aagaaaacat ctcgctggac 1560
ctgatccagc agtactacct gacctttaat ttcgacaacg agccggaaaa catttctatc 1620
gaaaacctga gctctgatat catcggccag ctggaactga tgccgaacat cgaacgtttc 1680
ccaaacggta aaaagtacga gctggacaaa tataccatgt tccactacct gcgcgcgcag 1740
gaatttgaac acggcaaatc ccgtatcgca ctgactaact ccgttaacga agctctgctc 1800
aacccgtccc gtgtatacac cttcttctct agcgactacg tgaaaaaggt caacaaagcg 1860
actgaagctg caatgttctt gggttgggtt gaacagcttg tttatgattt taccgacgag 1920
acgtccgaag tatctactac cgacaaaatt gcggatatca ctatcatcat cccgtacatc 1980
ggtccggctc tgaacattgg caacatgctg tacaaagacg acttcgttgg cgcactgatc 2040
ttctccggtg cggtgatcct gctggagttc atcccggaaa tcgccatccc ggtactgggc 2100
acctttgctc tggtttctta cattgcaaac aaggttctga ctgtacaaac catcgacaac 2160
gcgctgagca aacgtaacga aaaatgggat gaagtttaca aatatatcgt gaccaactgg 2220
ctggctaagg ttaatactca gatcgacctc atccgcaaaa aaatgaaaga agcactggaa 2280
aaccaggcgg aagctaccaa ggcaatcatt aactaccagt acaaccagta caccgaggaa 2340
gaaaaaaaca acatcaactt caacatcgac gatctgtcct ctaaactgaa cgaatccatc 2400
aacaaagcta tgatcaacat caacaagttc ctgaaccagt gctctgtaag ctatctgatg 2460
aactccatga tcccgtacgg tgttaaacgt ctggaggact tcgatgcgtc tctgaaagac 2520
gccctgctga aatacattta cgacaaccgt ggcactctga tcggtcaggt tgatcgtctg 2580
aaggacaaag tgaacaatac cttatcgacc gacatccctt ttcagctcag taaatatgtc 2640
gataaccaac gccttttgtc cactctagac tag 2673
<210>69
<211>890
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>69
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile 1le Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Leu Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly
450 455 460
Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val
465 470 475 480
Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn
485 490 495
Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
500 505 510
Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr
515 520 525
Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser
530 535 540
Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe
545 550 555 560
Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr
565 570 575
Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr
580 585 590
Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe
595 600 605
Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala
610 615 620
Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu
625 630 635 640
Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile
645 650 655
Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys
660 665 670
Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu
675 680 685
Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu
690 695 700
Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn
705 710 715 720
Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile
725 730 735
Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
740 745 750
Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala
755 760 765
Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn
770 775 780
Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile
785 790 795 800
Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val
805 810 815
Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu
820 825 830
Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp
835 840 845
Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val
850 855 860
Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val
865 870 875 880
Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
885 890
<210>70
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>70
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatatggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaattagcta accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>71
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>71
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Leu Ala Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>72
<211>2709
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>72
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatatggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaacgtaaga accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagactag 2709
<210>73
<211>902
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>73
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Asp
900
<210>74
<211>2889
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>74
ggatccttgg tacgagatga cgttgactat caaattttcc gcgactttgc ggaaaataaa 60
ggtaagtttt tcgtcggcgc cacagacctg tccgtcaaaa ataagagagg ccagaacatc 120
ggtaacgcac tgagcaacgt ccctatgatt gattttagtg tagcggacgt taataaacgg 180
attgcaaccg tcgttgatcc gcagtatgct gtcagcgtca aacatgctaa agcggaagtt 240
catacgttct attacgggca atataacggc cataacgatg tggctgataa agaaaatgaa 300
tatcgcgtgg tcgagcagaa caattacgaa ccgcacaaag cgtggggcgc gagtaattta 360
ggccgcctgg aggactataa catggcccgt ttcaataaat tcgtgaccga ggtagcaccg 420
atcgccccca cagatgctgg tgggggcctg gatacctaca aagataaaaa ccgcttctct 480
agcttcgtgc gcattggcgc cggtcgtcag ctcgtgtacg agaagggtgt ctatcaccag 540
gaaggtaatg aaaaggggta cgacctccgt gatttgtccc aggcgtatcg ctacgctatt 600
gccggaaccc cgtataaaga tattaatatc gatcaaacca tgaataccga aggcctaatt 660
ggtttcggga atcataataa gcaatatagc gcagaagagc taaagcaggc cctcagccaa 720
gatgcgttaa ccaattacgg agtgttaggc gatagcggca gtccgctgtt tgccttcgat 780
aaacagaaaa atcaatgggt gtttctgggc acttatgatt attgggccgg atatggtaaa 840
aagagctggc aggaatggaa tatttataaa aaggaattcg cagacaaaat caagcagcat 900
gacaacgcag gtacggtgaa ggggaacggc gaacatcact ggaagacgac cggcacgaat 960
agtcatatcg gatcgacggc cgttcgcctg gcgaacaatg agggcgatgc aaacaatggg 1020
caaaacgtga cctttgagga caacggtacc ctggtcctta accagaacat aaatcagggc 1080
gcgggaggct tgttctttaa aggcgactat actgttaagg gagcaaacaa tgacatcacc 1140
tggttagggg ccggtattga cgttgcggat ggaaaaaagg tggtttggca ggttaaaaac 1200
cctaacgggg accggctggc aaaaatcggc aaagggacat tggaaattaa tggtaccggt 1260
gtgaatcagg gtcagctgaa agtgggagat gggaccgtga ttctgaacca gaaagcagac 1320
gctgacaaaa aggtgcaagc ctttagccaa gtaggaattg ttagtggtcg tggcacactc 1380
gtcttgaact caagcaacca aataaatccg gataacctgt actttggatt tcgtggcgga 1440
cgcctggatg ctaacgggaa tgatctgacc tttgaacata tccgtaacgt tgacgagggt 1500
gcgcgcatag ttaatcataa tactgaccat gcatcaacta tcaccttgac cgggaaaagt 1560
ctgattacaa acccaaactc tctgtcagta cattccatcc agaatgatta tgatgaagac 1620
gattactcat actattaccg gccgcgtaga ccaattccac aaggtaaaga tctttattac 1680
aaaaattacc gttattacgc attaaaatcc ggagggcggc tgaatgcacc tatgccggaa 1740
aatggcgtgg ccgaaaacaa tgactggatt tttatgggtt atactcaaga agaggctcgc 1800
aaaaatgcaa tgaaccataa aaataaccga aggatcggtg atttcggcgg atttttcgat 1860
gaggaaaatg gtaaaggtca caatggtgcg ctgaatctaa attttaacgg caaaagtgcc 1920
cagaaacgtt tccttctgac tggtggcgct aatctgaatg gtaaaatcag tgtgacgcag 1980
ggtaacgtgc tgctttctgg ccggccaact ccgcatgcac gtgattttgt aaataaatcg 2040
agcgctcgta aagatgcgca tttttctaaa aataacgagg tcgtgtttga agatgactgg 2100
ataaatcgca cctttaaagc ggcagaaatc gcggttaatc agagtgcgag cttttcatcg 2160
ggtaggaatg tatctgatat tacagcaaac attacagcca ctgataatgc gaaggtcaac 2220
ctgggttata aaaacggtga tgaagtttgt gttcgatcgg attacacggg ctatgttacc 2280
tgcaacactg gcaatctgtc tgataaagcg cttaactctt ttgacgccac gcgcattaac 2340
gggaatgtga acctgaacca aaacgctgcc ttggtacttg gtaaggccgc gttgtggggt 2400
aaaattcagg gccagggcaa ctcccgtgtg tctctgaacc agcactcgaa gtggcacctg 2460
acgggggact cgcaggtgca caacttgtcc ctggccgata gccatattca ccttaacaat 2520
gcgtccgatg cccagtcagc taataaatat catacgatca aaatcaatca cctctctggc 2580
aacggtcact ttcactactt aacggattta gcaaaaaact taggggataa agtcctggta 2640
aaagaatcag cgagcggaca ttatcagtta catgtacaga acaaaacagg cgagccaaat 2700
caggaaggcc ttgacttatt tgatgcttca tcggtacaag atcgttccag actgttcgtt 2760
tcactcgcga atcactacgt tgatctgggt gcgctgcgct atactataaa gacggaaaat 2820
ggcataacac gcctctataa tccctatgcc ggtaacggcc gtccggtgaa acctgctccc 2880
tgcgtcgac 2889
<210>75
<211>4296
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>75
ggatccttgg tacgagatga cgttgactat caaattttcc gcgactttgc ggaaaataaa 60
ggtaagtttt tcgtcggcgc cacagacctg tccgtcaaaa ataagagagg ccagaacatc 120
ggtaacgcac tgagcaacgt ccctatgatt gattttagtg tagcggacgt taataaacgg 180
attgcaaccg tcgttgatcc gcagtatgct gtcagcgtca aacatgctaa agcggaagtt 240
catacgttct attacgggca atataacggc cataacgatg tggctgataa agaaaatgaa 300
tatcgcgtgg tcgagcagaa caattacgaa ccgcacaaag cgtggggcgc gagtaattta 360
ggccgcctgg aggactataa catggcccgt ttcaataaat tcgtgaccga ggtagcaccg 420
atcgccccca cagatgctgg tgggggcctg gatacctaca aagataaaaa ccgcttctct 480
agcttcgtgc gcattggcgc cggtcgtcag ctcgtgtacg agaagggtgt ctatcaccag 540
gaaggtaatg aaaaggggta cgacctccgt gatttgtccc aggcgtatcg ctacgctatt 600
gccggaaccc cgtataaaga tattaatatc gatcaaacca tgaataccga aggcctaatt 660
ggtttcggga atcataataa gcaatatagc gcagaagagc taaagcaggc cctcagccaa 720
gatgcgttaa ccaattacgg agtgttaggc gatagcggca gtccgctgtt tgccttcgat 780
aaacagaaaa atcaatgggt gtttctgggc acttatgatt attgggccgg atatggtaaa 840
aagagctggc aggaatggaa tatttataaa aaggaattcg cagacaaaat caagcagcat 900
gacaacgcag gtacggtgaa ggggaacggc gaacatcact ggaagacgac cggcacgaat 960
agtcatatcg gatcgacggc cgttcgcctg gcgaacaatg agggcgatgc aaacaatggg 1020
caaaacgtga cctttgagga caacggtacc ctggtcctta accagaacat aaatcagggc 1080
gcgggaggct tgttctttaa aggcgactat actgttaagg gagcaaacaa tgacatcacc 1140
tggttagggg ccggtattga cgttgcggat ggaaaaaagg tggtttggca ggttaaaaac 1200
cctaacgggg accggctggc aaaaatcggc aaagggacat tggaaattaa tggtaccggt 1260
gtgaatcagg gtcagctgaa agtgggagat gggaccgtga ttctgaacca gaaagcagac 1320
gctgacaaaa aggtgcaagc ctttagccaa gtaggaattg ttagtggtcg tggcacactc 1380
gtcttgaact caagcaacca aataaatccg gataacctgt actttggatt tcgtggcgga 1440
cgcctggatg ctaacgggaa tgatctgacc tttgaacata tccgtaacgt tgacgagggt 1500
gcgcgcatag ttaatcataa tactgaccat gcatcaacta tcaccttgac cgggaaaagt 1560
ctgattacaa acccaaactc tctgtcagta cattccatcc agaatgatta tgatgaagac 1620
gattactcat actattaccg gccgcgtaga ccaattccac aaggtaaaga tctttattac 1680
aaaaattacc gttattacgc attaaaatcc ggagggcggc tgaatgcacc tatgccggaa 1740
aatggcgtgg ccgaaaacaa tgactggatt tttatgggtt atactcaaga agaggctcgc 1800
aaaaatgcaa tgaaccataa aaataaccga aggatcggtg atttcggcgg atttttcgat 1860
gaggaaaatg gtaaaggtca caatggtgcg ctgaatctaa attttaacgg caaaagtgcc 1920
cagaaacgtt tccttctgac tggtggcgct aatctgaatg gtaaaatcag tgtgacgcag 1980
ggtaacgtgc tgctttctgg ccggccaact ccgcatgcac gtgattttgt aaataaatcg 2040
agcgctcgta aagatgcgca tttttctaaa aataacgagg tcgtgtttga agatgactgg 2100
ataaatcgca cctttaaagc ggcagaaatc gcggttaatc agagtgcgag cttttcatcg 2160
ggtaggaatg tatctgatat tacagcaaac attacagcca ctgataatgc gaaggtcaac 2220
ctgggttata aaaacggtga tgaagtttgt gttcgatcgg attacacggg ctatgttacc 2280
tgcaacactg gcaatctgtc tgataaagcg cttaactctt ttgacgccac gcgcattaac 2340
gggaatgtga acctgaacca aaacgctgcc ttggtacttg gtaaggccgc gttgtggggt 2400
aaaattcagg gccagggcaa ctcccgtgtg tctctgaacc agcactcgaa gtggcacctg 2460
acgggggact cgcaggtgca caacttgtcc ctggccgata gccatattca ccttaacaat 2520
gcgtccgatg cccagtcagc taataaatat catacgatca aaatcaatca cctctctggc 2580
aacggtcact ttcactactt aacggattta gcaaaaaact taggggataa agtcctggta 2640
aaagaatcag cgagcggaca ttatcagtta catgtacaga acaaaacagg cgagccaaat 2700
caggaaggcc ttgacttatt tgatgcttca tcggtacaag atcgttccag actgttcgtt 2760
tcactcgcga atcactacgt tgatctgggt gcgctgcgct atactataaa gacggaaaat 2820
ggcataacac gcctctataa tccctatgcc ggtaacggcc gtccggtgaa acctgctccc 2880
tgcgtcgacg gcatcattac ctccaaaact aaatctctga tagaaggtag atttggcggt 2940
ttcacgggcg cacgcaaatc agcgcgtaaa cgtaagaacc aggcgctagc gggcggtggc 3000
ggtagcggcg gtggcggtag cggcggtggc ggtagcgcac tagtgctgca gtgtatcaag 3060
gttaacaact gggatttatt cttcagcccg agtgaagaca acttcaccaa cgacctgaac 3120
aaaggtgaag aaatcacctc agatactaac atcgaagcag ccgaagaaaa catctcgctg 3180
gacctgatcc agcagtacta cctgaccttt aatttcgaca acgagccgga aaacatttct 3240
atcgaaaacc tgagctctga tatcatcggc cagctggaac tgatgccgaa catcgaacgt 3300
ttcccaaacg gtaaaaagta cgagctggac aaatatacca tgttccacta cctgcgcgcg 3360
caggaatttg aacacggcaa atcccgtatc gcactgacta actccgttaa cgaagctctg 3420
ctcaacccgt cccgtgtata caccttcttc tctagcgact acgtgaaaaa ggtcaacaaa 3480
gcgactgaag ctgcaatgtt cttgggttgg gttgaacagc ttgtttatga ttttaccgac 3540
gagacgtccg aagtatctac taccgacaaa attgcggata tcactatcat catcccgtac 3600
atcggtccgg ctctgaacat tggcaacatg ctgtacaaag acgacttcgt tggcgcactg 3660
atcttctccg gtgcggtgat cctgctggag ttcatcccgg aaatcgccat cccggtactg 3720
ggcacctttg ctctggtttc ttacattgca aacaaggttc tgactgtaca aaccatcgac 3780
aacgcgctga gcaaacgtaa cgaaaaatgg gatgaagttt acaaatatat cgtgaccaac 3840
tggctggcta aggttaatac tcagatcgac ctcatccgca aaaaaatgaa agaagcactg 3900
gaaaaccagg cggaagctac caaggcaatc attaactacc agtacaacca gtacaccgag 3960
gaagaaaaaa acaacatcaa cttcaacatc gacgatctgt cctctaaact gaacgaatcc 4020
atcaacaaag ctatgatcaa catcaacaag ttcctgaacc agtgctctgt aagctatctg 4080
atgaactcca tgatcccgta cggtgttaaa cgtctggagg acttcgatgc gtctctgaaa 4140
gacgccctgc tgaaatacat ttacgacaac cgtggcactc tgatcggtca ggttgatcgt 4200
ctgaaggaca aagtgaacaa taccttatcg accgacatcc cttttcagct cagtaaatat 4260
gtcgataacc aacgcctttt gtccactcta gactag 4296
<210>76
<211>1431
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>76
Gly Ser Leu Val Arg Asp Asp Val Asp Tyr Gln Ile Phe Arg Asp Phe
1 5 10 15
Ala Glu Asn Lys Gly Lys Phe Phe Val Gly Ala Thr Asp Leu Ser Val
20 25 30
Lys Asn Lys Arg Gly Gln Asn Ile Gly Asn Ala Leu Ser Asn Val Pro
35 40 45
Met Ile Asp Phe Ser Val Ala Asp Val Asn Lys Arg Ile Ala Thr Val
50 55 60
Val Asp Pro Gln Tyr Ala Val Ser Val Lys His Ala Lys Ala Glu Val
65 70 75 80
His Thr Phe Tyr Tyr Gly Gln Tyr Asn Gly His Asn Asp Val Ala Asp
85 90 95
Lys Glu Asn Glu Tyr Arg Val Val Glu Gln Asn Asn Tyr Glu Pro His
100 105 110
Lys Ala Trp Gly Ala Ser Asn Leu Gly Arg Leu Glu Asp Tyr Asn Met
115 120 125
Ala Arg Phe Asn Lys Phe Val Thr Glu Val Ala Pro Ile Ala Pro Thr
130 135 140
Asp Ala Gly Gly Gly Leu Asp Thr Tyr Lys Asp Lys Asn Arg Phe Ser
145 150 155 160
Ser Phe Val Arg Ile Gly Ala Gly Arg Gln Leu Val Tyr Glu Lys Gly
165 170 175
Val Tyr His Gln Glu Gly Asn Glu Lys Gly Tyr Asp Leu Arg Asp Leu
180 185 190
Ser Gln Ala Tyr Arg Tyr Ala Ile Ala Gly Thr Pro Tyr Lys Asp Ile
195 200 205
Asn Ile Asp Gln Thr Met Asn Thr Glu Gly Leu Ile Gly Phe Gly Asn
210 215 220
His Asn Lys Gln Tyr Ser Ala Glu Glu Leu Lys Gln Ala Leu Ser Gln
225 230 235 240
Asp Ala Leu Thr Asn Tyr Gly Val Leu Gly Asp Ser Gly Ser Pro Leu
245 250 255
Phe Ala Phe Asp Lys Gln Lys Asn Gln Trp Val Phe Leu Gly Thr Tyr
260 265 270
Asp Tyr Trp Ala Gly Tyr Gly Lys Lys Ser Trp Gln Glu Trp Asn Ile
275 280 285
Tyr Lys Lys Glu Phe Ala Asp Lys Ile Lys Gln His Asp Asn Ala Gly
290 295 300
Thr Val Lys Gly Asn Gly Glu His His Trp Lys Thr Thr Gly Thr Asn
305 310 315 320
Ser His Ile Gly Ser Thr Ala Val Arg Leu Ala Asn Asn Glu Gly Asp
325 330 335
Ala Asn Asn Gly Gln Asn Val Thr Phe Glu Asp Asn Gly Thr Leu Val
340 345 350
Leu Asn Gln Asn Ile Asn Gln Gly Ala Gly Gly Leu Phe Phe Lys Gly
355 360 365
Asp Tyr Thr Val Lys Gly Ala Asn Asn Asp Ile Thr Trp Leu Gly Ala
370 375 380
Gly Ile Asp Val Ala Asp Gly Lys Lys Val Val Trp Gln Val Lys Asn
385 390 395 400
Pro Asn Gly Asp Arg Leu Ala Lys Ile Gly Lys Gly Thr Leu Glu Ile
405 410 415
Asn Gly Thr Gly Val Asn Gln Gly Gln Leu Lys Val Gly Asp Gly Thr
420 425 430
Val Ile Leu Asn Gln Lys Ala Asp Ala Asp Lys Lys Val Gln Ala Phe
435 440 445
Ser Gln Val Gly Ile Val Ser Gly Arg Gly Thr Leu Val Leu Asn Ser
450 455 460
Ser Asn Gln Ile Asn Pro Asp Asn Leu Tyr Phe Gly Phe Arg Gly Gly
465 470 475 480
Arg Leu Asp Ala Asn Gly Asn Asp Leu Thr Phe Glu His Ile Arg Asn
485 490 495
Val Asp Glu Gly Ala Arg Ile Val Asn His Asn Thr Asp His Ala Ser
500 505 510
Thr Ile Thr Leu Thr Gly Lys Ser Leu Ile Thr Asn Pro Asn Ser Leu
515 520 525
Ser Val His Ser Ile Gln Asn Asp Tyr Asp Glu Asp Asp Tyr Ser Tyr
530 535 540
Tyr Tyr Arg Pro Arg Arg Pro Ile Pro Gln Gly Lys Asp Leu Tyr Tyr
545 550 555 560
Lys Asn Tyr Arg Tyr Tyr Ala Leu Lys Ser Gly Gly Arg Leu Asn Ala
565 570 575
Pro Met Pro Glu Asn Gly Val Ala Glu Asn Asn Asp Trp Ile Phe Met
580 585 590
Gly Tyr Thr Gln Glu Glu Ala Arg Lys Asn Ala Met Asn His Lys Asn
595 600 605
Asn Arg Arg Ile Gly Asp Phe Gly Gly Phe Phe Asp Glu Glu Asn Gly
610 615 620
Lys Gly His Asn Gly Ala Leu Asn Leu Asn Phe Asn Gly Lys Ser Ala
625 630 635 640
Gln Lys Arg Phe Leu Leu Thr Gly Gly Ala Asn Leu Asn Gly Lys Ile
645 650 655
Ser Val Thr Gln Gly Asn Val Leu Leu Ser Gly Arg Pro Thr Pro His
660 665 670
Ala Arg Asp Phe Val Asn Lys Ser Ser Ala Arg Lys Asp Ala His Phe
675 680 685
Ser Lys Asn Asn Glu Val Val Phe Glu Asp Asp Trp Ile Asn Arg Thr
690 695 700
Phe Lys Ala Ala Glu Ile Ala Val Asn Gln Ser Ala Ser Phe Ser Ser
705 710 715 720
Gly Arg Asn Val Ser Asp Ile Thr Ala Asn Ile Thr Ala Thr Asp Asn
725 730 735
Ala Lys Val Asn Leu Gly Tyr Lys Asn Gly Asp Glu Val Cys Val Arg
740 745 750
Ser Asp Tyr Thr Gly Tyr Val Thr Cys Asn Thr Gly Asn Leu Ser Asp
755 760 765
Lys Ala Leu Asn Ser Phe Asp Ala Thr Arg Ile Asn Gly Asn Val Asn
770 775 780
Leu Asn Gln Asn Ala Ala Leu Val Leu Gly Lys Ala Ala Leu Trp Gly
785 790 795 800
Lys Ile Gln Gly Gln Gly Asn Ser Arg Val Ser Leu Asn Gln His Ser
805 810 815
Lys Trp His Leu Thr Gly Asp Ser Gln Val His Asn Leu Ser Leu Ala
820 825 830
Asp Ser His Ile His Leu Asn Asn Ala Ser Asp Ala Gln Ser Ala Asn
835 840 845
Lys Tyr His Thr Ile Lys Ile Asn His Leu Ser Gly Asn Gly His Phe
850 855 860
His Tyr Leu Thr Asp Leu Ala Lys Asn Leu Gly Asp Lys Val Leu Val
865 870 875 880
Lys Glu Ser Ala Ser Gly His Tyr Gln Leu His Val Gln Asn Lys Thr
885 890 895
Gly Glu Pro Asn Gln Glu Gly Leu Asp Leu Phe Asp Ala Ser Ser Val
900 905 910
Gln Asp Arg Ser Arg Leu Phe Val Ser Leu Ala Asn His Tyr Val Asp
915 920 925
Leu Gly Ala Leu Arg Tyr Thr Ile Lys Thr Glu Asn Gly Ile Thr Arg
930 935 940
Leu Tyr Asn Pro Tyr Ala Gly Asn Gly Arg Pro Val Lys Pro Ala Pro
945 950 955 960
Cys Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly
965 970 975
Arg Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys
980 985 990
Asn Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
995 1000 1005
Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn
1010 1015 1020
Trp Asp Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp
1025 1030 1035
Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala
1040 1045 1050
Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu
l055 1060 1065
Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn
1070 1075 1080
Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro Asn Ile
1085 1090 1095
Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr Thr
1100 1105 1110
Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser
1115 1120 1125
Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro
1130 1135 1140
Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val
1145 1150 1155
Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln
1160 1165 1170
Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
1175 1180 1185
Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro
1190 1195 1200
Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly
1205 1210 1215
Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
1220 1225 1230
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr
1235 1240 1245
Ile Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu
1250 1255 1260
Ser Lys Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val
1265 1270 1275
Thr Asn Trp Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg
1280 1285 1290
Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys
1295 1300 1305
Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys
1310 1315 1320
Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys Leu Asn
1325 1330 1335
Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu Asn
1340 1345 1350
Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly
1355 1360 1365
Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu
1370 1375 1380
Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val
1385 1390 1395
Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile
1400 1405 1410
Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
1415 1420 1425
Thr Leu Asp
1430
<210>77
<211>1357
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>77
gctagcgggc ggtggcggta gcggcggtgg cggtagcggc ggtggcggta gcgcactagt 60
gctgcagtgt atcaaggtta acaactggga tttattcttc agcccgagtg aagacaactt 120
caccaacgac ctgaacaaag gtgaagaaat cacctcagat actaacatcg aagcagccga 180
agaaaacatc tcgctggacc tgatccagca gtactacctg acctttaatt tcgacaacga 240
gccggaaaac atttctatcg aaaacctgag ctctgatatc atcggccagc tggaactgat 300
gccgaacatc gaacgtttcc caaacggtaa aaagtacgag ctggacaaat ataccatgtt 360
ccactacctg cgcgcgcagg aatttgaaca cggcaaatcc cgtatcgcac tgactaactc 420
cgttaacgaa gctctgctca acccgtcccg tgtatacacc ttcttctcta gcgactacgt 480
gaaaaaggtc aacaaagcga ctgaagctgc aatgttcttg ggttgggttg aacagcttgt 540
ttatgatttt accgacgaga cgtccgaagt atctactacc gacaaaattg cggatatcac 600
tatcatcatc ccgtacatcg gtccggctct gaacattggc aacatgctgt acaaagacga 660
cttcgttggc gcactgatct tctccggtgc ggtgatcctg ctggagttca tcccggaaat 720
cgccatcccg gtactgggca cctttgctct ggtttcttac attgcaaaca aggttctgac 780
tgtacaaacc atcgacaacg cgctgagcaa acgtaacgaa aaatgggatg aagtttacaa 840
atatatcgtg accaactggc tggctaaggt taatactcag atcgacctca tccgcaaaaa 900
aatgaaagaa gcactggaaa accaggcgga agctaccaag gcaatcatta actaccagta 960
caaccagtac accgaggaag aaaaaaacaa catcaacttc aacatcgacg atctgtcctc 1020
taaactgaac gaatccatca acaaagctat gatcaacatc aacaagttcc tgaaccagtg 1080
ctctgtaagc tatctgatga actccatgat cccgtacggt gttaaacgtc tggaggactt 1140
cgatgcgtct ctgaaagacg ccctgctgaa atacatttac gacaaccgtg gcactctgat 1200
cggtcaggtt gatcgtctga aggacaaagt gaacaatacc ttatcgaccg acatcccttt 1260
tcagctcagt aaatatgtcg ataaccaacg ccttttgtcc actctagaaa tagaaggtag 1320
aagtgggcac catcaccatc accattaatg aaagctt 1357
<210>78
<211>2745
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>78
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaacgtaaga accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtatc aaggttaaca actgggattt attcttcagc 1500
ccgagtgaag acaacttcac caacgacctg aacaaaggtg aagaaatcac ctcagatact 1560
aacatcgaag cagccgaaga aaacatctcg ctggacctga tccagcagta ctacctgacc 1620
tttaatttcg acaacgagcc ggaaaacatt tctatcgaaa acctgagctc tgatatcatc 1680
ggccagctgg aactgatgcc gaacatcgaa cgtttcccaa acggtaaaaa gtacgagctg 1740
gacaaatata ccatgttcca ctacctgcgc gcgcaggaat ttgaacacgg caaatcccgt 1800
atcgcactga ctaactccgt taacgaagct ctgctcaacc cgtcccgtgt atacaccttc 1860
ttctctagcg actacgtgaa aaaggtcaac aaagcgactg aagctgcaat gttcttgggt 1920
tgggttgaac agcttgttta tgattttacc gacgagacgt ccgaagtatc tactaccgac 1980
aaaattgcgg atatcactat catcatcccg tacatcggtc cggctctgaa cattggcaac 2040
atgctgtaca aagacgactt cgttggcgca ctgatcttct ccggtgcggt gatcctgctg 2100
gagttcatcc cggaaatcgc catcccggta ctgggcacct ttgctctggt ttcttacatt 2160
gcaaacaagg ttctgactgt acaaaccatc gacaacgcgc tgagcaaacg taacgaaaaa 2220
tgggatgaag tttacaaata tatcgtgacc aactggctgg ctaaggttaa tactcagatc 2280
gacctcatcc gcaaaaaaat gaaagaagca ctggaaaacc aggcggaagc taccaaggca 2340
atcattaact accagtacaa ccagtacacc gaggaagaaa aaaacaacat caacttcaac 2400
atcgacgatc tgtcctctaa actgaacgaa tccatcaaca aagctatgat caacatcaac 2460
aagttcctga accagtgctc tgtaagctat ctgatgaact ccatgatccc gtacggtgtt 2520
aaacgtctgg aggacttcga tgcgtctctg aaagacgccc tgctgaaata catttacgac 2580
aaccgtggca ctctgatcgg tcaggttgat cgtctgaagg acaaagtgaa caatacctta 2640
tcgaccgaca tcccttttca gctcagtaaa tatgtcgata accaacgcct tttgtccact 2700
ctagaaatag aaggtagaag tgggcaccat caccatcacc attaa 2745
<210>79
<211>914
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>79
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Lys Val Asn Asn Trp Asp
485 490 495
Leu Phe Phe Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys
500 505 510
Gly Glu Glu Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn
515 520 525
Ile Ser Leu Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp
530 535 540
Asn Glu Pro Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile
545 550 555 560
Gly Gln Leu Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys
565 570 575
Lys Tyr Glu Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln
580 585 590
Glu Phe Glu His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn
595 600 605
Glu Ala Leu Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp
610 615 620
Tyr Val Lys Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly
625 630 635 640
Trp Val Glu Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val
645 650 655
Ser Thr Thr Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile
660 665 670
Gly Pro Ala Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val
675 680 685
Gly Ala Leu Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro
690 695 700
Glu Ile Ala Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile
705 710 715 720
Ala Asn Lys Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys
725 730 735
Arg Asn Glu Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp
740 745 750
Leu Ala Lys Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys
755 760 765
Glu Ala Leu Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr
770 775 780
Gln Tyr Asn Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn
785 790 795 800
Ile Asp Asp Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met
805 810 815
Ile Asn Ile Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met
820 825 830
Asn Ser Met Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala
835 840 845
Ser Leu Lys Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr
850 855 860
Leu Ile Gly Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu
865 870 875 880
Ser Thr Asp Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg
885 890 895
Leu Leu Ser Thr Leu Glu Ile Glu Gly Arg Ser Gly His His His His
900 905 910
His His
<210>80
<211>619
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>80
gctagcgggc ggtggcggta gcggcggtgg cggtagcggc ggtggcggta gcgcactagt 60
gctgcagtgt atcaatctgg attgggacgt aatccgtgat aagaccaaaa caaaaatcga 120
gtctttgaaa gaacacggcc cgatcaaaaa taagatgtct gaatcaccca ataaaactgt 180
ttcggaggaa aaagcgaaac agtatttgga agagtttcat caaaccgcgc ttgaacatcc 240
ggagctcagt gaactgaaaa cagtgacggg aacgaatcct gtttttgcag gcgcaaacta 300
tgcggcttgg gccgtgaatg ttgcccaagt aattgatagt gagaccgcag acaacctgga 360
aaagacgacc gcagcgttaa gcattttacc ggggattggt tccgtgatgg gtatagcgga 420
tggagcggtc caccataaca ctgaggaaat tgtcgcccag tcaatcgctc tgagttccct 480
gatggttgca caggctatcc cactcgtggg ggaactggtt gacataggtt tcgccgccta 540
caacttcgta gaaagcatta ttaatctttt tcaggtggtg cataacagct acaaccgccc 600
tctagaatga taaaagctt 619
<210>81
<211>1971
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>81
ggatccatgg agttcgttaa caaacagttc aactataaag acccagttaa cggtgttgac 60
attgcttaca tcaaaatccc gaacgctggc cagatgcagc cggtaaaggc attcaaaatc 120
cacaacaaaa tctgggttat cccggaacgt gataccttta ctaacccgga agaaggtgac 180
ctgaacccgc caccggaagc gaaacaggtg ccggtatctt actatgactc cacctacctg 240
tctaccgata acgaaaagga caactacctg aaaggtgtta ctaaactgtt cgagcgtatt 300
tactccaccg acctgggccg tatgctgctg actagcatcg ttcgcggtat cccgttctgg 360
ggcggttcta ccatcgatac cgaactgaaa gtaatcgaca ctaactgcat caacgttatt 420
cagccggacg gttcctatcg ttccgaagaa ctgaacctgg tgatcatcgg cccgtctgct 480
gatatcatcc agttcgagtg taagagcttt ggtcacgaag ttctgaacct cacccgtaac 540
ggctacggtt ccactcagta catccgtttc tctccggact tcaccttcgg ttttgaagaa 600
tccctggaag tagacacgaa cccactgctg ggcgctggta aattcgcaac tgatcctgcg 660
gttaccctgg ctcacgaact gattcatgca ggccaccgcc tgtacggtat cgccatcaat 720
ccgaaccgtg tcttcaaagt taacaccaac gcgtattacg agatgtccgg tctggaagtt 780
agcttcgaag aactgcgtac ttttggcggt cacgacgcta aattcatcga ctctctgcaa 840
gaaaacgagt tccgtctgta ctactataac aagttcaaag atatcgcatc caccctgaac 900
aaagcgaaat ccatcgtggg taccactgct tctctccagt acatgaagaa cgtttttaaa 960
gaaaaatacc tgctcagcga agacacctcc ggcaaattct ctgtagacaa gttgaaattc 1020
gataaacttt acaaaatgct gactgaaatt tacaccgaag acaacttcgt taagttcttt 1080
aaagttctga accgcaaaac ctatctgaac ttcgacaagg cagtattcaa aatcaacatc 1140
gtgccgaaag ttaactacac tatctacgat ggtttcaacc tgcgtaacac caacctggct 1200
gctaatttta acggccagaa cacggaaatc aacaacatga acttcacaaa actgaaaaac 1260
ttcactggtc tgttcgagtt ttacaagctg ctgtgcgtcg acggcatcat tacctccaaa 1320
actaaatctc tgatagaagg tagatacggt ggtttcctgg cgctagcggg cggtggcggt 1380
agcggcggtg gcggtagcgg cggtggcggt agcgcactag tgctgcagtg tatcaatctg 1440
gattgggacg taatccgtga taagaccaaa acaaaaatcg agtctttgaa agaacacggc 1500
ccgatcaaaa ataagatgtc tgaatcaccc aataaaactg tttcggagga aaaagcgaaa 1560
cagtatttgg aagagtttca tcaaaccgcg cttgaacatc cggagctcag tgaactgaaa 1620
acagtgacgg gaacgaatcc tgtttttgca ggcgcaaact atgcggcttg ggccgtgaat 1680
gttgcccaag taattgatag tgagaccgca gacaacctgg aaaagacgac cgcagcgtta 1740
agcattttac cggggattgg ttccgtgatg ggtatagcgg atggagcggt ccaccataac 1800
actgaggaaa ttgtcgccca gtcaatcgct ctgagttccc tgatggttgc acaggctatc 1860
ccactcgtgg gggaactggt tgacataggt ttcgccgcct acaacttcgt agaaagcatt 1920
attaatcttt ttcaggtggt gcataacagc tacaaccgcc ctctagaatg a 1971
<210>82
<211>656
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>82
Gly Ser Met Glu Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val
1 5 10 15
Asn Gly Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met
20 25 30
Gln Pro Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro
35 40 45
Glu Arg Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro
50 55 60
Pro Glu Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu
65 70 75 80
Ser Thr Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu
85 90 95
Phe Glu Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser
100 105 110
Ile Val Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu
115 120 125
Leu Lys Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly
130 135 140
Ser Tyr Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala
145 150 155 160
Asp Ile Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn
165 170 175
Leu Thr Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro
180 185 190
Asp Phe Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro
195 200 205
Leu Leu Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala
210 215 220
His Glu Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn
225 230 235 240
Pro Asn Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser
245 250 255
Gly Leu Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp
260 265 270
Ala Lys Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr
275 280 285
Tyr Asn Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser
290 295 300
Ile Val Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys
305 310 315 320
Glu Lys Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp
325 330 335
Lys Leu Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr
340 345 350
Glu Asp Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr
355 360 365
Leu Asn Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val
370 375 380
Asn Tyr Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala
385 390 395 400
Ala Asn Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr
405 410 415
Lys Leu Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys
420 425 430
Val Asp Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Ile Glu Gly Arg
435 440 445
Tyr Gly Gly Phe Leu Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly
450 455 460
Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu Gln Cys Ile Asn Leu
465 470 475 480
Asp Trp Asp Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu
485 490 495
Lys Glu His Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys
500 505 510
Thr Val Ser Glu Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln
515 520 525
Thr Ala Leu Glu His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly
530 535 540
Thr Asn Pro Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn
545 550 555 560
Val Ala Gln Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr
565 570 575
Thr Ala Ala Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile
580 585 590
Ala Asp Gly Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser
595 600 605
Ile Ala Leu Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly
610 615 620
Glu Leu Val Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile
625 630 635 640
Ile Asn Leu Phe Gln Val Val His Asn Ser Tyr Asn Arg Pro Leu Glu
645 650 655
<210>83
<211>1329
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>83
ggatccatgc ctattactat taacaatttt cgttatagcg atcccgtcaa caatgacacc 60
attatcatga tggaaccgcc atattgcaaa ggactggaca tttactataa agccttcaag 120
attactgacc gcatttggat tgttccagag cgttacgagt tcgggacgaa accagaagat 180
tttaacccgc cttcatcgct gatcgaagga gcatcagagt attacgatcc gaactatctg 240
cgtacggaca gcgataaaga ccgcttctta cagaccatgg tcaaactttt taaccgtatt 300
aagaacaatg tggccggaga agcactcttg gataagatta tcaacgcgat tccatacctg 360
ggcaattctt acagcctgct ggataaattt gacacaaata gtaattcagt cagctttaac 420
ctgttagaac aagatccgag tggcgcaacc acgaagtctg ccatgctgac aaatctgatc 480
atttttggtc caggtcctgt actgaataaa aatgaagtac gcggcatcgt tctccgcgtg 540
gacaataaga actacttccc atgccgtgac ggcttcggtt cgatcatgca gatggctttc 600
tgtccggagt acgttccgac gtttgataat gttattgaga atatcacgag tttaacaatc 660
ggtaagtcaa aatattttca agatccggcc cttctcctta tgcatgaact gattcacgtg 720
ctgcacggct tatatggtat gcaagtgtcc tcgcatgaaa tcattccgtc caaacaggaa 780
atttatatgc agcataccta cccgatttca gctgaagagt tgtttacgtt tggtggccag 840
gacgcgaatt tgatctccat cgacatcaaa aacgatctgt atgagaaaac attaaatgac 900
tataaagcga ttgcgaacaa actgtctcag gtgactagct gcaacgatcc taacattgat 960
attgattcct acaaacaaat ttatcaacag aaataccagt tcgataaaga cagcaatggt 1020
cagtatatcg taaacgaaga taaatttcag atcctgtata acagcattat gtatggcttt 1080
accgaaattg agttggggaa gaaatttaac attaaaaccc gtctgtctta ttttagtatg 1140
aaccatgatc cggtgaaaat ccccaatctg cttgatgata ccatttataa tgataccgaa 1200
gggttcaaca ttgaatctaa ggatctgaaa tccgaataca aaggccaaaa tatgcgtgtt 1260
aatactaacg ctttccgtaa tgttgatggt agtggactcg tctcgaaact gattgggttg 1320
tgtgtcgac 1329
<210>84
<211>2736
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>84
ggatccatgc ctattactat taacaatttt cgttatagcg atcccgtcaa caatgacacc 60
attatcatga tggaaccgcc atattgcaaa ggactggaca tttactataa agccttcaag 120
attactgacc gcatttggat tgttccagag cgttacgagt tcgggacgaa accagaagat 180
tttaacccgc cttcatcgct gatcgaagga gcatcagagt attacgatcc gaactatctg 240
cgtacggaca gcgataaaga ccgcttctta cagaccatgg tcaaactttt taaccgtatt 300
aagaacaatg tggccggaga agcactcttg gataagatta tcaacgcgat tccatacctg 360
ggcaattctt acagcctgct ggataaattt gacacaaata gtaattcagt cagctttaac 420
ctgttagaac aagatccgag tggcgcaacc acgaagtctg ccatgctgac aaatctgatc 480
atttttggtc caggtcctgt actgaataaa aatgaagtac gcggcatcgt tctccgcgtg 540
gacaataaga actacttccc atgccgtgac ggcttcggtt cgatcatgca gatggctttc 600
tgtccggagt acgttccgac gtttgataat gttattgaga atatcacgag tttaacaatc 660
ggtaagtcaa aatattttca agatccggcc cttctcctta tgcatgaact gattcacgtg 720
ctgcacggct tatatggtat gcaagtgtcc tcgcatgaaa tcattccgtc caaacaggaa 780
atttatatgc agcataccta cccgatttca gctgaagagt tgtttacgtt tggtggccag 840
gacgcgaatt tgatctccat cgacatcaaa aacgatctgt atgagaaaac attaaatgac 900
tataaagcga ttgcgaacaa actgtctcag gtgactagct gcaacgatcc taacattgat 960
attgattcct acaaacaaat ttatcaacag aaataccagt tcgataaaga cagcaatggt 1020
cagtatatcg taaacgaaga taaatttcag atcctgtata acagcattat gtatggcttt 1080
accgaaattg agttggggaa gaaatttaac attaaaaccc gtctgtctta ttttagtatg 1140
aaccatgatc cggtgaaaat ccccaatctg cttgatgata ccatttataa tgataccgaa 1200
gggttcaaca ttgaatctaa ggatctgaaa tccgaataca aaggccaaaa tatgcgtgtt 1260
aatactaacg ctttccgtaa tgttgatggt agtggactcg tctcgaaact gattgggttg 1320
tgtgtcgacg gcatcattac ctccaaaact aaatctctga tagaaggtag atttggcggt 1380
ttcacgggcg cacgcaaatc agcgcgtaaa cgtaagaacc aggcgctagc gggcggtggc 1440
ggtagcggcg gtggcggtag cggcggtggc ggtagcgcac tagtgctgca gtgtatcaag 1500
gttaacaact gggatttatt cttcagcccg agtgaagaca acttcaccaa cgacctgaac 1560
aaaggtgaag aaatcacctc agatactaac atcgaagcag ccgaagaaaa catctcgctg 1620
gacctgatcc agcagtacta cctgaccttt aatttcgaca acgagccgga aaacatttct 1680
atcgaaaacc tgagctctga tatcatcggc cagctggaac tgatgccgaa catcgaacgt 1740
ttcccaaacg gtaaaaagta cgagctggac aaatatacca tgttccacta cctgcgcgcg 1800
caggaatttg aacacggcaa atcccgtatc gcactgacta actccgttaa cgaagctctg 1860
ctcaacccgt cccgtgtata caccttcttc tctagcgact acgtgaaaaa ggtcaacaaa 1920
gcgactgaag ctgcaatgtt cttgggttgg gttgaacagc ttgtttatga ttttaccgac 1980
gagacgtccg aagtatctac taccgacaaa attgcggata tcactatcat catcccgtac 2040
atcggtccgg ctctgaacat tggcaacatg ctgtacaaag acgacttcgt tggcgcactg 2100
atcttctccg gtgcggtgat cctgctggag ttcatcccgg aaatcgccat cccggtactg 2160
ggcacctttg ctctggtttc ttacattgca aacaaggttc tgactgtaca aaccatcgac 2220
aacgcgctga gcaaacgtaa cgaaaaatgg gatgaagttt acaaatatat cgtgaccaac 2280
tggctggcta aggttaatac tcagatcgac ctcatccgca aaaaaatgaa agaagcactg 2340
gaaaaccagg cggaagctac caaggcaatc attaactacc agtacaacca gtacaccgag 2400
gaagaaaaaa acaacatcaa cttcaacatc gacgatctgt cctctaaact gaacgaatcc 2460
atcaacaaag ctatgatcaa catcaacaag ttcctgaacc agtgctctgt aagctatctg 2520
atgaactcca tgatcccgta cggtgttaaa cgtctggagg acttcgatgc gtctctgaaa 2580
gacgccctgc tgaaatacat ttacgacaac cgtggcactc tgatcggtca ggttgatcgt 2640
ctgaaggaca aagtgaacaa taccttatcg accgacatcc cttttcagct cagtaaatat 2700
gtcgataacc aacgcctttt gtccactcta gactag 2736
<210>85
<211>911
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>85
Gly Ser Met Pro Ile Thr Ile Asn Asn Phe Arg Tyr Ser Asp Pro Val
1 5 10 15
Asn Asn Asp Thr Ile Ile Met Met Glu Pro Pro Tyr Cys Lys Gly Leu
20 25 30
Asp Ile Tyr Tyr Lys Ala Phe Lys Ile Thr Asp Arg Ile Trp Ile Val
35 40 45
Pro Glu Arg Tyr Glu Phe Gly Thr Lys Pro Glu Asp Phe Asn Pro Pro
50 55 60
Ser Ser Leu Ile Glu Gly Ala Ser Glu Tyr Tyr Asp Pro Asn Tyr Leu
65 70 75 80
Arg Thr Asp Ser Asp Lys Asp Arg Phe Leu Gln Thr Met Val Lys Leu
85 90 95
Phe Asn Arg Ile Lys Asn Asn Val Ala Gly Glu Ala Leu Leu Asp Lys
100 105 110
Ile Ile Asn Ala Ile Pro Tyr Leu Gly Asn Ser Tyr Ser Leu Leu Asp
115 120 125
Lys Phe Asp Thr Asn Ser Asn Ser Val Ser Phe Asn Leu Leu Glu Gln
130 135 140
Asp Pro Ser Gly Ala Thr Thr Lys Ser Ala Met Leu Thr Asn Leu Ile
145 150 155 160
Ile Phe Gly Pro Gly Pro Val Leu Asn Lys Asn Glu Val Arg Gly Ile
165 170 175
Val Leu Arg Val Asp Asn Lys Asn Tyr Phe Pro Cys Arg Asp Gly Phe
180 185 190
Gly Ser Ile Met Gln Met Ala Phe Cys Pro Glu Tyr Val Pro Thr Phe
195 200 205
Asp Asn Val Ile Glu Asn Ile Thr Ser Leu Thr Ile Gly Lys Ser Lys
210 215 220
Tyr Phe Gln Asp Pro Ala Leu Leu Leu Met His Glu Leu Ile His Val
225 230 235 240
Leu His Gly Leu Tyr Gly Met Gln Val Ser Ser His Glu Ile Ile Pro
245 250 255
Ser Lys Gln Glu Ile Tyr Met Gln His Thr Tyr Pro Ile Ser Ala Glu
260 265 270
Glu Leu Phe Thr Phe Gly Gly Gln Asp Ala Asn Leu Ile Ser Ile Asp
275 280 285
Ile Lys Asn Asp Leu Tyr Glu Lys Thr Leu Asn Asp Tyr Lys Ala Ile
290 295 300
Ala Asn Lys Leu Ser Gln Val Thr Ser Cys Asn Asp Pro Asn Ile Asp
305 310 315 320
Ile Asp Ser Tyr Lys Gln Ile Tyr Gln Gln Lys Tyr Gln Phe Asp Lys
325 330 335
Asp Ser Asn Gly Gln Tyr Ile Val Asn Glu Asp Lys Phe Gln Ile Leu
340 345 350
Tyr Asn Ser Ile Met Tyr Gly Phe Thr Glu Ile Glu Leu Gly Lys Lys
355 360 365
Phe Asn Ile Lys Thr Arg Leu Ser Tyr Phe Ser Met Asn His Asp Pro
370 375 380
Val Lys Ile Pro Asn Leu Leu Asp Asp Thr Ile Tyr Asn Asp Thr Glu
385 390 395 400
Gly Phe Asn Ile Glu Ser Lys Asp Leu Lys Ser Glu Tyr Lys Gly Gln
405 410 415
Asn Met Arg Val Asn Thr Asn Ala Phe Arg Asn Val Asp Gly Ser Gly
420 425 430
Leu Val Ser Lys Leu Ile Gly Leu Cys Val Asp Gly Ile Ile Thr Ser
435 440 445
Lys Thr Lys Ser Leu Ile Glu Gly Arg Phe Gly Gly Phe Thr Gly Ala
450 455 460
Arg Lys Ser Ala Arg Lys Arg Lys Asn Gln Ala Leu Ala Gly Gly Gly
465 470 475 480
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Val Leu
485 490 495
Gln Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe Ser Pro Ser Glu
500 505 510
Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu Ile Thr Ser Asp
515 520 525
Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu Asp Leu Ile Gln
530 535 540
Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro Glu Asn Ile Ser
545 550 555 560
Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu Glu Leu Met Pro
565 570 575
Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu Leu Asp Lys Tyr
580 585 590
Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu His Gly Lys Ser
595 600 605
Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu Leu Asn Pro Ser
610 615 620
Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys Lys Val Asn Lys
625 630 635 640
Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu Gln Leu Val Tyr
645 650 655
Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr Asp Lys Ile Ala
660 665 670
Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala Leu Asn Ile Gly
675 680 685
Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu Ile Phe Ser Gly
690 695 700
Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala Ile Pro Val Leu
705 710 715 720
Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys Val Leu Thr Val
725 730 735
Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu Lys Trp Asp Glu
740 745 750
Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys Val Asn Thr Gln
755 760 765
Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu Glu Asn Gln Ala
770 775 780
Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn Gln Tyr Thr Glu
785 790 795 800
Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp Leu Ser Ser Lys
805 810 815
Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile Asn Lys Phe Leu
820 825 830
Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met Ile Pro Tyr Gly
835 840 845
Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys Asp Ala Leu Leu
850 855 860
Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly Gln Val Asp Arg
865 870 875 880
Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp Ile Pro Phe Gln
885 890 895
Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser Thr Leu Asp
900 905 910
<210>86
<211>180
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>86
ggatccacgc acgtcgacgc gattgatggt cgttttggcg gtttcacggg cgcacgcaaa 60
tcagcgcgta aacgtaagaa ccaggcgcta gcgggcggtg gcggtagcgg cggtggcggt 120
agcggcggtg gcggtagcgc actagtgctg cagacgcacg gtctagaatg ataaaagctt 180
<210>87
<211>2715
<212>DNA
<213>人工序列
<220>
<223>合成的
<400>87
ggatccgaat tcatgccgat caccatcaac aacttcaact acagcgatcc ggtggataac 60
aaaaacatcc tgtacctgga tacccatctg aataccctgg cgaacgaacc ggaaaaagcg 120
tttcgtatca ccggcaacat ttgggttatt ccggatcgtt ttagccgtaa cagcaacccg 180
aatctgaata aaccgccgcg tgttaccagc ccgaaaagcg gttattacga tccgaactat 240
ctgagcaccg atagcgataa agataccttc ctgaaagaaa tcatcaaact gttcaaacgc 300
atcaacagcc gtgaaattgg cgaagaactg atctatcgcc tgagcaccga tattccgttt 360
ccgggcaaca acaacacccc gatcaacacc tttgatttcg atgtggattt caacagcgtt 420
gatgttaaaa cccgccaggg taacaattgg gtgaaaaccg gcagcattaa cccgagcgtg 480
attattaccg gtccgcgcga aaacattatt gatccggaaa ccagcacctt taaactgacc 540
aacaacacct ttgcggcgca ggaaggtttt ggcgcgctga gcattattag cattagcccg 600
cgctttatgc tgacctatag caacgcgacc aacgatgttg gtgaaggccg tttcagcaaa 660
agcgaatttt gcatggaccc gatcctgatc ctgatgcatg aactgaacca tgcgatgcat 720
aacctgtatg gcatcgcgat tccgaacgat cagaccatta gcagcgtgac cagcaacatc 780
ttttacagcc agtacaacgt gaaactggaa tatgcggaaa tctatgcgtt tggcggtccg 840
accattgatc tgattccgaa aagcgcgcgc aaatacttcg aagaaaaagc gctggattac 900
tatcgcagca ttgcgaaacg tctgaacagc attaccaccg cgaatccgag cagcttcaac 960
aaatatatcg gcgaatataa acagaaactg atccgcaaat atcgctttgt ggtggaaagc 1020
agcggcgaag ttaccgttaa ccgcaataaa ttcgtggaac tgtacaacga actgacccag 1080
atcttcaccg aatttaacta tgcgaaaatc tataacgtgc agaaccgtaa aatctacctg 1140
agcaacgtgt ataccccggt gaccgcgaat attctggatg ataacgtgta cgatatccag 1200
aacggcttta acatcccgaa aagcaacctg aacgttctgt ttatgggcca gaacctgagc 1260
cgtaatccgg cgctgcgtaa agtgaacccg gaaaacatgc tgtacctgtt caccaaattt 1320
tgcgtcgacg cgattgatgg tcgttttggc ggtttcacgg gcgcacgcaa atcagcgcgt 1380
aaacgtaaga accaggcgct agcgggcggt ggcggtagcg gcggtggcgg tagcggcggt 1440
ggcggtagcg cactagtgct gcagtgtcgt gaactgctgg tgaaaaacac cgatctgccg 1500
tttattggcg atatcagcga tgtgaaaacc gatatcttcc tgcgcaaaga tatcaacgaa 1560
gaaaccgaag tgatctacta cccggataac gtgagcgttg atcaggtgat cctgagcaaa 1620
aacaccagcg aacatggtca gctggatctg ctgtatccga gcattgatag cgaaagcgaa 1680
attctgccgg gcgaaaacca ggtgttttac gataaccgta cccagaacgt ggattacctg 1740
aacagctatt actacctgga aagccagaaa ctgagcgata acgtggaaga ttttaccttt 1800
acccgcagca ttgaagaagc gctggataac agcgcgaaag tttacaccta ttttccgacc 1860
ctggcgaaca aagttaatgc gggtgttcag ggcggtctgt ttctgatgtg ggcgaacgat 1920
gtggtggaag atttcaccac caacatcctg cgtaaagata ccctggataa aatcagcgat 1980
gttagcgcga ttattccgta tattggtccg gcgctgaaca ttagcaatag cgtgcgtcgt 2040
ggcaatttta ccgaagcgtt tgcggttacc ggtgtgacca ttctgctgga agcgtttccg 2100
gaatttacca ttccggcgct gggtgcgttt gtgatctata gcaaagtgca ggaacgcaac 2160
gaaatcatca aaaccatcga taactgcctg gaacagcgta ttaaacgctg gaaagatagc 2220
tatgaatgga tgatgggcac ctggctgagc cgtattatca cccagttcaa caacatcagc 2280
taccagatgt acgatagcct gaactatcag gcgggtgcga ttaaagcgaa aatcgatctg 2340
gaatacaaaa aatacagcgg cagcgataaa gaaaacatca aaagccaggt tgaaaacctg 2400
aaaaacagcc tggatgtgaa aattagcgaa gcgatgaata acatcaacaa attcatccgc 2460
gaatgcagcg tgacctacct gttcaaaaac atgctgccga aagtgatcga tgaactgaac 2520
gaatttgatc gcaacaccaa agcgaaactg atcaacctga tcgatagcca caacattatt 2580
ctggtgggcg aagtggataa actgaaagcg aaagttaaca acagcttcca gaacaccatc 2640
ccgtttaaca tcttcagcta taccaacaac agcctgctga aagatatcat caacgaatac 2700
ttcaatctag actag 2715
<210>88
<211>904
<212>PRT
<213>人工序列
<220>
<223>合成的
<400>88
Gly Ser Glu Phe Met Pro Ile Thr Ile Asn Asn Phe Asn Tyr Ser Asp
1 5 10 15
Pro Val Asp Asn Lys Asn Ile Leu Tyr Leu Asp Thr His Leu Asn Thr
20 25 30
Leu Ala Asn Glu Pro Glu Lys Ala Phe Arg Ile Thr Gly Asn Ile Trp
35 40 45
Val Ile Pro Asp Arg Phe Ser Arg Asn Ser Asn Pro Asn Leu Asn Lys
50 55 60
Pro Pro Arg Val Thr Ser Pro Lys Ser Gly Tyr Tyr Asp Pro Asn Tyr
65 70 75 80
Leu Ser Thr Asp Ser Asp Lys Asp Thr Phe Leu Lys Glu Ile Ile Lys
85 90 95
Leu Phe Lys Arg Ile Asn Ser Arg Glu Ile Gly Glu Glu Leu Ile Tyr
100 105 110
Arg Leu Ser Thr Asp Ile Pro Phe Pro Gly Asn Asn Asn Thr Pro Ile
115 120 125
Asn Thr Phe Asp Phe Asp Val Asp Phe Asn Ser Val Asp Val Lys Thr
130 135 140
Arg Gln Gly Asn Asn Trp Val Lys Thr Gly Ser Ile Asn Pro Ser Val
145 150 155 160
Ile Ile Thr Gly Pro Arg Glu Asn Ile Ile Asp Pro Glu Thr Ser Thr
165 170 175
Phe Lys Leu Thr Asn Asn Thr Phe Ala Ala Gln Glu Gly Phe Gly Ala
180 185 190
Leu Ser Ile Ile Ser Ile Ser Pro Arg Phe Met Leu Thr Tyr Ser Asn
195 200 205
Ala Thr Asn Asp Val Gly Glu Gly Arg Phe Ser Lys Ser Glu Phe Cys
210 215 220
Met Asp Pro Ile Leu Ile Leu Met His Glu Leu Asn His Ala Met His
225 230 235 240
Asn Leu Tyr Gly Ile Ala Ile Pro Asn Asp Gln Thr Ile Ser Ser Val
245 250 255
Thr Ser Asn Ile Phe Tyr Ser Gln Tyr Asn Val Lys Leu Glu Tyr Ala
260 265 270
Glu Ile Tyr Ala Phe Gly Gly Pro Thr Ile Asp Leu Ile Pro Lys Ser
275 280 285
Ala Arg Lys Tyr Phe Glu Glu Lys Ala Leu Asp Tyr Tyr Arg Ser Ile
290 295 300
Ala Lys Arg Leu Asn Ser Ile Thr Thr Ala Asn Pro Ser Ser Phe Asn
305 310 315 320
Lys Tyr Ile Gly Glu Tyr Lys Gln Lys Leu Ile Arg Lys Tyr Arg Phe
325 330 335
Val Val Glu Ser Ser Gly Glu Val Thr Val Asn Arg Asn Lys Phe Val
340 345 350
Glu Leu Tyr Asn Glu Leu Thr Gln Ile Phe Thr Glu Phe Asn Tyr Ala
355 360 365
Lys Ile Tyr Asn Val Gln Asn Arg Lys Ile Tyr Leu Ser Asn Val Tyr
370 375 380
Thr Pro Val Thr Ala Asn Ile Leu Asp Asp Asn Val Tyr Asp Ile Gln
385 390 395 400
Asn Gly Phe Asn Ile Pro Lys Ser Asn Leu Asn Val Leu Phe Met Gly
405 410 415
Gln Asn Leu Ser Arg Asn Pro Ala Leu Arg Lys Val Asn Pro Glu Asn
420 425 430
Met Leu Tyr Leu Phe Thr Lys Phe Cys Val Asp Ala Ile Asp Gly Arg
435 440 445
Phe Gly Gly Phe Thr Gly Ala Arg Lys Ser Ala Arg Lys Arg Lys Asn
450 455 460
Gln Ala Leu Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
465 470 475 480
Gly Gly Ser Ala Leu Val Leu Gln Cys Arg Glu Leu Leu Val Lys Asn
485 490 495
Thr Asp Leu Pro Phe Ile Gly Asp Ile Ser Asp Val Lys Thr Asp Ile
500 505 510
Phe Leu Arg Lys Asp Ile Asn Glu Glu Thr Glu Val Ile Tyr Tyr Pro
515 520 525
Asp Asn Val Ser Val Asp Gln Val Ile Leu Ser Lys Asn Thr Ser Glu
530 535 540
His Gly Gln Leu Asp Leu Leu Tyr Pro Ser Ile Asp Ser Glu Ser Glu
545 550 555 560
Ile Leu Pro Gly Glu Asn Gln Val Phe Tyr Asp Asn Arg Thr Gln Asn
565 570 575
Val Asp Tyr Leu Asn Ser Tyr Tyr Tyr Leu Glu Ser Gln Lys Leu Ser
580 585 590
Asp Asn Val Glu Asp Phe Thr Phe Thr Arg Ser Ile Glu Glu Ala Leu
595 600 605
Asp Asn Ser Ala Lys Val Tyr Thr Tyr Phe Pro Thr Leu Ala Asn Lys
610 615 620
Val Asn Ala Gly Val Gln Gly Gly Leu Phe Leu Met Trp Ala Asn Asp
625 630 635 640
Val Val Glu Asp Phe Thr Thr Asn Ile Leu Arg Lys Asp Thr Leu Asp
645 650 655
Lys Ile Ser Asp Val Ser Ala Ile Ile Pro Tyr Ile Gly Pro Ala Leu
660 665 670
Asn Ile Ser Asn Ser Val Arg Arg Gly Asn Phe Thr Glu Ala Phe Ala
675 680 685
Val Thr Gly Val Thr Ile Leu Leu Glu Ala Phe Pro Glu Phe Thr Ile
690 695 700
Pro Ala Leu Gly Ala Phe Val Ile Tyr Ser Lys Val Gln Glu Arg Asn
705 710 715 720
Glu Ile Ile Lys Thr Ile Asp Asn Cys Leu Glu Gln Arg Ile Lys Arg
725 730 735
Trp Lys Asp Ser Tyr Glu Trp Met Met Gly Thr Trp Leu Ser Arg Ile
740 745 750
Ile Thr Gln Phe Asn Asn Ile Ser Tyr Gln Met Tyr Asp Ser Leu Asn
755 760 765
Tyr Gln Ala Gly Ala Ile Lys Ala Lys Ile Asp Leu Glu Tyr Lys Lys
770 775 780
Tyr Ser Gly Ser Asp Lys Glu Asn Ile Lys Ser Gln Val Glu Asn Leu
785 790 795 800
Lys Asn Ser Leu Asp Val Lys Ile Ser Glu Ala Met Asn Asn Ile Asn
805 810 815
Lys Phe Ile Arg Glu Cys Ser Val Thr Tyr Leu Phe Lys Asn Met Leu
820 825 830
Pro Lys Val Ile Asp Glu Leu Asn Glu Phe Asp Arg Asn Thr Lys Ala
835 840 845
Lys Leu Ile Asn Leu Ile Asp Ser His Asn Ile Ile Leu Val Gly Glu
850 855 860
Val Asp Lys Leu Lys Ala Lys Val Asn Asn Ser Phe Gln Asn Thr Ile
865 870 875 880
Pro Phe Asn Ile Phe Ser Tyr Thr Asn Asn Ser Leu Leu Lys Asp Ile
885 890 895
Ile Asn Glu Tyr Phe Asn Leu Asp
900
Claims (23)
1.单链的多肽融合蛋白,其从N到C端包含:
a).非细胞毒性的蛋白酶,所述蛋白酶能够剪切疼痛感应传入器中胞吐融合器的蛋白,其中所述非细胞毒性蛋白酶是梭菌神经毒素L-链或IgA蛋白酶;
b).蛋白酶剪切位点,在该位点所述融合蛋白可被蛋白酶剪切,其中所述蛋白酶剪切位点位于所述非细胞毒性蛋白酶与靶向部分之间;
c).能够结合所述疼痛感应传入器上之结合位点的阿片样物质靶向部分,所述结合位点能够进行细胞内吞作用,以被并入疼痛感应传入器中的内涵体内,其中所述靶向部分选自伤害感受肽、β-内啡肽、内啡素-1、内啡素-2、强啡肽、met-脑啡肽、leu-脑啡肽、甘丙肽和PAR-2肽;和
d).转运区域,其能够将所述蛋白酶从内涵体中跨内涵体膜转运,并进入疼痛感应传入器的细胞溶胶中;其中所述转运区域是梭菌神经毒素的HN区域,或是选自下述的转运区域:白喉毒素、假单胞菌外毒素的区域II、炭疽病毒素、源自流感病毒血凝素、塞姆利基森林病毒融合蛋白、水泡性口炎病毒糖蛋白G、SER病毒F蛋白、泡沫病毒包膜糖蛋白的融合和/或两亲肽;
其中所述靶向部分和所述蛋白酶剪切位点由0个氨基酸残基分隔。
2.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分是疼痛感应传入器上存在的受体的激动剂。
3.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分是初级疼痛感应传入器上存在的受体的激动剂。
4.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分结合ORL1受体。
5.根据权利要求4的融合蛋白,其中所述阿片样物质靶向部分特异地结合ORL1受体。
6.根据权利要求4的融合蛋白,其中所述阿片样物质靶向部分是ORL1受体的激动剂。
7.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分是SEQ ID No.38。
8.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分是SEQ ID Nos:40、42、44、46、48或50之一。
9.根据权利要求1的融合蛋白,其中所述阿片样物质靶向部分是伤害感受肽。
10.根据权利要求1的融合蛋白,其中所述融合蛋白包含纯化标记。
11.根据权利要求10的融合蛋白,其中所述融合蛋白包含纯化标记,其存在于所述融合蛋白的N-末端和/或C-末端。
12.根据权利要求10或11的融合蛋白,其中所述纯化标记通过肽间隔分子被连接到所述融合蛋白。
13.根据权利要求1的融合蛋白,其中所述转运区域由肽间隔分子与所述阿片样物质靶向部分分隔。
14.根据权利要求1所述多肽融合蛋白,其中所述多肽融合蛋白选自SEQ ID NOs:14、18、20、22、24、26、28、30、32、34、36、59、61、64、67、69、71、73、76、79、82、85或88中任一。
15.核酸序列,其编码根据权利要求1的多肽融合蛋白。
16.根据权利要求15的核酸序列,其中所述核酸分子选自下述任何之一:SEQ ID NOs:1-13、15、17、19、21、23、25、27、29、31、33、35、37、39、41、43、45、47、49、51、58、60、63、66、68、70、72、75、78、81、84或者87。
17.DNA载体,其包括启动子、根据权利要求15或者权利要求16的核酸序列,其中所述DNA序列位于所述启动子的下游,并且终止子位于DNA构建物的下游。
18.根据权利要求15或者权利要求16的DNA序列的互补DNA链。
19.用于制备根据权利要求1-14的任何一项所述的单链多肽融合蛋白的方法,包括:在宿主细胞中,表达根据权利要求15或者权利要求16的核酸序列,或者表达权利要求17的DNA载体。
20.制备非细胞毒性的物质的方法,包括:
a.使权利要求1-14中任意一项所定义的单链多肽融合蛋白与能够剪切所述蛋白酶剪切位点的蛋白酶接触;
b.剪切所述蛋白酶剪切位点;并由此形成双链融合蛋白。
21.非细胞毒性的多肽,可通过权利要求20所述的方法获得,其中所述多肽是双链多肽,并且其中:
(a).第一条链包含非细胞毒性的蛋白酶,所述蛋白酶能够剪切疼痛感应传入器中胞吐融合器的蛋白;其中所述非细胞毒性蛋白酶是梭菌神经毒素L-链或IgA蛋白酶;
(b).第二条链包含阿片样物质靶向部分和转运区域,其能够将蛋白酶从内涵体中跨内涵体膜转运并进入所述疼痛感应传入器的细胞溶胶中;其中所述转运区域是梭菌神经毒素的HN区域,或是选自下述的转运区域:白喉毒素、假单胞菌外毒素的区域II、炭疽病毒素、源自流感病毒血凝素、塞姆利基森林病毒融合蛋白、水泡性口炎病毒糖蛋白G、SER病毒F蛋白、泡沫病毒包膜糖蛋白的融合和/或两亲肽;
并且
所述第一条链和第二条链被二硫键连接在一起。
22.根据权利要求1-14的任何一项的融合蛋白或者根据权利要求21的多肽的用于制备药物中的用途,所述药物用于治疗、预防或缓解疼痛。
23.根据权利要求22的用途,其中所述疼痛是慢性疼痛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310439850.7A CN103602650B (zh) | 2006-06-01 | 2007-06-01 | 通过使用单链多肽融合蛋白进行疼痛的治疗 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0610867.4 | 2006-06-01 | ||
GBGB0610867.4A GB0610867D0 (en) | 2006-06-01 | 2006-06-01 | Treatment of pain |
PCT/GB2007/002049 WO2007138339A2 (en) | 2006-06-01 | 2007-06-01 | Treatment of pain by use of a single chain polypeptide fusion protein |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310439850.7A Division CN103602650B (zh) | 2006-06-01 | 2007-06-01 | 通过使用单链多肽融合蛋白进行疼痛的治疗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101495135A CN101495135A (zh) | 2009-07-29 |
CN101495135B true CN101495135B (zh) | 2013-10-30 |
Family
ID=36694795
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310439850.7A Expired - Fee Related CN103602650B (zh) | 2006-06-01 | 2007-06-01 | 通过使用单链多肽融合蛋白进行疼痛的治疗 |
CN2007800280890A Expired - Fee Related CN101495135B (zh) | 2006-06-01 | 2007-06-01 | 通过使用单链多肽融合蛋白进行疼痛的治疗 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310439850.7A Expired - Fee Related CN103602650B (zh) | 2006-06-01 | 2007-06-01 | 通过使用单链多肽融合蛋白进行疼痛的治疗 |
Country Status (8)
Country | Link |
---|---|
US (4) | US20100034802A1 (zh) |
EP (1) | EP2046370B1 (zh) |
CN (2) | CN103602650B (zh) |
BR (1) | BRPI0713355E8 (zh) |
ES (1) | ES2607789T3 (zh) |
GB (1) | GB0610867D0 (zh) |
MX (1) | MX337729B (zh) |
WO (1) | WO2007138339A2 (zh) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
AU2011202219B2 (en) * | 2005-12-01 | 2015-05-28 | Allergan Inc. | Fusion proteins |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US20090104234A1 (en) | 2007-10-23 | 2009-04-23 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
WO2009055351A1 (en) | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
ES2732205T3 (es) | 2008-06-12 | 2019-11-21 | Ipsen Bioinnovation Ltd | Proteínas de fusión para uso en el tratamiento del cáncer |
US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
EP2627350A1 (en) | 2010-10-14 | 2013-08-21 | Allergan, Inc. | Targeted delivery of targeted exocytosis modulators to the sphenopalatine ganglion for treatment of headache disorders |
US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
US20120244188A1 (en) | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20120251573A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Neuroendocrine Disorders |
US20120251574A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US20120251575A1 (en) | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Involuntary Movement Disorders |
US20120251518A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Sexual Dysfunction Disorders |
US20120251519A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Smooth Muscle Disorders |
US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
US20120251515A1 (en) | 2011-03-29 | 2012-10-04 | Allergan, Inc. | Endopeptidase Treatment of Cosmesis Disorders |
US8697090B2 (en) | 2011-05-05 | 2014-04-15 | Allergan, Inc. | Method of treating persistent genital arousal disorder with a neurotoxin |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
WO2012174123A1 (en) | 2011-06-13 | 2012-12-20 | Allergan, Inc. | Treatment of psychological trauma |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
RU2578475C2 (ru) | 2011-07-14 | 2016-03-27 | Аллерган, Инк. | Способы лечения недержания, связанного с половой активностью |
US20130171122A1 (en) | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
US9005628B2 (en) * | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
RU2673910C2 (ru) * | 2012-11-21 | 2018-12-03 | Ипсен Байоинновейшн Лимитед | Способ производства протеолитически процессированного полипептида |
WO2014100019A1 (en) | 2012-12-18 | 2014-06-26 | Allergan, Inc. | Prophylactic treatment of herpes recurrence |
ES2763352T3 (es) * | 2013-01-14 | 2020-05-28 | Infirst Healthcare Ltd | Composiciones de solución sólida y uso en inflamación crónica |
EP2943183A1 (en) * | 2013-01-14 | 2015-11-18 | InFirst Healthcare Limited | Compositions and methods for treating severe pain |
JP2016513082A (ja) * | 2013-01-28 | 2016-05-12 | ニューヨーク・ユニバーシティ | 無毒性神経毒誘導体を用いる治療方法 |
GB201312295D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Suppression of itch |
AU2015301737B2 (en) * | 2014-08-12 | 2021-01-28 | Biomadison, Inc. | Botulinum neurotoxins with modified light chain specifity and methods for producing same |
JP2018525021A (ja) | 2015-08-27 | 2018-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 疼痛の治療を目的とする組成物及び方法 |
CA3004933A1 (en) | 2015-11-09 | 2017-05-18 | Trustees Of Tufts College | Bam8-22 peptide compounds and methods for treating pain |
TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
US20210277071A1 (en) | 2016-09-29 | 2021-09-09 | Ipsen Biopharm Limited | Hybrid neurotoxins |
EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN112165955A (zh) * | 2018-05-21 | 2021-01-01 | 益普生生物制药有限公司 | 抑制骨癌引起的异常性疼痛 |
GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998007864A1 (en) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Recombinant toxin fragments |
CN1187217A (zh) * | 1995-04-21 | 1998-07-08 | 斯佩伍德实验室有限公司 | 能修饰外周感觉传入功能的肉毒毒素衍生物 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0861325A1 (de) * | 1995-11-16 | 1998-09-02 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine |
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
US7740868B2 (en) * | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US20080032931A1 (en) * | 1999-08-25 | 2008-02-07 | Steward Lance E | Activatable clostridial toxins |
US20090018081A1 (en) * | 1999-08-25 | 2009-01-15 | Allergan, Inc. | Activatable clostridial toxins |
EP1700918B1 (en) * | 1999-08-25 | 2014-01-15 | Allergan, Inc. | Activatable recombinant neurotoxins |
CA2392202C (en) | 1999-12-02 | 2012-02-28 | Microbiological Research Authority | Constructs for delivery of therapeutic agents to neuronal cells |
US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
IL153734A0 (en) * | 2000-06-28 | 2003-07-06 | Ira Sanders | Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
WO2003030828A2 (en) * | 2001-10-09 | 2003-04-17 | Synvax, Inc. | Nociceptin-based analgesics |
ITMI20022022A1 (it) | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
GB0228723D0 (en) * | 2002-12-09 | 2003-01-15 | Cambridge Biotechnology Ltd | Treatment of pain |
US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
GB0305149D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
DE602005011458D1 (de) | 2004-09-01 | 2009-01-15 | Allergan Inc | Abbaubare clostridientoxine |
JP4994241B2 (ja) * | 2004-11-22 | 2012-08-08 | ニューヨーク・ユニバーシティ | 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用 |
US8778634B2 (en) * | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
US8603779B2 (en) * | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US7659092B2 (en) * | 2004-12-01 | 2010-02-09 | Syntaxin, Ltd. | Fusion proteins |
GB0426397D0 (en) * | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
AU2005311086B2 (en) * | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
US8399400B2 (en) * | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8512984B2 (en) * | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
WO2006059105A2 (en) | 2004-12-01 | 2006-06-08 | Health Protection Agency | Non-cytotoxic Protein Conjugates |
US7817957B2 (en) | 2005-07-08 | 2010-10-19 | Ricoh Company, Ltd. | Double feed sensing device, double feed determining method and image forming apparatus |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US8993295B2 (en) * | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
WO2009055351A1 (en) * | 2007-10-23 | 2009-04-30 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
US20090104234A1 (en) * | 2007-10-23 | 2009-04-23 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using modified clostridial toxins |
WO2010085473A1 (en) * | 2009-01-20 | 2010-07-29 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
PL2406629T3 (pl) * | 2009-03-13 | 2014-07-31 | Allergan Inc | Immunologiczne oznaczenia endopeptydazy o przekierowanej aktywności |
US20100303789A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases |
US20100303791A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303757A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases |
GB201108108D0 (en) | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
-
2006
- 2006-06-01 GB GBGB0610867.4A patent/GB0610867D0/en not_active Ceased
-
2007
- 2007-06-01 MX MX2008015227A patent/MX337729B/es active IP Right Grant
- 2007-06-01 CN CN201310439850.7A patent/CN103602650B/zh not_active Expired - Fee Related
- 2007-06-01 WO PCT/GB2007/002049 patent/WO2007138339A2/en active Application Filing
- 2007-06-01 ES ES07733065.2T patent/ES2607789T3/es active Active
- 2007-06-01 BR BRC10713355A patent/BRPI0713355E8/pt active Search and Examination
- 2007-06-01 EP EP07733065.2A patent/EP2046370B1/en active Active
- 2007-06-01 US US12/303,078 patent/US20100034802A1/en not_active Abandoned
- 2007-06-01 CN CN2007800280890A patent/CN101495135B/zh not_active Expired - Fee Related
-
2010
- 2010-08-25 US US12/868,510 patent/US20110091437A1/en not_active Abandoned
-
2012
- 2012-01-27 US US13/360,565 patent/US9072736B2/en active Active
- 2012-03-13 US US13/419,381 patent/US9243301B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1187217A (zh) * | 1995-04-21 | 1998-07-08 | 斯佩伍德实验室有限公司 | 能修饰外周感觉传入功能的肉毒毒素衍生物 |
WO1998007864A1 (en) * | 1996-08-23 | 1998-02-26 | Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) | Recombinant toxin fragments |
Non-Patent Citations (3)
Title |
---|
John A. Chaddock et al.Retargeted Clostridial Endopeptidases: Inhibition of Nociceptive Neurotransmitter Release In Vitro, and Antinociceptive Activity in In Vivo Models of Pain.《Movement Disorders》.2004,第19卷S42–S47. * |
JohnA.Chaddocketal.RetargetedClostridialEndopeptidases:InhibitionofNociceptiveNeurotransmitterReleaseInVitro and Antinociceptive Activity in In Vivo Models of Pain.《Movement Disorders》.2004 |
Michael J. Duggan et al.Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinum Toxin A Endopeptidase Fragment and Erythrina cristagalli Lectin.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2002,第277卷(第38期),34846–34852. * |
Also Published As
Publication number | Publication date |
---|---|
ES2607789T3 (es) | 2017-04-04 |
EP2046370B1 (en) | 2016-08-10 |
CN103602650B (zh) | 2018-03-27 |
US9243301B2 (en) | 2016-01-26 |
BRPI0713355E8 (pt) | 2016-01-05 |
WO2007138339A3 (en) | 2008-11-27 |
US20110091437A1 (en) | 2011-04-21 |
WO2007138339A2 (en) | 2007-12-06 |
CN103602650A (zh) | 2014-02-26 |
MX337729B (es) | 2016-03-16 |
US20100034802A1 (en) | 2010-02-11 |
CN101495135A (zh) | 2009-07-29 |
BRPI0713355A2 (pt) | 2012-08-21 |
GB0610867D0 (en) | 2006-07-12 |
BRPI0713355E2 (pt) | 2015-09-08 |
MX2008015227A (es) | 2009-04-22 |
EP2046370A2 (en) | 2009-04-15 |
US20120230975A1 (en) | 2012-09-13 |
US20120189610A1 (en) | 2012-07-26 |
US9072736B2 (en) | 2015-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101495135B (zh) | 通过使用单链多肽融合蛋白进行疼痛的治疗 | |
DK2366399T3 (en) | Non-cytotoxic protein conjugates | |
CA2595115C (en) | Fusion proteins for treating, preventing or ameliorating pain | |
AU2005311098B2 (en) | Non-cytotoxic protein conjugates | |
US8603779B2 (en) | Non-cytotoxic protein conjugates | |
US9012195B2 (en) | Non-cytotoxic protein conjugates | |
AU2012200046B2 (en) | Fusion proteins | |
AU2011202225B2 (en) | Non-cytotoxic protein conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Oxfordshire Co-patentee after: Allergan Inc. Patentee after: SYNTAXIN LIMITED Address before: Oxfordshire Co-patentee before: Allergan Inc. Patentee before: Syntaxin Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131030 Termination date: 20210601 |